UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 10-K
(Mark One)
| x | ANNUAL REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2015.
or
| o | TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from
to .
Commission File Number 001-33672
NEURALSTEM, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
|
52-2007292 |
State
or other jurisdiction of
incorporation
or organization |
|
(I.R.S.
Employer
Identification
No.) |
|
|
|
20271
Goldenrod Lane
Germantown,
Maryland |
|
20876 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code (301)-366-4841
Securities registered pursuant to Section 12(b)
of the Act:
Title
of each class |
|
Name
of each exchange on which registered |
Common stock, $0.01 par
value |
|
NASDAQ Stock Market |
Securities registered pursuant to Section 12(g)
of the Act:
None
Indicate by check mark if the
registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ¨
Yes x No
Indicate by check mark if the registrant
is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ¨ Yes x No
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. x Yes
¨ No
Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). x
Yes ¨ No
Indicate by check mark if disclosure of
delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and
will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated
by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2
of the Exchange Act.
Large accelerated filer o |
|
|
Accelerated filer x |
|
|
|
|
Non-accelerated filer o |
(Do not check if a smaller reporting company) |
|
Smaller reporting company o |
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). ¨ Yes x
No
The aggregate market value of the voting
and non-voting common equity held by non-affiliates computed by reference to the price at which the Company’s common equity
was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter based upon the
closing price of the common stock as reported by NASDAQ on such date, was $168,902,179.
The number of shares outstanding of Registrant’s
common stock, $0.01 par value at March 1, 2016 was 92,044,042.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive
proxy statement relating to its 2016 annual meeting of shareholders (the “2016 Proxy Statement”) are incorporated
by reference into Part III of this Annual Report on Form 10-K where indicated. The 2016 Proxy Statement will be filed with the
U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
NEURALSTEM, INC
ANNUAL REPORT ON FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2015
INDEX
PART I
We urge you to read this
entire Annual Report on Form 10-K, including the “Risk Factors” section, the financial statements and related notes
included herein. As used in this Annual Report, unless context otherwise requires, the words “we,” “us,”
“our,” “the Company,” “Neuralstem” and “Registrant” refer to Neuralstem, Inc.
and its subsidiary Also, any reference to “common share” or “common stock,” refers to our $.01 par value
common stock.
SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS
Statements in this annual report that
are not strictly historical are forward-looking statements and include statements made pursuant to the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995 such as statements about products in development, results and
analyses of pre-clinical studies, clinical trials and studies, research and development expenses, cash expenditures, regulatory
applications and approvals, and third party relationships, among other matters. You can identify these forward-looking statements
because they involve our expectations, intentions, beliefs, plans, projections, anticipations, or other characterizations of future
events or circumstances and may often be identified by words such as “expect,” “anticipate,” “intend,”
“plan,” “believe,” “seek” or “will.”. These forward-looking statements are not
guarantees of future performance and are subject to substantial risks and uncertainties that may cause actual results to differ
materially from those in the forward-looking statements These Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially
from those expressed in our forward-looking statements include risks inherent in our ability to conduct and obtain successful
results from our clinical trials, our ability to commercialize our technology, our ability to obtain regulatory approval for our
product candidates, our ability to contract with third parties to adequately test and manufacture our proposed products, our ability
to protect our intellectual property rights and our ability to obtain additional financing to continue development efforts. These
forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, which
could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could
cause or contribute to such differences include, but are not limited to, those discussed in this Annual Report, and in particular,
the risks discussed under the caption “Risk Factors” in Item 1A and those discussed in other documents we file with
the Securities and Exchange Commission (SEC). We undertake no obligation to revise or publicly release the results of any revision
to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not
to place undue reliance on such forward-looking statements.
The information
contained herein is current as of the date of this Annual Report (December 31, 2015), unless another date is specified.
Overview
We are focused on the research, development
and commercialization of central nervous system therapies based on our proprietary human neuronal stem cells and our stem-cell
derived small molecule compounds. We are headquartered in Germantown, Maryland and have a wholly-owned subsidiary in China, Suzhou
Neuralstem Biopharmaceutical Co. Ltd., or Neuralstem China.
Our technology base has produced three
primary assets: Our NSI-189 small molecule program, our NSI-566 stem cell therapy program and our novel and proprietary new chemical
entity screening platform.
Our patented technology enables the commercial-scale
production of multiple types of central nervous system stem cells, which are under development for the potential treatment of
central nervous system diseases and conditions. In addition, this ability to generate human neural stem cell lines provides a
platform for chemical screening and discovery of novel compounds that Neuralstem believes may stimulate the brain's capacity to
generate neurons, potentially reversing pathologies associated with certain central nervous system (CNS) conditions. This proprietary
screening platform led to the discovery of NSI-189.
We have developed and maintain a portfolio
of patents and patent applications that form the proprietary base for our research and development efforts. We own or exclusively
license one hundred fourteen (114) U.S. and foreign issued patents and forty-seven (47) U.S. and foreign patent applications in
the field of regenerative medicine, related to our stem cell technologies as well as our small molecule compounds. At times we
have licensed the use of our intellectual property to third parties.
We believe our technology base, in combination
with our expertise, and collaborative projects with major research institutions, could facilitate the development and commercialization
of products for use in the treatment of a wide array of central nervous system disorders including neurodegenerative conditions
and regenerative repair of acute disease.
There can be no assurances that we will
ultimately produce any viable products or processes. Even if we are able to produce a commercially viable product, there are strong
competitors in this field and our products may not be able to successfully compete against them.
All of our research efforts to date are
at the pre-clinical or clinical stage of development. We are focused on leveraging our key assets, including our intellectual
property, proprietary technology, scientific team and facilities, to advance our technologies and clinical programs. In addition,
we are pursuing strategic collaborations with members of academia and industry.
Clinical Programs
We have devoted substantially all our
efforts to the pre-clinical and clinical development of our small molecule compounds and our stem cell therapeutics. Below is
a description of our most advanced clinical programs, their intended indication, current stage of development and our expected
future development plans:
In January, 2016, we announced a strategic
refocusing to concentrate the Company’s resources on the NSI-189 small molecule program. As part of this refocusing, the
Company announced that it will seek external funding to defray all, or substantially all, of the costs associated with the NSI-566
stem cell therapy program. The Company is in active conversations with a number of sources of funding to achieve this goal and
minimize any delay in progressing our stem cell therapy programs.
NSI - 189 (Small Molecule Pharmaceutical
Compound).
Major Depressive Disorder (MDD)
Major depressive disorder, or MDD (also
known as recurrent depressive disorder, clinical depression, major depression, unipolar depression, or unipolar disorder), is
a mental disorder characterized by episodes of all-encompassing low mood accompanied by low self-esteem and loss of interest or
pleasure in normally enjoyable activities. NSI-189 is being developed for the treatment of major depressive disorder and other
psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. NSI-189 is the lead compound in our neurogenic
small molecule drug platform. We believe that NSI-189 may provide an effective treatment for patients suffering from MDD by promoting
synaptogenesis or neurogenesis in the hippocampus.
In February of 2011, we commenced a Phase
I clinical trial (Phase Ia portion), NSI-189, at California Clinical Trials, LLC, in Glendale, California. The purpose of the
Phase Ia portion of the trial was to evaluate the safety of the drug in healthy volunteers. The Phase Ia portion tested a single
oral administration of NSI-189 in 24 healthy volunteers and was completed in October of 2011.
In December of 2011, we received authorization
from the FDA to commence the Phase Ib randomized, dose-escalating, placebo controlled clinical trial for the treatment of MDD.
The purpose of the Phase Ib portion of the clinical trial was to determine the drug safety and tolerability in three dosages in
diagnosed MDD patients. The Phase Ib portion consisted of patients with MDD receiving daily doses for 28 consecutive days with
an eight week observation period. The trial was completed in November 2013 and met its primary endpoints of safety and tolerability
and showed a promising reduction in depressive and cognitive symptoms across the secondary, explorative endpoints.
In September, 2015 we filed the regulatory
and clinical protocol with the Food and Drug Administration (FDA) for a Phase II, multi-site clinical trial in approximately 220
patients. In late February, Neuralstem received the Food and Drug Administration (FDA) approval for the Phase II clinical trial
which is expected to enroll the first subject in Q2 of 2016.
In February 2016, the Company received
approval from the FDA to commence its Phase 2 Major Depressive Disorder (MDD) trial.
Second Study:
We are exploring the expansion of the
NSI-189 program to include a second short-term study. The Company will provide an update in 2016.
NSI - 566 (Stem Cells).
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis, or ALS,
is a disease of the nerve cells in the brain and spinal cord that control voluntary muscle movement. In ALS, nerve cells (neurons)
waste away or die, and can no longer send messages to muscles. This eventually leads to muscle weakening, twitching, and an inability
to move the arms, legs, and body. The condition slowly gets worse. When the muscles in the chest area stop working, it becomes
hard or impossible to breathe. NSI-566 is under development as a potential treatment for ALS by providing cells designed to nurture
and protect the patients’ remaining motor neurons; and possibly repair some motor neurons which have not yet died but which
are diseased. Neuralstem received orphan designation by the FDA for NSI-566 in ALS.
In January 2010, we commenced the Phase
I trial of NSI-566 in ALS at Emory University in Atlanta Georgia. The purpose of the Phase I trial was to evaluate the safety
and transplantation technique of our proposed treatment and procedure. The dosing of patients in the Phase I trial, as designed,
was completed in August of 2012. We commenced our Phase II clinical trial for ALS in September of 2013. The Phase II dose escalation
trial enrolled 15 ambulatory patients in five different dosing cohorts, under an accelerated dosing and treatment schedule. Each
patient in the final cohort had two transplants, for a total of 18 surgeries. We have now completed all of the transplantations.
The observation period of six months after the last surgery concluded in January 2015. The Phase II ALS clinical trial met the
primary safety endpoints and established what we believe to be the maximum safe tolerated dose of 16 million cells delivered in
40 injections. In September 2015, nine-month Phase II and combined Phase I and Phase II data on the NSI-566 trial in amyotrophic
lateral sclerosis (ALS) was presented at the American Neurological Association Meeting by principal investigator Eva Feldman,
MD, PhD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University
of Michigan Health. The Company is in discussion with the FDA for planning of a larger registration directed, controlled trial.
In January, 2016, the Company announced
that it is in discussions with various governmental, state and non-profit organizations regarding funding grants for a registration
directed, controlled trial and that initiation of such a trial would, in part, be dependent upon significant funding from such
sources. To date, substantially all of the clinical costs of ALS studies undertaken by the Company have been funded by such grants.
Chronic Spinal Cord Injury
A spinal cord injury, or SCI, generally
refers to any injury to the spinal cord that is caused by trauma instead of disease although in some cases, it can be the result
of diseases. Chronic spinal cord injury refers to the time after the initial hospitalization. Spinal cord injuries are most often
traumatic, caused by lateral bending, dislocation, rotation, axial loading, and hyperflexion or hyperextension of the cord or
cauda equina. Motor vehicle accidents are the most common cause of SCIs, while other causes include falls, work-related accidents,
sports injuries, and penetrations such as stab or gunshot wounds. In certain instances, SCIs can also be of a non-traumatic origin,
as in the case of cancer, infection, intervertebral disc disease, vertebral injury and spinal cord vascular disease. We believe
that NSI-566 may provide an effective treatment for chronic spinal cord injury by “bridging the gap” in the spinal
cord circuitry created in traumatic spinal cord injury and providing new cells to help transmit the signal from the brain to points
at or below the point of injury.
During the first quarter of 2013, we received
authorization from the United States Food and Drug Administration, or FDA, to commence our proposed Phase I clinical trial to
treat chronic spinal cord injury. The entire trial will take place at The University of California, San Diego. The trial commenced
during the third quarter of 2014 and the first subject was treated in October 2014. The study enrolled four AIS A thoracic-spinal
cord injury subjects (motor and sensory complete), one-to-two years post-injury at the time of stem cell treatment. In January,
2016 we reported six month follow-up data on all four subjects. The stem cell treatment demonstrated feasibility and safety; there
were no serious adverse events. A self-reported ability to contract some muscles below the level of injury was confirmed via clinical
and electrophysiological follow-up examinations in one of the four subjects treated. There was no change in the clinical status
of the three other subjects.
To date, substantially all of the clinical
costs of this study have been funded by grants arranged through the University of California, San Diego (UCSD).
Motor Deficits Due to Ischemic Stroke
Ischemic strokes, the most common type
of stroke, occur as a result of an obstruction within a blood vessel supplying blood to the brain. Post-stroke motor deficits
include paralysis in arms and legs and can be permanent. We believe that NSI-566 may provide an effective treatment for restoring
motor deficits resulting from ischemic stroke by both creating new circuitry in the area of injury and through repairing and or
nurturing diseased cells to improve function in patients.
In the fourth quarter of 2013
the Company commenced a human clinical trial for treatment of motor deficits due to ischemic stroke. The trial is being
conducted by Neuralstem China, at BaYi Brain Hospital in Beijing, China utilizing our spinal cord stem cells. The trial
authorization encompasses a combined phase I/II/III design and will test direct injections of NSI-566 into the brain. The Phase I portion of the trial is designed to confirm the maximum safe
tolerated dose. To date, we have completed dosing the second of three planned cohorts.
To date, the Ischemic Stroke program has
been funded substantially by Neuralstem.
Markets
The table below summarizes the potential
United States patient populations by indication, for our proposed stem cell and small molecule products:
Medical
Condition | |
| Estimated
Number of Patients in United States | |
Small molecule compounds | |
| | |
Major Depressive
Disorder | |
| 14.8
million | (1) |
Stem cells | |
| | |
ALS | |
| 20,000 | (2) |
Alzheimer’s
Disease | |
| 5.3
million | (3) |
Spinal Cord Injury | |
| 240,000
– 337,000 | (4) |
Stroke | |
| 6.5
million | (5) |
(1) Anxiety and Depression Association
of America (ADAA), website: http://www.adaa.org/about-adaa/press-room/facts-statistics retrieved March 2016
(2) The ALS Association (ALSA), website:
http://www.alsa.org/about-als/facts-you-should-know.html retrieved March 2016
(3) Alzheimer’s Association
(AA), The 2015 Alzheimer’s Disease Facts and Figures, website: https://www.alz.org/facts/downloads/facts_figures_2015.pdf
retrieved March 2016
(4) National Spinal Cord Injury Statistical
Center, Facts and Figures at a Glance. Birmingham, AL: University of Alabama at Birmingham, website: https://www.nscisc.uab.edu/Public/Facts%202015.pdf
retrieved March 2016
(5) National Stroke Association (NSA),
website: retrieved March 2016 from www.stroke.org Technology
Stem Cells.
Our technology
enables the isolation and large-scale expansion of regionally specific, human neural stem cells from all areas of the developing
human brain and spinal cord, thus enabling the generation of physiologically relevant human neurons of all types. We believe that
our stem cell technology will assist the body in producing new cells to replace malfunctioning or dead cells as a way to treat
disease and injury. Many significant and currently untreatable human diseases arise from the loss or malfunction of specific cell
types in the body. Our focus is the development of effective methods to generate replacement cells from neural stem cells. We
believe that replacing damaged, malfunctioning or dead neural cells with fully functional ones may be a useful therapeutic strategy
in treating many diseases and conditions of the central nervous system. We own or exclusively license fifty-two (52) and foreign
issued patents and thirty-three (33) U.S. and foreign patent applications related to our stem cell technologies.
Small Molecule Pharmaceutical Compounds.
Utilizing our
proprietary stem cell derived, screening capability, we have developed and patented a series of small molecule compounds. We believe
the low molecular weight organic compounds can efficiently cross the blood/brain barrier. In mice, research indicated that the
small molecule compounds both stimulate neurogenesis of the hippocampus and increase its volume. Our collaborators at Massachusetts
General Hospital have presented the human data from the MDD trial which showed clinically meaningful and statistically significant
improvement in depressive and cognitive scales. We believe the small molecule compounds may assist promoting synaptogenesis or
neurogenesis in the human hippocampus documented in indications such as MDD.
Our small molecule compounds are covered
by sixty-two (62) exclusively owned U.S. and foreign issued patents and fourteen (14) exclusively owned U.S. and foreign patent
applications related to our small molecule compounds.
Research
Substantial resources are devoted to our
research programs in order to isolate and develop a series of neural stem cell banks that we believe can serve as a basis for
our therapeutic product candidates. Our efforts are directed at developing therapies utilizing our stem cells and small molecule
regenerative drug candidates. This research is conducted internally, through the use of third party laboratories and consulting
companies under our direct supervision, and through collaboration with academic institutes.
Manufacturing
We currently manufacture our cells both
in-house and on an outsourced basis. We outsource the manufacturing of our pharmaceutical compounds to third party manufacturers.
We manufacture, in-house, cells that are not required to meet stringent FDA requirements. We use these cells in our research and
collaborative programs. During 2015, we are began the process of bringing the manufacturing of our spinal cord stem cells, in-house.
We believe this will better assure the availability of our stem cells and to also lead to a reduction in per patient manufacturing
costs.
Intellectual Property
Our research and development is supported
by our intellectual property. We own or exclusively license one hundred fourteen (114) U.S. and foreign issued patents and forty-seven
(47) U.S. and foreign patent applications in the field of regenerative medicine, related to our stem cell technologies as well
as our small molecule compounds. Our issued patents have expiration dates ranging from 2016 through 2034. In our opinion the patents
expiring in 2016 are not critical to our business.
Our success will likely depend upon our
ability to preserve our technologies and operate without infringing the proprietary rights of other parties. However, we may rely
on certain proprietary technologies and know-how that are not patentable. We protect our proprietary information, in part, by
the use of confidentiality agreements with our employees, consultants and certain of our contractors.
When appropriate, we seek patent protection
for inventions in our core technologies and in ancillary technologies that support our core technologies or which we otherwise
believe will provide us with a competitive advantage. We accomplish this by filing patent applications for discoveries we make,
either alone or in collaboration with scientific collaborators and strategic partners. Typically, although not always, we file
patent applications both in the United States and in select international markets. In addition, we plan to obtain licenses or
options to acquire licenses to patent filings from other individuals and organizations that we anticipate could be useful in advancing
our research, development and commercialization initiatives and our strategic business interests.
In addition to patenting our technologies,
we also rely upon trade-secret protection for our confidential and proprietary information and take active measures to control
access to that information.
Our policy is to require our employees,
consultants and significant scientific collaborators and sponsored researchers to execute confidentiality and assignment of invention
agreements upon the commencement of an employment or consulting relationship with us. These agreements generally provide that
all confidential information developed or made known to the individual by us during the course of the individual's or entity’s
relationship with us, is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case
of employees and consultants, the agreements generally provide that all inventions conceived by the individual or entity in the
course of rendering services to us shall be our exclusive property.
The patent positions of pharmaceutical
and biotechnology companies, including ours, are uncertain and involve complex and evolving legal and factual questions. The coverage
sought in a patent application can be denied or significantly reduced before or after the patent is issued. Consequently, we do
not know whether any of our pending applications will result in the issuance of patents, or if any existing or future patents
will provide significant protection or commercial advantage or will be circumvented by others. Since patent applications are secret
until the applications are published (usually eighteen months after the earliest effective filing date), and since publication
of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain that we were
the first to make the inventions covered by each of our pending patent applications or that we were the first to file patent applications
for such inventions. There can be no assurance that patents will issue from our pending or future patent applications or, if issued,
that such patents will be of commercial benefit to us, afford us adequate protection from competing products, or not be challenged
or declared invalid.
In the event that a third party has also
filed a patent application relating to inventions claimed in our patent applications, we may have to participate in interference
proceedings declared by the United States Patent and Trademark Office or USPTO, to determine priority of invention, which could
result in substantial uncertainties and costs, even if the eventual outcome is favorable to us. There can be no assurance that
our patents, if issued, would be held valid by a court of competent jurisdiction.
A number of pharmaceutical, biotechnology
and other companies, universities and research institutions have filed patent applications or have been issued patents relating
to cell therapy, stem cells and other technologies potentially relevant to or required by our proposed products. We cannot predict
which, if any, of such applications will issue as patents or the claims that might be allowed.
If third party patents or patent applications
contain claims infringed by our technology and such claims are ultimately determined to be valid, there can be no assurance that
we would be able to obtain licenses to these patents at a reasonable cost, if at all, or be able to develop or obtain alternative
non-infringing technology. If we are unable to obtain such licenses or develop or obtain alternative non-infringing technology
at a reasonable cost, we may not be able to develop certain products commercially. There can be no assurance that we will not
be obliged to defend ourselves in court against allegations of infringement of third party patents. Patent litigation is very
expensive and could consume substantial resources and create significant uncertainties. An adverse outcome in such a suit could
subject us to significant liabilities to third parties, require us to seek licenses from third parties, or require us to cease
using such technology.
Competition
The pharmaceutical and biotechnology industries
are characterized by rapidly evolving technology and intense competition. Our competitors include major multinational pharmaceutical
companies, specialty biotechnology companies and chemical and medical products companies. Many of these companies are well-established
and possess greater resources for technical, research, development, financial, sales and marketing initiatives than we do. Other,
less well-established companies have formed or may form strategic collaborations, partnerships and other types of joint ventures
with larger, well established industry competitors that may provide research and development and commercialization advantages
to these competitors. Academic institutions, governmental agencies and other public and private research organizations are also
conducting and financing research activities which may produce products directly competitive to those we are developing. Moreover,
many of these competitors may be able obtain patent protection, or FDA and other regulatory approvals that may impede our freedom
to develop and commercialize our programs.
The diseases and medical conditions we
are targeting have a demographic in which there are large numbers of patients who do not respond to current therapies or have
limited therapies available. Nevertheless, we expect that our technologies and product candidates, if or when approved, will compete
with a variety of therapeutic products and procedures offered by other pharmaceutical and biotechnology companies. Many pharmaceutical
and biotechnology companies are investigating new drugs and therapeutic approaches for the same or similar indications. These
companies’ efforts may achieve new efficacy profiles, extend the therapeutic window for such products, alter the prognosis
of these diseases, or prevent their onset. We believe that our products, if or when approved, will attempt to compete with these
products principally on the basis of improved and extended efficacy and safety and their overall economic benefit to the health
care system. Competition for our products may be in the form of existing and new drugs, other forms of cell transplantation, surgical
procedures, gene therapy or other proprietary technology and expertise. We expect that all of these products will compete with
our product candidates, if or when approved, based on efficacy, safety, cost and intellectual property positions. We cannot be
certain that that other entities have not filed patents that block our freedom to commercialize our programs and we may be required
to seek licenses from these entities in order to commercialize certain of our proposed products, and such licenses may not be
granted or be extremely expensive to obtain.
If we develop products that receive regulatory
approval, they would then have to compete for market acceptance and market share. For our potential products, an important success
factor will be the timing of market introduction of competitive products. This timing will be a function of the relative speed
with which we and our competitors can develop products, complete the clinical testing and approval processes, and supply commercial
quantities of a product to the market. These competitive products may also impact the timing of clinical testing and approval
processes by limiting the number of clinical investigators and subjects available to test our potential products.
Government Regulation
Regulation by governmental authorities
in the United States and other countries is a significant factor in our research and development and will be a significant factor
in the manufacture and marketing of our proposed products. The nature and extent to which such regulation applies to us will vary
depending on the nature of any products we may develop. Governmental authorities, including the FDA and comparable regulatory
authorities in other countries, regulate the design, development, testing, manufacturing, safety, efficacy, labeling, storage,
record-keeping, advertising, promotion and marketing of pharmaceutical products, including drugs and biologics, under the Federal
Food, Drug, and Cosmetic Act, or FFDCA, and its implementing regulations, and, for biologics, under the Public Health Service
Act, or PHSA, and its implementing regulations. Non-compliance with applicable requirements can result in fines and other judicially
imposed sanctions, including product seizures, import restrictions, injunctive actions and criminal prosecutions of both companies
and individuals. In addition, administrative remedies can involve requests to recall violative products; the refusal of the government
to enter into supply contracts; or the refusal to approve pending product approval applications until manufacturing or other alleged
deficiencies are brought into compliance. The FDA also has the authority to cause the withdrawal of approval of a marketed product
or to impose labeling restrictions. The process of obtaining approvals and the subsequent compliance with appropriate statutes
and regulations require the expenditure of substantial time and money, and there can be no guarantee that approvals will be granted.
United States Product Development Process
We believe that, in the United States,
our human neuronal stem cell candidates are regulated as biologic pharmaceuticals, or biologics, and our small-molecule compounds
are regulated as drugs.
The process required by the FDA before
a drug or biological product may be marketed in the United States generally involves the following:
| · | Completion
of preclinical testing of new pharmaceutical or biological products, generally conducted
in the laboratory and in animal studies in accordance with GLPs, and applicable requirements
for the humane use of laboratory animals or other applicable regulations to evaluate
the potential efficacy and safety of the product candidate; |
| · | Submission
of the results of these studies to the FDA as part of an IND application, which must
become effective before clinical testing in humans can begin; |
| · | Performance
of adequate and well-controlled human clinical trials according to cGMPs and any additional
requirements for the protection of human research patients and their health information,
to establish the safety and efficacy of the product candidate for its intended use; |
| · | Submission
to the FDA of a biological license application, or BLA, for any biologic or a new drug
application, or NDA, for any new chemical entity drug we seek to market that includes
substantive evidence of safety, purity, and potency, or safety and effectiveness from
results of nonclinical testing and clinical trials; |
| · | Satisfactory
completion of an FDA inspection of the manufacturing facility or facilities where the
product is produced, packaged and distributed, to assess compliance with cGMPs, to assure
that the facilities, methods and controls are adequate to preserve the product’s
identity, strength, quality and purity, and, if applicable, the FDA’s current good
tissue practices, or GTPs, for the use of human cellular and tissue products; |
| · | Potential
FDA audit of the nonclinical study and clinical trial sites that generated the data in
support of the BLA or NDA; and |
| · | FDA
review and approval of the NDA, or licensure, of the BLA. |
Typically, human clinical evaluation involves
a time-consuming and costly three-phase process.
| · | Phase
1. The product is initially introduced into healthy human volunteers and tested for safety.
In the case of some products for severe or life-threatening diseases, especially when
the product may be too inherently toxic to ethically administer to healthy volunteers,
the initial human testing is often conducted in patients. |
| · | Phase
2. The product is evaluated in a limited patient population to identify possible adverse
effects and safety risks, to preliminarily evaluate the efficacy of the product for specific
targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. |
| · | Phase
3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency,
and safety in an expanded patient population at geographically dispersed clinical trial
sites. These clinical trials are intended to establish the overall risk to benefit ratio
of the product and provide an adequate basis for product labeling. |
Post-approval clinical trials, sometimes
referred to as Phase IV clinical trials, may be required and conducted after initial marketing approval. These clinical trials
are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for
long-term safety follow-up.
During all phases of clinical development,
regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators.
Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Clinical trials may not be
completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may
suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being
exposed to an unacceptable health risk, including risks inferred from other unrelated similar trials. Similarly, an institutional
review board, or IRB, can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being
conducted in accordance with the IRB’s requirements or if the product has been associated with unexpected serious harm to
patients.
Human cell-based therapies in the field
of regenerative medicine are relatively novel. Because this is a relatively new and expanding area of novel therapeutic interventions,
there can be no assurance as to the length of the trial period, the number of patients the FDA will require to be enrolled in
the trials in order to establish the safety, efficacy, purity and potency of such products, or that the data generated in these
trials will be acceptable to the FDA to support marketing approval.
United States Review and Approval Process
After the completion of clinical trials
of a product candidate, FDA approval of a BLA or NDA must be obtained before commercial marketing of the product. The BLA or NDA
must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition
of the product, proposed labeling and other relevant information as well as a significant user fee. The FDA may grant deferrals
for submission of data, or full or partial waivers. The testing and approval processes require substantial time and effort and
there can be no assurance that the FDA will accept the BLA or NDA for filing and, even if filed, that any approval will be granted
on a timely basis, if at all.
The FDA may refuse to file any BLA or
NDA that it deems incomplete or not properly reviewable at the time of submission, and may request additional information. Once
the submission is accepted for filing, the FDA reviews the BLA or NDA to determine, among other things, whether the proposed product
is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is safe
and effective for its intended use, and in each case, whether the product is being manufactured in accordance with cGMP or GTP,
if applicable. During the product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy,
or REMS, is necessary to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA or
NDA must submit a proposed REMS. The FDA will not approve a BLA or NDA without a REMS, if required.
Notwithstanding the submission of relevant
data and information, the FDA may ultimately decide that the BLA or NDA does not satisfy its regulatory criteria for approval
and deny approval via a letter detailing such deficiencies. Data obtained from clinical trials are not always conclusive and the
FDA may interpret data differently than we interpret the same data. If the FDA denies an application, the applicant may either
resubmit the BLA or NDA, addressing all of the deficiencies identified by the FDA, or withdraw the application.
United States Post-Approval Requirements
Any products for which we receive FDA
approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting
of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and
distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards
for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described
in the product’s approved uses, known as off-label use, limitations on industry-sponsored scientific and educational activities
and requirements for promotional activities involving the internet.
In addition, quality control and manufacturing
procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term stability
of the product. We rely, and expect to continue to rely, on third parties for the production of some, or all, clinical and commercial
quantities of our products in accordance with cGMP and GTP regulations, as applicable. Manufacturers and other entities involved
in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain
state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with
cGMP, GTP and other laws.
The FDA also may require post-marketing
testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown
problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse
publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications
with doctors, and civil or criminal penalties, among others. Also, new government requirements, including those resulting from
new legislation, may be established, or the FDA’s policies may change, which could delay or prevent regulatory approval
of our product candidates under development.
European, China and Other Regulatory Review and Approval
Whether or not FDA approval has been obtained,
approval of a product by comparable regulatory authorities in Europe, China and other countries will be necessary prior to commencement
of marketing the product in such countries. The regulatory authorities in each country may impose their own requirements and may
refuse to grant an approval, or may require additional data before granting it, even though the relevant product has been approved
by the FDA or another authority. As with the FDA, the regulatory authorities in the European Union, China and other developed
countries have lengthy approval processes for biological and pharmaceutical products. The process for gaining approval in particular
countries varies, but generally follows a similar sequence to that described for FDA approval.
Other Health Care Laws
In the event any of proposed products
are ever approved for marketing, we may also be subject to healthcare regulation and enforcement by the federal government and
the states and foreign governments where we may market our product candidates, if approved. These laws include, without
limitation, state and federal anti-kickback, fraud and abuse, false claims, physician sunshine and privacy and security laws and
regulations.
Other Regulations
We are also subject to various U.S. federal,
state, local and international laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing
practices and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious
disease agents, used in connection with our business. We cannot accurately predict the extent of government regulation which might
result from future legislation or administrative action.
For additional information about governmental
regulations as well as risk related to our business that could affect our planned and intended business operations, see the “Risk
Factors” Section of this Annual Report.
Executive Officers
The following sets forth our current executive
officers and information concerning their age and background:
Name | |
Position | |
Age | | |
Position Since | |
Richard J. Daly | |
Chief Executive Officer, President, | |
| 54 | | |
| 2016 | |
| |
| |
| | | |
| | |
Karl Johe, Ph.D. | |
Chief Scientific Officer | |
| 55 | | |
| 1996 | |
| |
| |
| | | |
| | |
Jonathan Lloyd Jones | |
Chief Financial Officer | |
| 55 | | |
| 2015 | |
Mr. Richard J. Daly, age
54, has been Chief Executive Officer, President and a director since February of 2016. Mr. Daly has over 25 years of commercial
pharmaceutical experience working in positions of progressive responsibility in sales, marketing and operations. From November
2015 until February 2016, Mr. Daly was a managing partner at Ravine Rock Partners, LLC, a bio-pharmaceutical consulting company.
Prior to that, from August 2013 until November 2014, Mr. Daly was the President of U.S. Diabetes, a subsidiary of AstraZeneca
Pharmaceutical LP. From October 2011 until November 2012, Mr. Daly was a founding partner, board member and investor in SagePath
Partners LLC, a commercial outsourcing provider to the pharmaceutical industry. Between July 2008 and October 2011, Mr.
Daly was executive vice president of North and South America for Takeda NA, the north American subsidiary of Takeda Pharmaceuticals
(TSE: TYO). Since June 2015, Mr. Daly has served on the board of directors and on the Compensation and Commercial Committees
for Synergy Pharmaceuticals (NASDAQ: SGYP). Since February 2015, Mr. Daly has also served on the board of directors and on the
Compensation Committee of Catalyst Pharmaceuticals (NASDAQ: CPRX). Mr. Daly holds a BS in Microbiology from The University
of Notre Dame and an MBA from Northwestern University's Kellogg Graduate School of Management. In evaluating Mr. Daly’s
specific experience, qualifications, attributes and skills in connection with his appointment to our board, we took into account
his prior work with both public and private organizations, including his experience in building biopharmaceutical organizations,
his strong business development background and his past experience and relationships in the biopharma and biotech fields.
Dr. Karl Johe, Ph.D., age
55, has been a director, Chairman of the Board and our Chief Scientific Officer since 1996. Dr. Johe has over 15
years of research and laboratory experience. Dr. Johe is the sole inventor of Neuralstem’s granted stem cell patents and
is responsible for the strategic planning and development of our therapeutic products. Dr. Johe received his Bachelor of Arts
Degree in Chemistry and a Master’s Degree from the University of Kansas. Dr. Johe received his doctorate from the Albert
Einstein College of Medicine of Yeshiva University. From 1993 to January 1997, Dr. Johe served as a Staff Scientist at the Laboratory
of Molecular Biology of the National Institute of Neurological Disease and Stroke in Bethesda, Maryland. While holding this position,
Dr. Johe conducted research on the isolation of neural stem cells, the elucidation of mechanisms directing cell type specification
of central nervous system stem cells and the establishment of an in vitro model of mammalian neurogenesis. In evaluating Dr. Johe’s
specific experience, qualifications, attributes and skills in connection with his appointment to our board, we took into account
his extensive experience in international science and business communities. Dr. Johe is also multilingual.
Mr. Jonathan Lloyd Jones, ACA, MBA,
age 55, has been our Chief Financial Officer since May of 2015. Mr. Lloyd Jones has over 30 years
of experience in finance and corporate development. Mr. Lloyd Jones was previously the Chief Financial Officer of Juniper
Pharmaceuticals, Inc. (formerly Columbia Pharmaceuticals) (NASDAQ: JNP) from 2013 to 2014 and served as the Chief Financial Officer
and Vice President of Corporate Development at TetraLogic Pharmaceuticals, Inc. (NASDAQ: TLOG) from 2011 to 2012. Prior
to that, Mr. Lloyd Jones served as an independent consultant for bio-tech companies from 2010 to 2011. Mr. Lloyd
Jones served as Vice President, Finance for TransMolecular, Inc., a privately held bio-tech company from 2006 to 2010. From 1996
to 2006, Mr. Lloyd Jones held positions of increasing seniority at Genzyme, Inc. (now Sanofi-Aventis) (NYSE: ADR) most recently,
as Senior Director of Corporate Development. Mr. Lloyd Jones is a member of the Institute of Chartered Accountants
in England & Wales. He received his bachelor of science in business studies from the University of Bradford in England (1981),
and a master of business administration with a dual major in strategic management and finance from The Wharton School of
the University of Pennsylvania.
Employees
As of January 31, 2016, we had
thirty three (33) full-time employees. Of these full-time employees, twenty five (25) work on research and
development and clinical operations eight (8) in administration. We also use the services of numerous outside consultants in
business and scientific matters.
Our Corporate Information
We were incorporated in Delaware in 2001.
Our principal executive offices are located at 20271 Goldenrod Lane, Germantown, Maryland 20876, and our telephone number
is (301) 366-4841. Our website is located at www.neuralstem.com.
In addition to announcing material financial
information through our investor relations website, press releases, SEC filings and public conference calls and webcasts, we also
intend to use the following social media channels as a means of disclosing information about the company, its services and other
matters and for complying with our disclosure obligations under Regulation FD:
· Neuralstem’s
Twitter Account (https://twitter.com/Neuralstem_Inc) |
· Neuralstem’s
Facebook Page (https://www.facebook.com/Neuralstem) |
· Neuralstem’s
Company Blog (http://neuralstem.com/neuralstem-ceo-blog) |
· Neuralstem’s
Google+ Page (https://plus.google.com/u/0/b/104875574397171789280/104875574397171789280/posts) |
· Neuralstem’s
LinkedIn Company Page (http://www.linkedin.com/company/neuralstem-inc-) |
|
· Neuralstem Asia’s
Tencent Weibo Account ( http://t.qq.com/neuralstem) |
The information we post through these
social media channels may be deemed material. Accordingly, investors should monitor these accounts and the blog, in addition to
following the company’s press releases, SEC filings and public conference calls and webcasts. This list may be updated from
time to time.
We have not incorporated by reference
into this report the information in, or that can be accessed through, our website or social media channels, and you should
not consider it to be a part of this report.
Where to Find More Information
We make our public filings with the SEC,
including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all exhibits
and amendments to these reports. Also our executive officers, directors and holders of more than 10% of our common stock, file
reports with the SEC on Forms 3, 4 and 5 regarding their ownership of our securities. These materials are available on the
SEC’s web site, http://www.sec.gov. You may also read or copy any materials we file with the SEC at the SEC’s
Public Reference Room at 100 F Street, N.E., Washington, DC 20549. You may obtain information on the operation of the
Public Reference Room by calling the SEC at 1-800-SEC-0330. Alternatively, you may obtain copies of these filings, including exhibits,
by writing or telephoning us at:
NEURALSTEM, INC
20271 Goldenrod Lane
Germantown, Maryland 20876
Attn: Chief Financial Officer
Tel: (301) 366-4841
Investing
in our common stock involves a high degree of risk. We have described below a number of uncertainties and risks which, in addition
to uncertainties and risks presented elsewhere in this Annual Report, may adversely affect our business, operating results and
financial condition. The uncertainties and risks enumerated below as well as those presented elsewhere in this Annual Report
should be considered carefully in evaluating our company and our business and the value of our securities.
Risks Relating to Our Stage of Development and Capital Structure
We may not be able to continue as
a going concern if we do not obtain additional financing by June 2016.
The Company has incurred losses since
its inception and has not demonstrated an ability to generate revenues from sales or services. These factors create substantial
doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include
any adjustment that might be necessary if the Company is unable to continue as a going concern.
The ability of the Company to continue
as a going concern is dependent on generating cash from the sale of its common stock and/or obtaining debt financing.
Our cash and cash equivalents balance
at December 31, 2015 was approximately $12,234,000. Based on our current expected level of operating expenditures, we expect to
be able to fund our operations for the next five to six months from that date. Our ability to continue as a going concern is wholly
dependent upon obtaining sufficient financing to fund our operations. Management has discussed various financing options with
financial institutions and believes that it will receive cash adequate to fund operations through December 31, 2016 however, there
can be no assurance the Company will be successful in these efforts.
Accordingly, despite our ability to secure
capital in the past, there is no assurance that additional equity or debt financing will be available to us when needed. In the
event that we are not able to secure financing, we may be forced to curtail operations, delay or stop ongoing clinical trials,
cease operations altogether or file for bankruptcy.
Our auditors have expressed substantial
doubt about our ability to continue as a going concern.
Our auditors’ report on our December
31, 2015 financial statements expressed an opinion that our capital resources as of the date of their Audit Report were not sufficient
to sustain operations or complete our planned activities for the upcoming year unless we raised additional funds. Accordingly,
our current cash level raises substantial doubt about our ability to continue as a going concern past June 2016. If we do not
obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means
that our shareholders may lose their entire investment.
Risks Relating to Our Stage of Development and Capital Structure
We have a history of losses.
Since inception
in 1996 and through December 31, 2015, we have accumulated losses totaling approximately $171,959,000. On December 31, 2015, we
had a working capital surplus of approximately $7,006,000 and stockholders’ equity of approximately $4,967,000. Our net
losses for the three most recent fiscal years have been approximately $20,904,000, $22,629,000, and $19,832,000 for 2015, 2014,
and 2013, respectively. Although from 2013 through 2015 we recognized revenue as a result of us providing subcontractor services
and the licensing of our intellectual property, we have generated no significant revenue from the sales of our proposed products.
Our ability to
generate revenues and achieve profitability will depend upon our ability to complete the development of our proposed products,
obtain the required regulatory approvals, manufacture and market and sell our proposed products. To date, we have not generated
any revenue from the commercial sale of our proposed products. No assurances can be given as to exactly when, if at all, we will
be able to fully develop, commercialize, market, sell and/or derive any, let alone material, revenues from our proposed products.
We will need to raise additional
capital to continue operations.
Since our inception,
we have funded our operations through the sale of our securities, credit facilities, the exercise of options and warrants, and
to a lesser degree, from grants and research contracts and other revenue generating activities such as licensing. As of December
31, 2015, we had cash, cash equivalents and short-term investments on hand of approximately $12,234,000. We cannot assure you
that we will be able to secure additional capital through financing transactions, including issuance of debt, licensing agreements
or grants. Our inability to license our intellectual property, obtain grants or secure additional financing will materially impact
our ability to fund our current and planned operations.
We have spent
and expect to continue spending substantial cash in the research, development, clinical and pre-clinical testing of our proposed
products with the goal of ultimately obtaining FDA approval to market such products. We will require additional capital to conduct
research and development, establish and conduct clinical and pre-clinical trials, enter into commercial-scale manufacturing arrangements
and to provide for marketing and distribution of our products. We cannot assure you that financing will be available if needed.
If additional financing is not available, we may not be able to fund our operations, develop or enhance our technologies, take
advantage of business opportunities or respond to competitive market pressures. If we exhaust our cash reserves and are unable
to secure adequate additional financing, we may be unable to meet operating obligations which could result in us initiating bankruptcy
proceedings or delaying, or eliminating some or all of our research and product development programs.
We will need to raise additional
capital to pay our indebtedness as it comes due.
We have a substantial
level of debt. As of December 31, 2015, we had approximately $8,335,000 in aggregate principal amount long-term indebtedness
outstanding. Under our amended loan and security agreement, we were required to make monthly interest only payments through September
2015; and are required to make monthly interest and principal payments of approximately $435,000 per month from October 2015 through
March 2017 and make a balloon payment for the remaining principal in April 2017. As security for such indebtedness, we have pledged
substantially all of our assets, including our intellectual property. If we are unable to make the required payments, or if we
fail to comply with the various requirements and covenants of our indebtedness, we would be in default, which would permit the
holders of our indebtedness to accelerate the maturity and require immediate repayment and lead to potential foreclosure on the
assets securing the debt. Any default under our indebtedness would have a material adverse effect on our business, operating results
and financial condition. Additionally, our amended loan and security agreement governing our $10 million loan also contains a
number of affirmative and restrictive covenants, including reporting requirements and other collateral limitations, certain limitations
on liens and indebtedness, dispositions, mergers and acquisitions, restricted payments and investments, corporate changes and
limitations on waivers and amendments to certain agreements, our organizational documents, and documents relating to debt that
is subordinate to our obligations under the credit facility. Our failure to comply with the covenants in the amended loan and
security agreement could result in an event of default that, if not cured or waived, could result in the acceleration of all or
a substantial portion of our debt and potential foreclosure on the assets securing the debt. If we are unable to refinance or
repay our indebtedness as it becomes due, including upon an event of default, we may become insolvent and be unable to continue
operations.
Risks Relating to Our Business
Our business
is dependent on the successful development of our product candidates and our ability to raise additional capital.
Our business
is significantly dependent on our product candidates which are currently at different phases of pre-clinical and clinical development.
The process to approve our product candidates is time-consuming, involves substantial expenditures of resources, and depends upon
a number of factors, including the availability of alternative treatments, and the risks and benefits demonstrated in the clinical
trials. Our success will depend on our ability to achieve scientific and technological advances and to translate such advances
into FDA-approvable, commercially competitive products on a timely basis. Failure can occur at any stage of the process. If we
are not successful in developing our product candidates, we will have invest substantial amounts of time and money without developing
revenue-producing products. As we enter a more extensive clinical program for our product candidates, the data generated in these
studies may not be as compelling as the earlier results. This, in turn, could adversely impact our ability to raise additional
capital and pursue our business plan and planned research and development efforts.
Our proposed
products are not likely to be commercially available for at least several years, if at all. Our development schedules for our
proposed products may be affected by a variety of factors, including technological difficulties, clinical trial failures, regulatory
hurdles, competitive products, intellectual property challenges and/or changes in governmental regulation, many of which will
not be within our control. Any delay in the development, introduction or marketing of our product candidates could result either
in such products being marketed at a time when their cost and performance characteristics would not be competitive in the marketplace
or in the shortening of their commercial lives. In light of the long-term nature of our projects, the unproven technology involved
and the other factors described elsewhere in this section, there can be no assurance that we will be able to successfully complete
the development or marketing of any of our proposed product candidates.
Our business
relies on technologies that we may not be able to commercially develop and we are unable to predict when or if we will be able
to earn revenues.
We have allocated
the majority of our resources to the development of our stem cell and small molecule technologies. Our ability to generate revenue
and operate profitably will depend on being able to develop these technologies for human applications. These are emerging technologies
that may have limited human application. We cannot guarantee that we will be able to develop our technologies or that if developed,
our technologies will result in commercially viable products or have any commercial utility or value. We anticipate that the commercial
sale of our proposed products and/or royalty/licensing fees related to our technologies, will be our primary sources of revenue.
We recognized revenue of approximately $10,000, $19,000, and $110,000 for the years ended December 31, 2015, 2014, and 2013, respectively
related to the licensing of certain intellectual property to third parties and certain subcontractor services that we provided.
If we are unable to develop our technologies, we may never realize any significant revenue. Additionally, given the uncertainty
of our technologies, product candidates and the need for government regulatory approval, we cannot predict when, or if ever, we
will be able to realize revenues related to our products. As a result, we will be primarily dependent on our ability to raise
capital through the sale of our securities for the foreseeable future.
Our product
development programs are based on novel technologies in an emerging field and are inherently risky.
We are subject to the risks inherent in
the development of products based on new technologies. The novel nature of therapies in the field of regenerative medicine creates
significant challenges in regard to product development and optimization, manufacturing, government regulation, third party reimbursement,
and market acceptance. For example, the pathway to regulatory approval for cell-based therapies, including our product candidates,
may be more complex and lengthy than the pathway for conventional drugs. These challenges may prevent us from developing and commercializing
products on a timely or profitable basis or at all. Regenerative medicine is still an emerging field. There can be no assurances
that we will ultimately produce any viable commercialized products and processes. Even if we are able to produce a commercially
viable product, there may be strong competitors in this field and our products may not be able to successfully compete against
them.
Our stem cell therapy programs rely
on experimental surgical devices and experimental and highly invasive surgical procedures.
We are subject to the risks inherent in
the use and development of experimental surgical devices and procedures. We have limited experience with medical devices and must
rely on outside consultants and manufacturers to develop and seek any required approvals for the device we use in connection with
our stem cell therapy program. Additionally, the surgical procedures required to administer our stem cell therapy is experimental,
highly invasive and is required to be performed by highly experienced neurosurgeons who have received special training. We cannot
guarantee consistent and safe performance of the device or the surgical procedure. A surgery related adverse event may result
in a clinical hold and may have long-term and damaging effects on our ability to complete development of the stem cell therapy
programs, including the completion of any ongoing or planned clinical trials. Even if one or more of our programs is successful
and receives marketing approval from a regulatory authority, due to the specialized nature of the device and surgical procedure,
there may not be sufficient train surgeons to administer our therapy.
We are
unable to predict when or if we will be able to earn revenues.
Given the uncertainty
of our technologies and the need for government regulatory approval, we cannot predict when, or if ever, we will be able to realize
revenues related to our products.
Our proposed
products are not likely to be commercially available for at least several or more years, if ever. Accordingly, we do not foresee
generating any significant revenue during such time. As a result, we will be primarily dependent on our ability to raise capital
through the sale of our securities to fund our operations for the foreseeable future.
Our inability
to manufacture and store our stem cells in-house that are used in our products could adversely impact our business.
We currently
outsource most of the manufacturing of our stem cells and small molecule pharmaceutical compounds to third party contractors and
as such have limited ability to adequately control the manufacturing process and the safe storage thereof. Any manufacturing or
storage irregularity, error, or failure to comply with applicable regulatory procedure would require us to find new third parties
to outsource our manufacturing and storage responsibilities or our business would be impacted. Additionally, as part of our business
plan, we are developing in-house manufacturing capabilities but there can be no assurance that such capabilities will be successfully
developed or if developed, be sufficient to meet our demands. And delays in the development of such in-house manufacturing capabilities
could adversely affect our plans.
If we are
unable to complete pre-clinical and clinical testing and trials or if clinical trials of our product candidates are prolonged,
delayed, suspended or terminated, our business and results of operations could be materially harmed.
We are currently
in clinical trials for NSI-566 and NSI-189, two of our proposed products, with regard to multiple indications. Although we have
commenced a number of trials, the ultimate outcome of the trials is uncertain. If we are unable to satisfactorily complete such
trials, or if such trials yield unsatisfactory results, we may be unable to obtain regulatory approval for and commercialize our
proposed products. No assurances can be given that our clinical trials will be completed or result in successful outcomes. A number
of events, including any of the following, could delay the completion of our planned clinical trials and negatively impact our
ability to obtain regulatory approval for, and to market and sell, a particular product candidate:
| · | conditions
imposed on us by the FDA or any foreign regulatory authority regarding the scope or design
of our clinical trials; |
| · | delays
in obtaining, or our inability to obtain, required approvals from institutional review
boards, or IRBs, or other reviewing entities at clinical sites selected for participation
in our clinical trials; |
| · | insufficient
supply or deficient quality of our product candidates or other materials necessary to
conduct our clinical trials; |
| · | delays
in obtaining regulatory agency agreement for the conduct of our clinical trials; |
| · | lower
than anticipated enrollment and retention rate of subjects in clinical trials; |
| · | serious
and unexpected side effects experienced by patients in our clinical trials which are
related to the use of our product candidates; or |
| · | failure
of our third-party contractors to meet their contractual obligations to us in a timely
manner. |
Clinical trials
may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended
or terminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board,
or DSMB, overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors. Additionally, changes
in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes.
Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the cost, timing
or successful completion of a clinical trial. We do not know whether our clinical trials will be conducted as planned, will need
to be restructured or will be completed on schedule, if at all. Delays in our clinical trials will result in increased development
costs for our drug candidates. In addition, if we experience delays in the completion of, or if we terminate, any of our clinical
trials, the commercial prospects for our drug candidates may be harmed and our ability to generate product revenues will be jeopardized.
Furthermore, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also
ultimately lead to the denial of regulatory approval of a drug candidate. If regulatory authorities do not approve our products
or if we fail to maintain regulatory compliance, we would be unable to commercialize our proposed products, and our business and
results of operations could be materially harmed.
The results
of pre-clinical studies and clinical trials may not be predictive of the results of our later-stage clinical trials and our proposed
products may not have favorable results in later-stage clinical trials or receive regulatory approval.
Positive results
from pre-clinical studies or our Phase I and Phase II trials should not be relied upon as evidence that our clinical trials will
succeed. Even if our product candidates achieve positive results in pre-clinical studies or during our Phase I and Phase II studies,
we will be required to demonstrate through further clinical trials that our product candidates are safe and effective for use
in a diverse population before we can seek regulatory approvals for their commercial sale. There is typically an extremely high
rate of attrition from the failure of product candidates as they proceed through clinical trials. If any product candidate fails
to demonstrate sufficient safety and efficacy in any clinical trial, then we may experience potentially significant delays in,
or be required to abandon, development of that product candidate. Additionally, failure to demonstrate safety and efficacy results
acceptable to the FDA in later stage trials could impair our development prospects and even prevent regulatory approval of our
current and future product candidates. Any such delays or abandonment in our development efforts of any of our product candidates
would materially impair our ability to generate revenues.
Our research and development
expenses are subject to uncertainty.
Factors affecting our research and
development expenses include, but are not limited to:
| · | competition
from companies that have substantially greater assets and financial resources than we
have; |
| · | need for acceptance
of our proposed products; |
| · | ability to
anticipate and adapt to a competitive market and rapid technological developments; |
| · | amount and
timing of operating costs and capital expenditures relating to outsourcing of manufacturing
and management of pre-clinical and clinical trials; |
| · | need to rely
on multiple levels of outside funding due to the length of drug development cycles and
governmental approved protocols associated with the pharmaceutical industry; and |
| · | dependence
upon key personnel including key independent consultants and advisors. |
There can be
no guarantee that our research and development expenses will be consistent from period to period. We may be required to accelerate
or delay incurring certain expenses depending on the results of our studies and the availability of adequate funding.
We are subject to numerous risks
inherent in conducting clinical trials.
We outsource
the management of our clinical trials to third parties. Agreements with clinical investigators and medical institutions for clinical
testing and with other third parties for data management services, place substantial responsibilities on these parties that, if
unmet, could result in delays in, or termination of, our clinical trials. For example, if any of our clinical trial sites fail
to comply with FDA-approved good clinical practices, we may be unable to use the data gathered at those sites. If these clinical
investigators, medical institutions or other third parties do not carry out their contractual duties or obligations or fail to
meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to
adhere to our clinical protocols or for other reasons, our clinical trials may be extended, delayed or terminated, and we may
be unable to obtain regulatory approval for, or successfully commercialize, our proposed products. Delays in recruitment, lack
of clinical benefit or unacceptable side effects would delay or prevent the completion of our clinical trials.
We or our regulators
may suspend or terminate our clinical trials for a number of reasons. We may voluntarily suspend or terminate our clinical trials
if at any time we believe they present an unacceptable risk to the patients enrolled in our clinical trials or do not demonstrate
clinical benefit. In addition, regulatory agencies may order the temporary or permanent discontinuation of our clinical trials
at any time if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements
or that they present an unacceptable safety risk to the patients enrolled in our clinical trials.
Our clinical
trial operations are subject to regulatory inspections at any time. If regulatory inspectors conclude that we or our clinical
trial sites are not in compliance with applicable regulatory requirements for conducting clinical trials, we may receive reports
of observations or warning letters detailing deficiencies, and we will be required to implement corrective actions. If regulatory
agencies deem our responses to be inadequate, or are dissatisfied with the corrective actions we or our clinical trial sites have
implemented, our clinical trials may be temporarily or permanently discontinued, we may be fined, we or our investigators may
be precluded from conducting any ongoing or any future clinical trials, the government may refuse to approve our marketing applications
or allow us to manufacture or market our products, and we may be criminally prosecuted.
The lengthy approval
process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval
for our proposed products, which would materially harm our business, results of operations and prospects.
There are
no assurances that we will be able to submit a pre-market application or obtain FDA approval in order to market and sell our products.
There can be
no assurance that even if the clinical trial of any potential product candidate is successfully initiated and completed, that
we will be able to submit a Biologics License Application (“BLA”) or New Drug Application (“NDA”) to the
FDA, or that any BLA or NDA that we submit will be approved in a timely manner, if at all. If we are unable to submit a BLA or
NDA with respect to any future product, or if such application is not approved by the FDA, we will be unable to commercialize
that product. The FDA can and does reject BLAs and NDAs and may require additional clinical trials, even when product candidates
performed well or achieved favorable results during initial clinical trials. If we fail to commercialize our product candidates
and are unable to generate sufficient revenues to attain profitability our business will be adversely effected.
The manufacturing
of stem cell-based therapeutic products is novel and dependent upon specialized key materials.
The manufacturing
of stem cell-based therapeutic products is a complicated and difficult process, dependent upon substantial know-how and subject
to the need for continual process improvements. We depend almost exclusively on third party manufacturers to supply our cells.
In addition, our suppliers’ ability to scale-up manufacturing to satisfy the various requirements of our planned clinical
trials is uncertain. Manufacturing irregularities or lapses in quality control could have a material adverse effect on our business.
Additionally, many of the materials that we use to prepare our cell-based products are highly specialized, complex and available
from only a limited number of suppliers. The loss of one or more of these sources would likely delay our ability to conduct planned
clinical trials and otherwise adversely affect our business.
We may
be subject to litigation that will be costly to defend or pursue and uncertain in its outcome.
Our business
may bring us into conflict with licensees, licensors, or others with whom we have contractual or other business relationships
or with our competitors or others whose interests differs from ours. If we are unable to resolve these conflicts on terms that
are satisfactory to all parties, we may become involved in litigation brought by or against such parties. Any litigation is likely
to be expensive and may require a significant amount of management's time and attention, at the expense of other aspects of our
business. The outcome of litigation is always uncertain, and in some cases could include judgments against us which could have
a materially adverse effect on our business.
We may not be able to obtain necessary licenses to third-party patents and other rights.
A number of companies,
universities and research institutions have filed patent applications or have received patents relating to technologies in our
field. We cannot predict which, if any, of these applications will issue as patents or how many of these issued patents will be
found valid and enforceable. There may also be existing issued patents on which we would infringe by the commercialization of
our product candidates. If so, we may be prevented from commercializing these products unless the third party is willing to grant
a license to us. We may be unable to obtain licenses to the relevant patents at a reasonable cost, if at all, and may also be
unable to develop or obtain alternative non-infringing technology. If we are unable to obtain such licenses or develop non-infringing
technology at a reasonable cost, our business could be significantly harmed. Also, any infringement lawsuits commenced against
us may result in significant costs, divert our management’s attention and result in an award against us for substantial
damages, or potentially prevent us from continuing certain operations.
We may
not be able to obtain government or third-party payor coverage and reimbursement.
Our ability to
successfully commercialize our product candidates, if approved, depends to a significant degree on the ability of patients to
be reimbursed for the costs of such products and related treatments. We cannot assure you that reimbursement in the U.S. or in
foreign countries will be available for any products developed, or, if available, will not decrease in the future, or that reimbursement
amounts will not reduce the demand for, or the price of, our products. There is considerable pressure to reduce the cost of therapeutic
products. Government and other third party payors are increasingly attempting to contain health care costs by limiting both coverage
and the level of reimbursement for new therapeutic products and by refusing, in some cases, to provide any coverage for uses of
approved products for disease indications for which the FDA or other relevant authority has not granted marketing approval. Moreover,
in some cases, government and other third party payors have refused to provide reimbursement for uses of approved products for
disease indications for which the FDA or other relevant authority has granted marketing approval. Significant uncertainty exists
as to the reimbursement status of newly approved health-care products or novel therapies such as ours. We cannot predict what
additional regulation or legislation relating to the health care industry or third-party coverage and reimbursement may be enacted
in the future or what effect such regulation or legislation may have on our business. If additional regulations are overly onerous
or expensive or if healthcare related legislation makes our business more expensive or burdensome than originally anticipated,
we may be forced to significantly downsize our business plans or completely abandon the current business model.
Our products may not be profitable
due to manufacturing costs and our inability to receive favorable pricing.
Our products
may be significantly more expensive to manufacture than other drugs or therapies currently on the market today due to a fewer
number of potential manufacturers, greater level of needed expertise and other general market conditions affecting manufacturers
of our proposed products. Even if we are able to receive approval for the reimbursement of our proposed products the amount of
reimbursement may be significantly less than the manufacturing costs of our products. Additionally, other market factors may limit
the price which we can charge for our proposed products while still being competitive. Accordingly, even if we are successful
in developing our proposed products, we may not be able to charge a high enough price for us to earn a profit.
We are dependent on the acceptance
of our products by the healthcare community.
Our product candidates,
if approved for marketing, may not achieve market acceptance since hospitals, physicians, patients or the medical community, in
general, may decide not to accept and utilize these products. The products that we are attempting to develop represent substantial
departures from established treatment methods and will compete with a number of more conventional therapies marketed by major
pharmaceutical companies. If the healthcare community does not accept our products for any reason, our business will be materially
harmed.
We depend on key employees and
consultants for our continued operations and future success.
We are highly
dependent on our chief executive officer, chief scientific officer and outside consultants. Although we have entered
into employment and consulting agreements with these parties, these agreements can be terminated at any time. The loss
of any of these key employees or consultants could adversely affect our opportunities and materially harm our future prospects. In
addition, we anticipate growth and expansion into areas and activities requiring additional expertise, such as clinical testing,
regulatory compliance, manufacturing and marketing. We anticipate the need for additional management personnel as well
as the development of additional expertise by existing management personnel. There is intense competition for qualified personnel
in the areas of our present and planned activities, and there can be no assurance that we will be able to attract and retain the
qualified personnel necessary for the development our business.
The employment contracts of certain key employees contain significant anti-termination provisions which could make changes
in management difficult or expensive.
We have entered
into employment agreements with Messrs. Daly and Lloyd Jones and Dr. Johe. Each of these employment agreements require the payment
of severance, in the event certain conditions are met, if these individuals are terminated. These provisions will make the replacement
of these employees very costly and could cause difficulty in effecting a change in control.
Our competition has significantly
greater experience and financial resources.
The biotechnology
industry is characterized by rapid technological developments and a high degree of competition. We compete against numerous companies,
many of which have substantially greater resources. Several such enterprises have initiated cell therapy research programs and/or
efforts to treat the same diseases which we target. Given our current stage of development and resources, it may be extremely
difficult for us to compete against more developed companies.
As a result,
our proposed products could become obsolete before we recoup any portion of our related research and development and commercialization
expenses. Competition in the biopharmaceutical industry is based significantly on scientific and technological factors. These
factors include the availability of patent and other protection for technology and products, the ability to commercialize technological
developments and the ability to obtain governmental approval for testing, manufacturing and marketing. We compete with specialized
biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies
that are applying biotechnology to their operations. Many major pharmaceutical companies have developed or acquired internal biotechnology
capabilities or made commercial arrangements with other biopharmaceutical companies. These companies, as well as academic institutions
and governmental agencies and private research organizations, also compete with us in recruiting and retaining highly qualified
scientific personnel and consultants. Our ability to compete successfully with other companies in the pharmaceutical field will
also depend to a considerable degree on the continuing availability of capital to us.
We believe that
our proposed products under development and in pre-clinical testing and clinical trials will address unmet medical needs for those
indications for which we are focusing our development efforts. Our competition will be determined in part by the potential indications
for which our proposed products are developed and ultimately approved by regulatory authorities. Additionally, the timing of market
introduction of some of our proposed products or of competitors’ products may be an important competitive factor. Accordingly,
the relative speed with which we can develop our proposed products, complete preclinical testing, clinical trials and approval
processes and supply commercial quantities to market is expected to be important competitive factors. We expect that competition
among products approved for sale will be based on various factors, including product efficacy, safety, reliability, availability,
price and patent position.
Our outsource model depends
on third parties to assist in developing and testing our proposed products.
Our strategy
for the development, clinical and pre-clinical testing and commercialization of our proposed products is based in large part on
an outsource model. This model requires us to engage third parties in order to further develop our technology and products as
well as for the day to day operations of our business. In the event we are not able to enter into such relationships in the future,
our ability to operate and develop products may be seriously hindered or we may be required to spend considerable time and resources
to bring such functions in-house. Either outcome could result in our inability to develop a commercially feasible product or in
the need for substantially more working capital to complete the research in-house.
The commercialization of therapeutic
products exposes us to product liability claims.
Product liability
claims could result in substantial litigation costs and damage awards against us. We attempt to mitigate this risk by obtaining
and maintaining appropriate insurance coverage. Historically, we have obtained liability insurance that covers our clinical trials.
If we begin commercializing products, we will need to increase our insurance coverage. We may not be able to obtain insurance
on acceptable terms, if at all, and the policy limits on our insurance policies may be insufficient to cover our liability.
We currently
rely heavily upon third party FDA-regulated manufacturers and suppliers for our products
We currently
manufacture our cells both in-house and on an outsource basis. We outsource the manufacturing of our pharmaceutical compound to
third party manufacturers. We manufacture cells in-house which are not required to meet stringent FDA requirements. We use these
cells in our research and collaborative programs. At present, we outsource all the manufacturing and storage of our stem cells
and pharmaceuticals compound to be used in pre-clinical and clinical works, and which are subject to higher FDA requirements,
to Charles River Laboratories, Inc., of Wilmington, Massachusetts (stem cells) and Albany Molecular Resources, Inc. (small molecule).
Failure by our contract manufacturer to achieve and maintain high manufacturing standards could result in patient injury or death,
product recalls or withdrawals, delays or failures in testing or delivery, cost overruns, or other problems that could seriously
hurt our business. Contract manufacturers may encounter difficulties involving production yields, quality control, and quality
assurance. These manufacturers are subject to ongoing periodic and unannounced inspections by the FDA and corresponding state
and foreign agencies to ensure strict compliance with cGMPs, GTPs and other applicable government regulations and corresponding
foreign standards; however, we do not have control over third-party manufacturers’ compliance with these regulations and
standards.
Because manufacturing
facilities are subject to regulatory oversight and inspection, failure to comply with regulatory requirements could result in
material manufacturing delays and product shortages, which could delay or otherwise negatively impact our clinical trials and
product development. Moreover, we do not have quantity or volume commitment orders from these manufacturers and we cannot assure
you that the manufacturers will be able to manufacture in the quantity we require on a timely basis or at all. In the event we
are required to seek alternative third party suppliers or manufacturers, they may require us to purchase a minimum amount of materials
or could require other unfavorable terms. Any such event would materially impact our business prospects and could delay the development
of our products. Moreover, there can be no assurance that any manufacturer or supplier that we select will be able to supply our
products in a timely or cost effective manner or in accordance with applicable regulatory requirements or our specifications.
In addition, due to the novelty of our products and product development, there can be no assurances that we would be able to find
other suitable third party FDA-regulated manufacturers on a timely basis and at terms reasonable to us. Even if we were to locate
alternative manufacturers there may be delays before they are able to begin manufacturing. Failure to secure such third party
manufacturers or suppliers would materially impact our business.
We rely
on third parties to conduct our clinical trials and perform data collection and analysis, which may result in costs and delays
that prevent us from successfully commercializing our product candidates.
We do not have
the in-house capability to conduct clinical trials for our product candidates. We rely, and will rely in the future, on medical
institutions, clinical investigators, contract research organizations, contract laboratories, and collaborators to perform data
collection and analysis and other aspects of our clinical trials. Our reliance on these third parties for clinical development
activities results in reduced control over these activities. Furthermore, these third parties may also have relationships with
other entities, some of which may be our competitors. Our preclinical activities or clinical trials conducted in reliance on third
parties may be delayed, suspended, or terminated if:
| · | the
third parties do not successfully carry out their contractual duties; |
| · | the
third parties fail to meet FDA and other regulatory obligations or expected deadlines; |
| · | we
replace a third party for any reason; or |
| · | the
quality or accuracy of the data obtained by third parties is compromised due to their
failure to adhere to clinical protocols, regulatory requirements, or for other reasons. |
Third party performance
failures may increase our development costs, delay our ability to obtain regulatory approval, and delay or prevent the commercialization
of our product candidates. While we believe that there are numerous alternative sources to provide these services, in the event
that we seek such alternative sources, we may not be able to enter into replacement arrangements without incurring delays or additional
costs.
Risks Relating to Intellectual
Property
We may not be able to withstand
challenges to our intellectual property rights.
We rely on our
intellectual property, including issued and applied-for patents, as the foundation of our business. Our intellectual property
rights may come under challenge. No assurances can be given that our current and potential future patents will survive such challenges.
For example, in 2005 one of our patents was challenged in the USPTO. Although we prevailed in this particular matter, these cases
are complex, lengthy, expensive, and could potentially be adjudicated adversely to our interests, removing the protection afforded
by an issued patent. The viability of our business would suffer if such patent protection were limited or eliminated. Moreover,
the costs associated with defending or settling intellectual property claims would likely have a material adverse effect on our
business and future prospects.
We may not be able to adequately
protect against the piracy of the intellectual property in foreign jurisdictions.
We conduct research
in countries outside of the U.S., including through our subsidiary in the People’s Republic of China. A number of our competitors
are located in these countries and may be able to access our technology or test results. The laws protecting intellectual property
in some of these countries may not adequately protect our trade secrets and intellectual property. The misappropriation of our
intellectual property may materially impact our position in the market and any competitive advantages, if any, that we may have.
Risks Relating to Our Common Stock
The market price for our common
shares is particularly volatile.
The market for
our common shares is characterized by significant price volatility when compared to seasoned issuers, and we expect that our share
price will continue to be more volatile than those of a seasoned issuer. The volatility in our share price is attributable to
a number of factors. Mainly however, we are a speculative or “risky” investment due to our limited operating history,
lack of significant revenues to date and the uncertainty of FDA approval. As a consequence of this enhanced risk, more risk-adverse
investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be
more inclined to sell their shares on the market more quickly and at greater discounts than would be the case with the stock of
a seasoned issuer. Additionally, in the past, plaintiffs have often initiated securities class action litigation against a company
following periods of volatility in the market price of its securities. We may in the future be the target of similar litigation.
Securities litigation could result in substantial costs and liabilities and could divert management’s attention and resources.
The following
factors may add to the volatility in the price of our common shares: actual or anticipated variations in our quarterly or annual
operating results; the results of clinical trials for our product candidates;
FDA’s determination with respect to filings for new clinical studies, new drug applications and new indications; government
regulations; announcements of significant acquisitions, strategic partnerships or joint ventures; our capital commitments; offerings
of our securities and additions or departures of our key personnel. Many of these factors are beyond our control and may decrease
the market price of our common shares, regardless of our operating performance. We cannot make any predictions or projections
as to what the prevailing market price for our common shares will be at any time, including as to whether our common shares will
sustain their current market prices, or as to what effect the sale of shares or the availability of common shares for sale at
any time will have on the prevailing market price.
The requirements
of being a public company may strain our resources, divert management’s attention and affect our ability to attract and
retain qualified board members.
As a public company,
we incur significant legal, accounting and other expenses that we would not incur as a private company, including costs associated
with public company reporting requirements. We also incur costs associated with the Sarbanes-Oxley Act of 2002, as amended, the
Dodd-Frank Wall Street Reform and Consumer Protection Act and related rules implemented or to be implemented by the SEC and the
Nasdaq. The expenses incurred by public companies generally for reporting, insurance and corporate governance purposes have been
increasing. We expect these rules and regulations to increase our legal and financial compliance costs and to make some activities
more time-consuming and costly. These laws and regulations could also make it more difficult or costly for us to obtain certain
types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and
coverage or incur substantially higher costs to obtain the same or similar coverage. These laws and regulations could also make
it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as
our executive officers and may divert management’s attention. Furthermore, if we are unable to satisfy our obligations as
a public company, we could be subject to delisting of our common stock, fines, sanctions and other regulatory action and potentially
civil litigation.
We have
never paid a cash dividend and do not intend to pay cash dividends on our common stock in the foreseeable future.
We have never
paid cash dividends nor do we anticipate paying cash dividends in the foreseeable future. Accordingly, any return on your investment
will be as a result of stock appreciation if any. Additionally, we are prohibited from paying any cash dividends under the terms
of our loan and security agreement.
Our anti-takeover
provisions may delay or prevent a change of control, which could adversely affect the price of our common stock.
Our amended and
restated certificate of incorporation and amended and restated bylaws contain provisions that may make it difficult to remove
our board of directors and management and may discourage or delay “change of control” transactions, which could adversely
affect the price of our common stock. These provisions include, among others:
| · | our
board of directors is divided into three classes, with each class serving for a staggered
three-year term, which prevents stockholders from electing an entirely new board of directors
at an annual meeting; |
| · | advance
notice procedures that stockholders must comply with in order to nominate candidates
to our board of directors and propose matters to be brought before an annual meeting
of our stockholders may discourage or deter a potential acquirer from conducting a solicitation
of proxies to elect the acquirer’s own slate of directors or otherwise attempting
to obtain control of our company; and |
| · | our
board of directors may, without stockholder approval, issue series of preferred stock,
or rights to acquire preferred stock, that could dilute the interest of, or impair the
voting power of, holders of our common stock or could also be used as a method of discouraging,
delaying or preventing a change of control. |
If securities
or industry analysts do not publish research reports, or publish unfavorable research about our business, the price and trading
volume of our common stock could decline.
The trading market
for our common stock will depend in part on the research and reports that securities or industry analysts publish about us and
our business. We currently have limited research coverage by securities and industry analysts. In the event an analyst downgrades
our securities, the price of our securities would likely decline. If analysts cease to cover us or fails to publish regular reports
on us, interest in our securities could decrease, which could cause the price of our common stock and other securities and their
trading volume to decline.
Our charter
documents and Delaware law contain provisions that could make it difficult for us to be acquired in a transaction that might be
beneficial to our stockholders.
Our board of
directors has the authority to issue shares of preferred stock and to fix the rights, preferences, privileges, and restrictions
of these shares without stockholder approval. Additionally, our Bylaws provide for a staggered board. These
provisions in our charter documents, along with certain provisions under Delaware law, may make it more difficult for a third
party to acquire us or discourage a third party from attempting to acquire us, even if the acquisition might be beneficial to
our stockholders.
Our board
of directors has broad discretion to issue additional securities which might dilute the net tangible book value per share of our
common stock for existing stockholders.
We are entitled
under our certificate of incorporation to issue up to 300,000,000 shares of common stock and 7,000,000 “blank check”
shares of preferred stock. Shares of our blank check preferred stock provide our board of directors with broad authority to determine
voting, dividend, conversion, and other rights. As of December 31, 2015 we have issued and outstanding 92,005,705 shares of common
stock and we have 39,537,741 shares of common stock reserved for future grants under our equity compensation plans and for issuances
upon the exercise or conversion of currently outstanding options, warrants and convertible securities. As of December 31, 2015,
we had no shares of preferred stock issued and outstanding. Accordingly, we are entitled to issue up to 168,456,555 additional
shares of common stock and 7,000,000 additional shares of “blank check” preferred stock. Our board may generally issue
those common and preferred shares, or convertible securities to purchase those shares, without further approval by our shareholders.
Any preferred shares we may issue will have such rights, preferences, privileges and restrictions as may be designated from time-to-time
by our board, including preferential dividend rights, voting rights, conversion rights, redemption rights and liquidation provisions.
It is likely that we will be required to issue a large amount of additional securities to raise capital in order to further our
development and marketing plans. It is also likely that we will be required to issue a large amount of additional securities to
directors, officers, employees and consultants as compensatory grants in connection with their services, both in the form of stand-alone
grants or under our various stock plans. The issuance of additional securities may cause substantial dilution to our shareholders.
Risks Related
to Government Regulation and Approval of our Product Candidates.
The regulatory
approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and
our products may not receive regulatory approval.
The time required to obtain approval by
the FDA and comparable foreign authorities is inherently unpredictable but typically takes many years following the commencement
of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition,
approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course
of a drug candidate’s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for
any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to
develop in the future will ever obtain regulatory approval.
Our drug candidates could fail to receive regulatory approval
for many reasons, including the following:
| · | the
FDA or comparable foreign regulatory authorities may disagree with the design or implementation
of our clinical trials; |
| · | we
may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory
authorities that a product candidate is safe and effective for its proposed indication; |
| · | the
results of clinical trials may not meet the level of statistical significance required
by the FDA or comparable foreign regulatory authorities for approval; |
| · | we
may be unable to demonstrate that a product candidate’s clinical and other benefits
outweigh its safety risks; |
| · | the
FDA or comparable foreign regulatory authorities may disagree with our interpretation
of data from preclinical studies or clinical trials; |
| · | the
data collected from clinical trials of our product candidates may not be sufficient to
support the submission of a BLA, NDA or other submission or to obtain regulatory approval
in the United States or elsewhere; |
| · | the
FDA or comparable foreign regulatory authorities may fail to approve the manufacturing
processes or facilities of third-party manufacturers with which we contract for clinical
and commercial supplies; or |
| · | the
approval policies or regulations of the FDA or comparable foreign regulatory authorities
may significantly change in a manner rendering our clinical data insufficient for approval. |
We are currently
undertaking clinical trials for our lead products candidates NSI-189 and NSI-566. We cannot assure you that we will
successfully complete any clinical trials in connection with such INDs. Further, we cannot predict when we might first
submit any product license application (NDA or BLA) for FDA approval or whether any such product license application will be granted
on a timely basis, if at all. Moreover, we cannot assure you that FDA approvals for any products developed by us will
be granted on a timely basis, if at all. Any delay in obtaining, or failure to obtain, such approvals could have a material adverse
effect on the marketing of our products and our ability to generate product revenue.
In addition,
even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited
indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on
the performance of costly post-marketing clinical trials, or may approve a drug candidate with a label that does not include the
labeling claims necessary or desirable for the successful commercialization of that drug candidate. Any of the foregoing scenarios
could materially harm the commercial prospects for our drug candidates.
Development of our product candidates is subject to extensive government regulation.
Our research
and development efforts, as well as any future clinical trials, and the manufacturing and marketing of any products we may develop,
will be subject to, and restricted by, extensive regulation by governmental authorities in the U.S. and other countries. The process
of obtaining FDA and other necessary regulatory approvals is lengthy, expensive and uncertain. FDA and other legal and regulatory
requirements applicable to our proposed products could substantially delay or prevent us from initiating additional clinical trials.
We may fail to obtain the necessary approvals to commence clinical testing or to manufacture or market our potential products
in reasonable time frames, if at all. In addition, the U.S. Congress and other legislative bodies may enact regulatory reforms
or restrictions on the development of new therapies that could adversely affect the regulatory environment in which we operate
or the development of any products we may develop.
A substantial
portion of our research and development entails the use of stem cells obtained from human tissue. The U.S. federal and state governments
and other jurisdictions impose restrictions on the acquisition and use of human tissue, including those incorporated in federal
Good Tissue Practice, or “GTP,” regulations. These regulatory and other constraints could prevent us from obtaining
cells and other components of our products in the quantity or of the quality needed for their development or commercialization.
These restrictions change from time to time and may become more onerous. Additionally, we may not be able to identify or develop
reliable sources for the cells necessary for our potential products — that is, sources that follow all state and federal
laws and guidelines for cell procurement. Certain components used to manufacture our stem and progenitor cell product candidates
will need to be manufactured in compliance with the FDA’s GMP. Accordingly, we will need to enter into supply agreements
with companies that manufacture these components to GMP standards. There is no assurance that we will be able to enter into any
such agreements.
Noncompliance
with applicable regulatory requirements can subject us, our third party suppliers and manufacturers and our other collaborators
to administrative and judicial sanctions, such as, among other things, warning letters, fines and other monetary payments, recall
or seizure of products, criminal proceedings, suspension or withdrawal of regulatory approvals, interruption or cessation of clinical
trials, total or partial suspension of production or distribution, injunctions, limitations on or the elimination of claims we
can make for our products, refusal of the government to enter into supply contracts or fund research, or government delay in approving
or refusal to approve new drug applications.
We cannot predict if or when
we will be able to commercialize our products due to regulatory constraints.
Federal, state
and local governments and agencies in the U.S. (including the FDA) and governments in other countries have significant regulations
in place that govern many of our activities. We are, or may become, subject to various federal, state and local laws,
regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental
use of animals and the use and disposal of hazardous or potentially hazardous substances used in connection with its research
and development work. The preclinical testing and clinical trials of our proposed products are subject to extensive government
regulation that may prevent us from creating commercially viable products. In addition, our sale of any commercially viable product
will be subject to government regulation from several standpoints, including manufacturing, advertising, marketing, promoting,
selling, labeling and distributing. If, and to the extent that, we are unable to comply with these regulations, our
ability to earn revenues, if any, will be materially and negatively impacted.
If our
clinical trials fail to demonstrate that any of our product candidates are safe and effective for the treatment of particular
diseases, the FDA may require us to conduct additional clinical trials or may not grant us marketing approval for such product
candidates for those diseases.
We are not permitted
to market our product candidates in the United States until we receive approval of a BLA or NDA from the FDA. Before obtaining
regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate with evidence
gathered in preclinical and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction
of the FDA and, with respect to approval in other countries, similar regulatory authorities in those countries, that the product
candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls
used to produce the product are compliant with applicable statutory and regulatory requirements. Our failure to adequately demonstrate
the safety and effectiveness of any of our product candidates for the treatment of particular diseases may delay or prevent our
receipt of the FDA’s approval and, ultimately, may prevent commercialization of our product candidates for those diseases.
The FDA has substantial discretion in deciding whether, based on the benefits and risks in a particular disease, any of our product
candidates should be granted approval for the treatment of that particular disease. Even if we believe that a clinical trial or
trials has demonstrated the safety and statistically significant efficacy of any of our product candidates for the treatment of
a disease, the results may not be satisfactory to the FDA. Preclinical and clinical data can be interpreted by the FDA and other
regulatory authorities in different ways, which could delay, limit or prevent regulatory approval. If regulatory delays are significant
or regulatory approval is limited or denied altogether, our financial results and the commercial prospects for those of our product
candidates involved will be harmed, and our prospects for profitability will be significantly impaired.
Satisfaction
of these and other regulatory requirements is costly, time consuming, uncertain, and subject to unanticipated delays. Despite
our efforts, our drug candidates may not:
| · | offer
improvement over existing comparable products; |
| · | be
proven safe and effective in clinical trials; or |
| · | meet
applicable regulatory standards. |
In addition,
in the course of its review of a BLA or NDA or other regulatory application, the FDA or other regulatory authorities may conduct
audits of the practices and procedures of a company and its suppliers and contractors concerning manufacturing, clinical study
conduct, non-clinical studies and several other areas. If the FDA and/or other regulatory authorities conducts an audit relating
to a BLA, NDA or other regulatory application and finds a significant deficiency in any of these or other areas, the FDA or other
regulatory authorities could delay or not approve such BLA, NDA or other regulatory application. If regulatory delays are significant
or regulatory approval is limited or denied altogether, our financial results and the commercial prospects for those of our products
or product candidates involved will be harmed, and our prospects for profitability will be significantly impaired.
Both before
and after marketing approval, our product candidates are subject to extensive and rigorous ongoing regulatory requirements and
continued regulatory review, and if we fail to comply with these continuing requirements, we could be subject to a variety of
sanctions.
Both before and
after the approval of our product candidates, we, our product candidates, our operations, our facilities, our suppliers, and our
contract manufacturers, contract research organizations, and contract testing laboratories are subject to extensive regulation
by governmental authorities in the United States and other countries, with regulations differing from country to country. In the
United States, the FDA regulates, among other things, the pre-clinical testing, clinical trials, manufacturing, safety, efficacy,
potency, labeling, packaging, adverse event reporting, storage, record keeping, quality systems, advertising, promotion, sale
and distribution of therapeutic products. These requirements include submissions of safety and other post-marketing information
and reports, registration, as well as continued compliance with cGMP, requirements and current good clinical practice, or cGCP,
requirements for any clinical trials that we conduct post-approval. Failure to comply with applicable requirements could result
in, among other things, one or more of the following actions: restrictions on the marketing of our products or their manufacturing
processes, notices of violation, untitled letters, warning letters, civil penalties, fines and other monetary penalties, unanticipated
expenditures, delays in approval or refusal to approve a product candidate, suspension or withdrawal of regulatory approvals,
product, seizure or detention, voluntary or mandatory product recalls and related publicity requirements, interruption of manufacturing
or clinical trials, operating restrictions, injunctions, import or export bans, and criminal prosecution. We or the FDA, or an
institutional review board, may suspend or terminate human clinical trials at any time on various grounds, including a finding
that the subjects are being exposed to an unacceptable health risk.
The FDA’s policies may change and
additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates.
If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we
are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely
affect our business, prospects and ability to achieve or sustain profitability.
If side effects are identified during
the time our drug candidates are in development or after they are approved and on the market, we may choose to or be required
to perform lengthy additional clinical trials, discontinue development of the affected drug candidate, change the labeling of
any such products, or withdraw any such products from the market, any of which would hinder or preclude our ability to generate
revenues.
Undesirable side effects caused by our
drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. The drug-related
side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential
product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Even
if any of our drug candidates receives marketing approval, as greater numbers of patients use a drug following its approval, an
increase in the incidence of side effects or the incidence of other post-approval problems that were not seen or anticipated during
pre-approval clinical trials could result in a number of potentially significant negative consequences, including:
| · | regulatory
authorities may withdraw their approval of the product; |
| · | regulatory
authorities may require the addition of labeling statements, such as warnings or contraindications; |
| · | we
may be required to change the way the product is administered, conduct additional clinical
trials or change the labeling of the product; |
| · | we
could be sued and held liable for harm caused to patients; and |
| · | our
reputation may suffer. |
Any of these events could substantially
increase the costs and expenses of developing, commercializing and marketing any such drug candidates or could harm or prevent
sales of any approved products.
Even if our product candidates receive
regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States.
In order to market any products outside
of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding
safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative
review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval.
The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United
States as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure
or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure
to obtain regulatory approval in other countries or any delay or setback in obtaining such approval would impair our ability to
develop foreign markets for our drug candidates.
Our product candidates for which
we intend to seek approval as biologic products may face competition sooner than anticipated.
We expect our stem cell product candidates
to be regulated by the FDA as biologic products and we intend to seek approval for these products pursuant to the BLA pathway.
The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for the approval of biosimilar
and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and
approve biosimilar biologics, including the possible designation of a biosimilar as “interchangeable” based on its
similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA
until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted
and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it
is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a
material adverse effect on the future commercial prospects for our biologic products.
We believe that any of our product candidates
approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that
this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our drug candidates
to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated.
Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way
that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of
marketplace and regulatory factors that are still developing.
| ITEM 1B. | UNRESOLVED
STAFF COMMENTS |
None
We currently operate two facilities located
in the United States and one facility located in China. Our corporate offices and primary research facilities are located in Germantown,
Maryland, where we license approximately 3,100 square feet. This license provides for monthly payments of approximately $10,200
per month with the term expiring on December 31, 2016.
In 2015, we entered into a lease consisting
of approximately 3,100 square feet of research space in San Diego, California. This lease provides for current monthly payments
of approximately $11,000 and expires on August 31, 2018.
We also lease a research facility in People’s
Republic of China. This lease expires on September 30, 2018 with lease payments of approximately $3,200 per month.
As of the date of this Annual Report,
there are no material pending legal or governmental proceedings relating to our company or properties to which we are a party,
and to our knowledge there are no material proceedings to which any of our directors, executive officers or affiliates are a party
adverse to us or which have a material interest adverse to us.
| ITEM 4. | MINE
SAFETY DISCLOSURE |
Not Applicable
PART II
| ITEM 5. | MARKET
FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES
OF EQUITY SECURITIES |
Market Information
Our common stock is traded on The Nasdaq
Capital Market under the symbol "CUR." The following table sets forth, for the periods indicated, the high and low sale
prices for our common stock.
| |
High | | |
Low | |
2015 | |
| | |
| |
First Quarter | |
$ | 3.92 | | |
$ | 1.78 | |
Second Quarter | |
$ | 2.39 | | |
$ | 1.46 | |
Third Quarter | |
$ | 2.02 | | |
$ | 1.02 | |
Fourth Quarter | |
$ | 1.35 | | |
$ | 0.98 | |
2014 | |
| | | |
| | |
First Quarter | |
$ | 4.80 | | |
$ | 2.76 | |
Second Quarter | |
$ | 4.81 | | |
$ | 2.96 | |
Third Quarter | |
$ | 4.25 | | |
$ | 2.67 | |
Fourth Quarter | |
$ | 3.39 | | |
$ | 2.12 | |
Holders
As of February 28, 2016 our common stock
was held by approximately 326 record holders. Because many of our shares of common stock are held by brokers and other institutions
on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these holders.
Dividends
We have not paid any cash dividends to
date and have no plans to do so in the immediate future. Additionally, we are prohibited from paying any cash dividends under
the terms of our loan and security agreement.
Equity Compensation Plan Information
The following table sets forth information with respect to
our equity compensation plans as of December 31, 2015.
Plan Category | |
Number of Securities
to be Issued upon Exercise of Outstanding Options and Rights (a) | | |
Weighted-
Average Exercise Price for Outstanding Options and Rights (b) | | |
Number of Securities
Remaining Available for
Future Issuance under
Equity compensation
Plans (Excluding
Securities Reflected in
Column (a)) (c) | |
Equity compensation plans approved by security holders | |
| | | |
| | | |
| | |
2005 Stock Plan, as amended and restated | |
| 580,000 | | |
$ | 1.23 | | |
| - | |
2007 Stock Plan | |
| 5,886,318 | | |
$ | 3.17 | | |
| 115,105 | |
2010 Equity Compensation Plan | |
| 10,787,536 | | |
$ | 1.27 | | |
| 2,516,686 | |
Equity compensation plans not approved by security holders | |
| N/A | | |
| N/A | | |
| N/A | |
Total | |
| 17,253,853 | | |
$ | 2.08 | | |
| 2,631,791 | |
Performance Graph
The following graph compares total stockholder
returns of Neuralstem, Inc. for the period commencing on December 31, 2010 and ending on December 31, 2015, to four indices: The
total return for our stock and for each index assumes an initial investment of $100 and the reinvestment of dividends, although
we have never declared dividends on Neuralstem stock, and is based on the returns of the component companies weighted according
to their capitalizations as of the end of each quarterly period. The stock price performance included in this graph is not necessarily
indicative of future stock price performance. For the period represented, we traded on the NYSE MKT from December 31, 2010 to
July 10, 2015. On July 13, 2015, we commended trading on the NASDAQ Capital Market under the symbol “CUR”.
Recent Sales or Issuances of Unregistered Securities
The following information is given with
regard to unregistered securities sold during the period covered by this report. The unregistered securities were issued pursuant
to section 4(2) of the Securities Act:
| · | In
February of 2015, we issued a total of 19,206 shares of common stock upon the cashless
exercise of 44,000 outstanding common stock purchase warrants. The warrants had an average
exercise price of $2.13. |
| · | In
July 2015, we issued one of our legal advisors a common stock purchase warrant to purchase
150,000 shares of our common stock at an exercise price of $1.87 per share in exchange
for certain legal work. The warrant vests monthly over one year from the grant date,
has a term of 5 years and will expire on June 30, 2020. Any vested portion of the warrant
can be exercised after 6 months from the issuance date on a cashless basis at any time
that the shares underlying the warrant are not subject to a registration statement. The
warrant provides for an adjustment to the purchase price and number of shares underlying
the warrant upon stock dividends and splits. The warrant does not contain any price protection
provisions with regard to subsequent financings. |
| · | On
February 15, 2016, as an inducement to Mr. Daly’s employment, we granted an inducement
option to purchase 2,750,000 shares of Common Stock. The option has a term of ten (10)
years, and vests as follows: (i) 687,500 options vest on the six (6) month anniversary
of the grant date, (ii) 687,500 options vest on the one (1) year anniversary of the grant
date and the remaining 1,375,000 options vesting quarterly over the subsequent three
(3) year period such that the option will be fully vested on the four (4) year anniversary
of the grant date. |
2016 fundraising
placeholder
| ITEM 6. | SELECTED
FINANCIAL DATA |
| |
Year Ended December 31, | |
Statement of Operations Data: | |
2015 | | |
2014 | | |
2013 | | |
2012 | | |
2011 | |
Revenues | |
$ | 10,417 | | |
$ | 18,833 | | |
$ | 110,000 | | |
$ | 407,708 | | |
$ | 390,625 | |
Total operating expenses | |
$ | 19,166,945 | | |
$ | 17,454,682 | | |
$ | 12,633,941 | | |
$ | 10,564,164 | | |
$ | 13,381,095 | |
Operating loss | |
$ | (19,156,528 | ) | |
$ | (17,435,849 | ) | |
$ | (12,523,941 | ) | |
$ | (10,156,456 | ) | |
$ | (12,990,470 | ) |
Interest expense | |
$ | (1,816,206 | ) | |
$ | (1,620,776 | ) | |
$ | (1,394,274 | ) | |
$ | (2,699 | ) | |
$ | (821 | ) |
Warrant issuance and modification expense | |
$ | - | | |
$ | (3,109,850 | ) | |
$ | (5,017,156 | ) | |
$ | - | | |
$ | - | |
Gain (loss) from change in fair value adjustment of warrant obligations | |
$ | - | | |
$ | (334,133 | ) | |
$ | (965,329 | ) | |
$ | - | | |
$ | 161,809 | |
Loss on debt extinguishment | |
$ | - | | |
$ | (445,787 | ) | |
$ | - | | |
$ | - | | |
$ | - | |
Litigation settlement | |
$ | - | | |
$ | 250,000 | | |
$ | 838 | | |
$ | 3,484 | | |
$ | - | |
Net loss | |
$ | (20,903,901 | ) | |
$ | (22,628,744 | ) | |
$ | (19,831,862 | ) | |
$ | (10,121,517 | ) | |
$ | (12,518,527 | ) |
Net loss per share - basic and diluted | |
$ | (0.23 | ) | |
$ | (0.26 | ) | |
$ | (0.27 | ) | |
$ | (0.17 | ) | |
$ | (0.26 | ) |
| |
As of December 31, | |
Balance Sheet Data: | |
2015 | | |
2014 | | |
2013 | | |
2012 | | |
2011 | |
Cash and equivalents | |
$ | 4,716,533 | | |
$ | 12,518,980 | | |
$ | 16,846,052 | | |
$ | 7,443,773 | | |
$ | 2,352,013 | |
Short-term investments | |
$ | 7,517,453 | | |
$ | 15,007,478 | | |
$ | - | | |
$ | - | | |
$ | - | |
Working capital | |
$ | 7,005,612 | | |
$ | 24,153,087 | | |
$ | 11,682,987 | | |
$ | 5,896,454 | | |
$ | 590,385 | |
Total assets | |
$ | 15,048,264 | | |
$ | 29,844,075 | | |
$ | 19,413,536 | | |
$ | 8,750,079 | | |
$ | 4,086,177 | |
Long-term debt, net of discount | |
$ | 8,026,550 | | |
$ | 8,786,482 | | |
$ | 7,697,331 | | |
$ | - | | |
$ | - | |
Fair value of derivative instruments | |
$ | - | | |
$ | - | | |
$ | 1,417,527 | | |
$ | - | | |
$ | - | |
Total stockholders' equity | |
$ | 4,967,278 | | |
$ | 17,719,336 | | |
$ | 8,418,199 | | |
$ | 6,972,633 | | |
$ | 1,659,818 | |
| ITEM 7. | MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
Our Management’s
Discussion and Analysis of Financial Condition and Results of Operations or MD&A, is provided in addition to the accompanying
financial statements and notes to assist readers in understanding our results of operations, financial condition and cash flows.
Our MD&A is organized as follows:
| · | Executive
Overview — Overview discussion of our business in order to provide context
for the remainder of MD&A. |
| · | Trends
& Outlook — Discussion of what we view as the overall trends affecting
our business and the strategy for 2016. |
| · | Critical
Accounting Policies— Accounting policies that we believe are important to understanding
the assumptions and judgments incorporated in our reported financial results and forecasts. |
| · | Results
of Operations— Analysis of our financial results comparing the: (i) year ended
December 31, 2015 to the comparable period of 2014 and (ii) year ended December 31, 2014
to the comparable period of 2013. |
| · | Liquidity
and Capital Resources—Analysis of cash flows and discussion of our financial
condition and future liquidity needs. |
Executive Overview
We are focused on the development and
commercialization of treatments based on human neuronal stem cells and the development and commercialization of treatments using
small molecule compounds. We are headquartered in Germantown, Maryland and have a wholly-owned subsidiary in China.
We have developed and maintain a portfolio
of patents and patent applications that form the proprietary base for our research and development efforts. We own or exclusively
license one hundred fourteen (114) U.S. or foreign issued patents and forty-seven (47) U.S. and foreign patent applications in
the field of regenerative medicine, related to our stem cell technologies as well as our small molecule compounds. At times, we
have licensed the use of our intellectual property to third parties.
All of our research efforts to date are
at the pre-clinical or clinical stage of development. We are focused on leveraging our key assets, including our intellectual
property, proprietary technology, scientific team and facilities, to advance our technologies and clinical programs. In addition,
we are pursuing strategic collaborations with members of academia and industry.
We have not derived any revenue or cash
flows from the sale or commercialization of our products. In the past, we have derived limited revenue from the licensing of certain
intellectual property to third parties and from consulting fees. As a result, we have incurred annual operating losses since inception
and expect to continue to incur substantial operating losses in the future. Therefore, we are dependent upon external financing
and revenue from collaborative research arrangements with sponsors to finance our operations. We have no such collaborative research
arrangements at this time and there can be no assurance that such financing or partnering revenue will be available when needed
or on terms acceptable to us.
Before we can derive revenue or cash inflows
from the commercialization of any of our proposed product candidates, we will need to: (i) conduct substantial testing of our
proposed products, (ii) undertake pre-clinical and clinical testing for specific disease indications; and (iii), obtain required
regulatory approvals. These steps are risky, expensive and time consuming.
Trends & Outlook
We generated
no revenues from the sale of our proposed therapies for any of the years presented. We are mainly focused on successfully managing
our current clinical trials related to our stem cell technology and small molecule compounds. We are also pursuing pre-clinical
studies on other central nervous system indications in preparation for additional clinical trials.
In the first
quarter of 2013 and the third quarter of 2012, we licensed the use of certain of our intellectual property to third parties. During
the years ended December 31, 2015, 2014, and 2013 , we recognized approximately $10,000, $19,000, and $110,000 of revenue, respectively,
related to up-front payments and ongoing fees under these licenses.
On a long-term
basis, we anticipate that our revenue will be derived primarily from licensing fees and sales of our cell based therapy and small
molecule compounds. Because we are at such an early stage in the clinical trials process, we are not yet able to accurately predict
when we will have a product ready for commercialization, if ever.
Research and Development Expenses
Our research
and development expenses consist primarily of contractor and personnel expenses associated with clinical trials and regulatory
submissions; costs associated with preclinical activities such as proof of principle for new indications; toxicology studies;
costs associated with cell processing and process development; facilities-related costs and supplies. Clinical trial expenses
include payments to research organizations, contract manufacturers, clinical trial sites, consultants and laboratories for testing
clinical samples.
We focus on the
development of treatment candidates with potential uses in multiple indications, and use employee and infrastructure resources
across several projects. Accordingly, many of our costs are not attributable to a specifically identified product and we do not
account for internal research and development costs on a project-by-project basis.
For a further description of these clinical
trials, see the section of this report entitled “Clinical Programs” contained in Item 1. Of this Annual Report.
We expect that
research and development expenses, which include expenses related to our ongoing clinical trials, will increase in the future,
as funding allows and we proceed into our anticipated Phase II trials. To the extent that it is practical, we will continue to
outsource much of our efforts, including product manufacture, proof of principle and pre-clinical testing, toxicology, tumorigenicity,
dosing rationale, and development of clinical protocol and IND applications. This approach allows us to use the best expertise
available for each task and permits staging new research projects to fit available cash resources.
In June 2010
we formed a wholly owned subsidiary in the People’s Republic of China. This subsidiary primarily: (i) conducts pre-clinical
research with regard to proposed stem cells therapies, and (ii) oversees our approved future clinical trials in China, including
the current trial to treat motor deficits due to ischemic stroke. Through December 31, 2015 this subsidiary has incurred expenses
of approximately $796,000.
General and Administrative Expenses
General and administrative
expenses are primarily comprised of salaries, benefits and other costs associated with our operations including, finance, human
resources, information technology, public relations, legal fees, facilities and other external general and administrative services.
Critical Accounting Policies
Our consolidated
financial statements have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management
to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Note 2
of the Notes to Consolidated Financial Statements included elsewhere herein describes the significant accounting policies used
in the preparation of the financial statements. Certain of these significant accounting policies are considered to be critical
accounting policies, as defined below.
A critical accounting
policy is defined as one that is both material to the presentation of our financial statements and requires management to make
difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations.
Specifically, critical accounting estimates have the following attributes: (1) we are required to make assumptions about
matters that are highly uncertain at the time of the estimate; and (2) different estimates we could reasonably have used,
or changes in the estimate that are reasonably likely to occur, would have a material effect on our financial condition or results
of operations.
Estimates and
assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience
and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change
as new events occur, as additional information is obtained and as our operating environment changes. These changes have historically
been minor and have been included in the financial statements as soon as they became known. Based on a critical assessment of
our accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management
believes that our financial statements are fairly stated in accordance with U.S. GAAP, and present a meaningful presentation of
our financial condition and results of operations. We believe the following critical accounting policies reflect our more significant
estimates and assumptions used in the preparation of our consolidated financial statements:
Use
of Estimates - Our financial statements prepared in accordance with U.S. GAAP require us to make estimates and assumptions
that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Specifically, we have estimated the expected economic life and value of our
patent technology, our net operating loss carryforward and related valuation allowance for tax purposes and our stock -based compensation
expenses related to employees, directors, consultants and investment banks. Actual results could differ from those estimates.
Long
Lived Intangible Assets - Our long lived intangible assets consist of our intellectual property patents including primarily
legal fees associated with the filings and in defense of our patents. The assets are amortized on a straight-line basis over the
expected useful life which we define as ending on the expiration of the patent group. These assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. We assess this
recoverability by comparing the carrying amount of the asset to the estimated undiscounted future cash flows to be generated by
the asset. If an asset is deemed to be impaired, we estimate the impairment loss by determining the excess of the asset’s
carrying amount over the estimated fair value. These determinations use assumptions that are highly subjective and include a high
degree of uncertainty. During the years ended December 31, 2015, 2014 and 2013, no significant impairment losses were recognized.
Fair Value Measurements
- The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, other
short-term investments, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The
fair value of our long-term indebtedness is estimated based on the quoted prices for the same or similar issues or on the current
rates offered to the Company for debt of the same remaining maturities. The fair values of our derivative instruments were estimated
using Level 3 unobservable inputs.
Share-Based
Compensation - We account for share-based compensation at fair value; accordingly we expense the estimated fair value
of share-based awards over the requisite service period. Share-based compensation cost for stock options and warrants issued to
employees and board members is determined at the grant date using an option pricing model. Option pricing models require us to
make assumptions, including expected volatility and expected term of the options. If any of the assumptions we use in the model
were to significantly change, stock based compensation expense may be materially different. Share-based compensation cost for
restricted stock and restricted stock units issued to employees and board members is determined at the grant date based on the
closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as expense
on a straight-line basis over the requisite service period.
Comparison of Our Results of Operations for the Year Ended
December 31, 2015 and 2014
Revenue
We did not generate
any revenues from the sale of our proposed products in 2015 or 2014. During 2015 and 2014, we recognized revenue of approximately
$10,000 and $19,000, respectively related to the licensing of certain of our intellectual properties to third parties. The revenue
in 2015 and 2014 consisted solely of ongoing, annual license fees.
Operating Expenses
Operating expenses for 2015 and 2014 were as follows:
| |
Year Ended December 31, | | |
Increase (Decrease) | |
| |
2015 | | |
2014 | | |
$ | | |
% | |
Operating Expenses | |
| | | |
| | | |
| | | |
| | |
Research & development costs | |
$ | 12,637,278 | | |
$ | 8,361,559 | | |
$ | 4,275,719 | | |
| 51 | % |
General & administrative expenses | |
| 6,529,667 | | |
| 9,093,123 | | |
| (2,563,456 | ) | |
| -28 | % |
Total expense | |
$ | 19,166,945 | | |
$ | 17,454,682 | | |
$ | 1,712,263 | | |
| 10 | % |
Research and Development Expenses
Our research
and development expenses consist primarily of contractor and personnel expenses associated with clinical trials and regulatory
submissions; costs associated with preclinical activities such as proof of principle for new indications; toxicology studies;
costs associated with cell processing and process development; facilities-related costs and supplies. Clinical trial expenses
include payments to research organizations, contract manufacturers, clinical trial sites, consultants and laboratories for testing
clinical samples.
The increase
of approximately $4,276,000 or 51% in research and development expenses was primarily attributable to a $924,000 increase in payroll
and related expense due to increased salaries and headcount and a $3,443,000 increase in project and lab expenses.. These increased
expenses are all related to a ramping up of our pre-clinical and clinical trial efforts and are expected to continue into subsequent
periods.
General and Administrative Expenses
General and administrative
expenses are primarily comprised of salaries, benefits and other costs associated with our operations including, finance, human
resources, information technology, public relations, legal fees, facilities and other external general and administrative services.
The decrease
of approximately of approximately $2,563,000 or 28% in general and administrative expenses was primarily attributable to
a $1,794,000
decrease in non-cash stock based compensation related to a consultant achieving a performance based milestone which resulted in
a term extension of certain common stock purchase warrants in the previous year, and $1,443,000 decrease in legal, consulting
and other external advisory fees. This was partially offset by an increase of $494,000 increase in payroll and related expenses
due to current year headcount increases.
Other income (expense)
Other expense
totaled approximately $1,747,000 and $5,193,000 in the years ended December 31, 2015 and 2014, respectively. This reduction of
expense was primarily the result of the non-recurrence of a warrant modification expense in 2014 of $3,110,000.
Comparison of Our Results of Operations for the Year Ended
December 31, 2014 and 2013
Revenue
We did not generate
any revenues from the sale of our proposed products in 2014 or 2013. During 2014 and 2013, we recognized revenue of approximately
$19,000 and $110,000, respectively related to the licensing of certain of our intellectual properties to third parties. The revenue
in 2013 included up-front fees for new licenses while the revenue recognized in 2014 consisted solely of ongoing, annual license
fees.
Operating Expenses
Operating expenses for 2014 and 2013 were as follows:
| |
Year Ended December 31, | | |
Increase (Decrease) | |
| |
2014 | | |
2013 | | |
$ | | |
% | |
Operating Expenses | |
| | |
| | |
| | |
| |
Research & development costs | |
$ | 8,361,559 | | |
$ | 7,285,752 | | |
$ | 1,075,807 | | |
| 15 | % |
General & administrative expenses | |
| 9,093,123 | | |
| 5,348,189 | | |
| 3,744,934 | | |
| 70 | % |
Total expense | |
$ | 17,454,682 | | |
$ | 12,633,941 | | |
$ | 4,820,741 | | |
| 38 | % |
Research and Development Expenses
Our research
and development expenses consist primarily of contractor and personnel expenses associated with clinical trials and regulatory
submissions; costs associated with preclinical activities such as proof of principle studies for new indications; toxicology studies;
costs associated with cell processing and process development; facilities-related costs and supplies. Clinical trial expenses
include payments to research organizations, contract manufacturers, clinical trial sites, consultants and laboratories for testing
clinical samples.
The increase
of approximately $1,076,000 or 15% in research in development expenses was primarily attributable to a $674,000 increase in payroll
and related expense due to increased headcount, a $140,000 increase in project and lab expenses and a $112,000 increase
in travel and related expense due to our clinical trial activities. These increased expenses are all related to a ramping up of
our pre-clinical and clinical trial efforts and are expected to continue into subsequent periods.
General and Administrative Expenses
General and administrative
expenses are primarily comprised of salaries, benefits and other costs associated with our operations including, finance, human
resources, information technology, public relations, legal fees, facilities and other external general and administrative services.
The increase
of approximately $3,745,000 or 70% in general and administrative expenses was primarily attributable to a $1,953,000 increase
in non-cash stock based compensation expense primarily related to a consultant achieving a performance based milestone which resulted
in a term extension of certain common stock purchase warrants, a $1,010,000 increase in legal and professional fees related to
patent, litigation and other corporate matters, a $554,00 increase in consulting fees primarily related to new business development
efforts and a $236,000 increase in payroll and related expenses due to current year headcount increases.
Other income (expense)
Other expense totaled approximately $5,193,000
and $7,308,000 in the years ended December 31, 2014 and 2013, respectively. Other expense in 2014 consisted primarily of a $3,110,000
expense related to our extension of certain common stock purchase warrants, $1,621,000 of interest expense primarily related to
our long-term debt, a $446,000 loss on our debt amendment transaction, and a $334,000 expense related to the change in fair value
of the Company’s warrant liabilities partially offset by approximately $250,000 of income from a milestone payment from
a legal settlement.
Liquidity and
Capital Resources
Since our inception, we have financed our operations through the sales of our securities, issuance of
long-term debt, the exercise of investor warrants, and to a lesser degree from grants and research contracts as well as the licensing
of our intellectual property to third parties. In February and March of 2015, we issued 812,423 shares of common stock at
an average price of $3.77 per share generating gross proceeds of approximately $3,064,000 and net proceeds of approximately $2,932,000
($3.61 per share) after deducting commissions and fees of approximately $132,000.
Our independent registered public accounting
firm has included an explanatory paragraph with respect to our ability to continue as a going concern in its report on our consolidated
financial statements for the year ended December 31, 2015. The presence of the going concern explanatory paragraph may suggest
that we may not have sufficient liquidity or minimum cash levels to operate the business.
Our Cash and Cash Equivalent
balances of approximately $12.2 million as at December 31, 2015 are only sufficient to fund operations through June, 2016. We
will require additional capital to conduct research and development, establish and conduct clinical and pre-clinical trials,
enter into commercial-scale manufacturing arrangements and to provide for marketing and distribution of our products.
Management is in ongoing discussions regarding various financing options with financial institutions and believes that it
will receive cash adequate to fund operations through December 31, 2016. We cannot assure you that we will be able to secure
such additional financing or that the expected income will materialize. Several factors will affect our ability to raise
additional funding, including, but not limited to market conditions, interest rates and, more specifically, our progress in
our exploratory, preclinical and future clinical development programs.
Cash Flows – 2015 compared
to 2014
| |
Year Ended December 31, | | |
Increase (Decrease) | |
| |
2015 | | |
2014 | | |
$ | | |
% | |
| |
| | |
| | |
| | |
| |
Cash and cash equivalents | |
$ | 4,716,533 | | |
$ | 12,518,980 | | |
$ | (7,802,447 | ) | |
| -62 | % |
Short term investments | |
| 7,517,453 | | |
| 15,007,478 | | |
| (7,490,025 | ) | |
| -50 | % |
Total cash and short term investments | |
$ | 12,233,986 | | |
$ | 27,526,458 | | |
$ | (15,292,472 | ) | |
| -56 | % |
| |
| | | |
| | | |
| | | |
| | |
Net cash used in operating activities | |
$ | (18,931,665 | ) | |
$ | (11,706,688 | ) | |
$ | (7,224,977 | ) | |
| 62 | % |
Net cash provided by (used in) investing | |
$ | 7,246,441 | | |
$ | (15,563,826 | ) | |
$ | 22,810,267 | | |
| -147 | % |
Net cash provided by financing activities | |
$ | 3,887,189 | | |
$ | 22,944,425 | | |
$ | (19,057,236 | ) | |
| -83 | % |
The decrease in our cash and short term
investments was primarily due to our use of cash in operating activities of approximately $18,932,000, partially offset by the
proceeds from sales of stock and from the exercise of warrants.
Net Cash Used in Operating Activities
The increase
in cash used in operating activities during 2015 as compared to 2014 was primarily the result increased project and payroll related
expenses associated with increased clinical and pre-clinical activities.
Net Cash Used in Investing Activities
The increase
in cash received in investing activities during 2015 as compared to 2014 was primarily due to the use of short term investments
to fund ongoing operating expenses and reduced investment activities during 2015 compared to 2014.
Net Cash Provided by Financing
Activities
Net cash provided
by financing activities decreased by approximately $19,057,000 in 2015 compared to 2014. In 2015, we raised approximately $6,005,000
in proceeds from sales of securities and exercise of warrants. In 2014 we raised approximately $19.560,000, net from the sale
of our securities pursuant to a registered direct offering and approximately $4,213,000 of net proceeds pursuant to our debt amendment
transaction.
Cash Flows – 2014 compared
to 2013
| |
Year Ended December 31, | | |
Increase (Decrease) | |
| |
2014 | | |
2013 | | |
$ | | |
% | |
| |
| | |
| | |
| | |
| |
Cash and cash equivalents | |
$ | 12,518,980 | | |
$ | 16,846,052 | | |
$ | (4,327,072 | ) | |
| -26 | % |
Short term investments | |
| 15,007,478 | | |
| - | | |
| 15,007,478 | | |
| - | % |
Total cash and short term investments | |
$ | 27,526,458 | | |
$ | 16,846,052 | | |
$ | 10,680,406 | | |
| 63 | % |
| |
| | | |
| | | |
| | | |
| | |
Net cash used in operating activities | |
$ | (11,706,688 | ) | |
$ | (10,591,617 | ) | |
$ | (1,115,071 | ) | |
| 11 | % |
Net cash used in investing activities | |
$ | (15,563,826 | ) | |
$ | (537,050 | ) | |
$ | (15,026,776 | ) | |
| 2798 | % |
Net cash provided by financing activities | |
$ | 22,944,425 | | |
$ | 20,524,702 | | |
$ | 2,419,723 | | |
| 12 | % |
The increase in our cash and short term
investments was primarily due to our raising approximately $19,468,000, net through the sale of our common stock and warrants
and $4,213,000 net in our debt amendment transaction partially offset by our cash used in operations.
Net Cash Used in Operating Activities
The increase
in cash used in operating activities during 2014 as compared to 2013 was primarily the result of a $2,797,000 increase in our
net loss partially offset by changes in our operating assets and liabilities.
Net Cash Used in Investing Activities
The increase
in our use of cash in investing activities during 2014 as compared to 2013 was primarily due to approximately $15,007,000 of purchases,
net of maturities of short term investments using the proceeds from our January 2014 registered direct offering.
Net Cash Provided by Financing
Activities
In 2014 we raised
approximately $19,468,000, net through the sale of our common stock and warrants, $4,213,000 from our debt amendment transaction
and $1,795,000 from exercises of stock purchase warrants. These were partially offset by $1,929,000 of principal payments on our
long-term debt and the $426,000 payment of taxes related to stock option exercises.
In 2013 we raised
approximately $7,048,000, net through the sale of our common stock and warrants, $7,551,000 from the issuance of long-term debt
and $6,108,000 from exercises of stock purchase warrants.
Future
Liquidity and Needs
We have incurred
significant operating losses and negative cash flows since inception. We have not achieved profitability and may not be able to
realize sufficient revenue to achieve or sustain profitability in the future. We do not expect to be profitable in the next several
years, but rather expect to incur additional operating losses. We have limited liquidity and capital resources and must obtain
significant additional capital resources in order to sustain our product development efforts, for acquisition of technologies
and intellectual property rights, for preclinical and clinical testing of our anticipated products, pursuit of regulatory approvals,
acquisition of capital equipment, laboratory and office facilities, establishment of production capabilities, for general and
administrative expenses and other working capital requirements. We rely on cash balances and the proceeds from the offering of
our securities, exercise of outstanding warrants and grants to fund our operations.
We intend to
pursue opportunities to obtain additional financing in the future through the sale of our securities and additional research grants.
We currently have two shelf registration statements that are effective. On June 19, 2014, our shelf registration statement registering
the sale of up to $100 million of our securities was declared effective by the SEC. To date, we have not sold any securities under
this shelf registration statement. On September 13, 2013, our shelf registration statement (Registration No. 333-190936) registering
the sale of up to $50 million of our securities was declared effective by the SEC. To date, through February 29, 2016 we
have sold or reserved for sale upon the exercise of outstanding warrants approximately $47.2 million of securities under this
shelf registration statement. Additionally, securities sold pursuant to our At the Market Offering Agreement (see below) are being
sold pursuant to this registration statement and accordingly, we have reserved the balance of approximately $2.8 million of securities
pursuant thereto. We anticipate conducting financing in the future based on our shelf registration statement when and if financing
opportunities arise.
In October 2013,
we entered into an At the Market Offering Agreement with T.R. Winston & Company as our sales agent pursuant to which we can
sell up to $25 million of our common stock. The At the Market Offering Agreement was entered into pursuant to a takedown from
our shelf registration statement declared effective on September 13, 2013 (Registration No. 333-190936). To date through
December 31, 2015 we have sold 2,202,580 shares under such agreement at an average price per share of $3.16 resulting in gross
proceeds of approximately $6,965,000 and net proceeds of approximately $6,665,000 .
Future sales under our agreement are limited to approximately $1.8 million which is the amount available under our shelf registration
of which the At the Market Offering Agreement is part of.
The source, timing
and availability of any future financing will depend principally upon market conditions, interest rates and, more specifically,
our progress in our exploratory, preclinical and future clinical development programs. Funding may not be available when needed,
at all, or on terms acceptable to us. Lack of necessary funds may require us, among other things, to delay, scale back or eliminate
some or all of our research and product development programs, planned clinical trials, and/or our capital expenditures or to license
our potential products or technologies to third parties.
Contractual Obligations
As of December 31, 2015, our contractual obligations were as
follows:
Contractual Obligations | |
Less than 1 year | | |
1 - 3 Years | | |
3 - 5 Years | | |
More than 5 Years | | |
Total | |
Operating facility leases | |
$ | 309,286 | | |
$ | 331,412 | | |
$ | - | | |
$ | - | | |
$ | 640,697 | |
Long-term debt | |
| 4,569,537 | | |
| 3,765,569 | | |
| - | | |
| - | | |
| 8,335,106 | |
Total contractual obligations | |
$ | 4,878,822 | | |
$ | 4,096,981 | | |
$ | - | | |
$ | - | | |
$ | 8,975,803 | |
Off-balance Sheet Arrangements
None.
| ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURE
ABOUT MARKET RISK |
Financial instruments that potentially
subject us to concentrations of credit risk consist primarily of cash equivalents and short-term investments. Our investment policy,
approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit
risk concentrations. In addition, our CDs are invested through the Certificate of Deposit Account Registry Service (“CDARS”)
program which reduces or eliminates our risk related to concentrations of investments above FDIC insurance levels. We limit our
credit and liquidity risks through our investment policy and through regular reviews of our portfolio against our policy. Because
of the short-term maturities, we do not believe that a one-half percentage point increase or decrease in interest rates would
have had a material effect on our interest income.
We are subject to interest rate risk on
our long-term debt which contains a floating interest rate based on Wall Street Journal published prime rate. For the year ended
December 31, 2015 a one percentage point increase in the prime rate would have increased our interest expense by approximately
$188,000.
Our foreign operations in China subject
us to changes in foreign exchange rates. Changes in rates for the year ended December 31, 2015 would not have had a material effect
as the operations were limited. Future changes to foreign exchange rates could have a material effect on us as our clinical trial
activity increases.
| ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and
Stockholders of Neuralstem, Inc.
Germantown, Maryland
We have audited the accompanying consolidated balance sheets
of Neuralstem, Inc. (the “Company”) as of December 31, 2015 and 2014, and the consolidated statements of operations
and comprehensive loss, changes in stockholders’ equity, and cash flows for each of the years in the three-year period ended
December 31, 2015. We also have audited the Company’s internal control over financial reporting as of December 31, 2015,
based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). The Company’s management is responsible for these consolidated financial
statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of
internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over
Financial Reporting. Our responsibility is to express an opinion on these financial statements and an opinion on the Company’s
internal control over consolidated financial reporting based on our audits.
We conducted our audits in accordance with the standards of
the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement and whether effective
internal control over financial reporting was maintained in all material respects. Our audits of the consolidated financial statements
included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the
accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation.
Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting,
assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal
control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the
circumstances. We believe that our audits provide a reasonable basis for our opinions.
A company’s internal control over financial reporting
is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control
over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
In
our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial
position of Neuralstem, Inc. as of December 31, 2015 and 2014, and the results of their operations and their cash flows for
each of the years in the three year period ended December 31, 2015 in conformity with accounting principles generally
accepted in the United States of America. Also in our opinion, Neuralstem, Inc. maintained, in all material respects,
effective internal control over financial reporting as of December 31, 2015, based on criteria established in Internal
Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO).
The accompanying consolidated financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1, the Company has suffered recurring
losses from operations and has an accumulated deficit that raises substantial doubt about its ability to continue as a going concern.
Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
/s/ Stegman & Company
Baltimore, Maryland
March 14, 2016
Neuralstem, Inc.
Consolidated Balance Sheets
| |
December 31, | |
| |
2015 | | |
2014 | |
| |
| | |
| |
ASSETS | |
| | | |
| | |
CURRENT ASSETS | |
| | | |
| | |
Cash and cash equivalents | |
$ | 4,716,533 | | |
$ | 12,518,980 | |
Short term investments | |
| 7,517,453 | | |
| 15,007,478 | |
Trade and other receivables | |
| 37,316 | | |
| 225,524 | |
Deferred financing fees, current portion | |
| 89,562 | | |
| 135,694 | |
Prepaid expenses | |
| 1,159,782 | | |
| 274,106 | |
Total current assets | |
| 13,520,646 | | |
| 28,161,782 | |
| |
| | | |
| | |
Property and equipment, net | |
| 343,200 | | |
| 301,265 | |
Patents, net | |
| 1,103,467 | | |
| 1,233,172 | |
Deferred financing fees, net of current portion | |
| 9,154 | | |
| 89,143 | |
Other assets | |
| 71,797 | | |
| 58,713 | |
Total assets | |
$ | 15,048,264 | | |
$ | 29,844,075 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 1,455,826 | | |
$ | 2,504,978 | |
Accrued bonuses | |
| 161,362 | | |
| 646,960 | |
Current portion of long-term debt, net of discount | |
| 4,634,742 | | |
| 730,012 | |
Other current liabilities | |
| 263,104 | | |
| 126,745 | |
Total current liabilities | |
| 6,515,034 | | |
| 4,008,695 | |
| |
| | | |
| | |
Long-term debt, net of discount and current portion | |
| 3,391,808 | | |
| 8,056,470 | |
Other long term liabilities | |
| 174,144 | | |
| 59,574 | |
Total liabilities | |
| 10,080,986 | | |
| 12,124,739 | |
| |
| | | |
| | |
Commitments and contingencies (Note 10) | |
| | | |
| | |
| |
| | | |
| | |
STOCKHOLDERS' EQUITY | |
| | | |
| | |
Preferred stock, 7,000,000 shares authorized, zero shares issued and outstanding | |
| - | | |
| - | |
Common stock, $0.01 par value; 300 million shares authorized, 92,005,705 and 87,789,679 shares
issued and outstanding in 2015 and 2014, respectively | |
| 920,057 | | |
| 877,897 | |
Additional paid-in capital | |
| 176,002,832 | | |
| 167,890,220 | |
Accumulated other comprehensive income | |
| 3,071 | | |
| 6,000 | |
Accumulated deficit | |
| (171,958,682 | ) | |
| (151,054,781 | ) |
Total stockholders' equity | |
| 4,967,278 | | |
| 17,719,336 | |
Total liabilities and stockholders' equity | |
$ | 15,048,264 | | |
$ | 29,844,075 | |
See accompanying notes to consolidated
financial statements.
Neuralstem, Inc.
Consolidated Statements of Operations
and Comprehensive Loss
| |
Year Ended December 31, | |
| |
2015 | | |
2014 | | |
2013 | |
| |
| | |
| | |
| |
Revenues | |
$ | 10,417 | | |
$ | 18,833 | | |
$ | 110,000 | |
| |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | |
Research and development costs | |
| 12,637,278 | | |
| 8,361,559 | | |
| 7,285,752 | |
General and administrative expenses | |
| 6,529,667 | | |
| 9,093,123 | | |
| 5,348,189 | |
Total operating expenses | |
| 19,166,945 | | |
| 17,454,682 | | |
| 12,633,941 | |
Operating loss | |
| (19,156,528 | ) | |
| (17,435,849 | ) | |
| (12,523,941 | ) |
| |
| | | |
| | | |
| | |
Other income (expense): | |
| | | |
| | | |
| | |
Interest income | |
| 69,549 | | |
| 67,651 | | |
| 68,000 | |
Interest expense | |
| (1,816,206 | ) | |
| (1,620,776 | ) | |
| (1,394,274 | ) |
Warrant modification expense | |
| - | | |
| (3,109,850 | ) | |
| (5,017,156 | ) |
Loss from change in fair value of derivative instruments | |
| - | | |
| (334,133 | ) | |
| (965,329 | ) |
Loss on debt extinguisment | |
| - | | |
| (445,787 | ) | |
| - | |
Other expense | |
| (716 | ) | |
| - | | |
| - | |
Litigation settlement | |
| - | | |
| 250,000 | | |
| 838 | |
Total other income (expense) | |
| (1,747,373 | ) | |
| (5,192,895 | ) | |
| (7,307,921 | ) |
| |
| | | |
| | | |
| | |
Net loss | |
$ | (20,903,901 | ) | |
$ | (22,628,744 | ) | |
$ | (19,831,862 | ) |
| |
| | | |
| | | |
| | |
Net loss per share - basic and diluted | |
$ | (0.23 | ) | |
$ | (0.26 | ) | |
$ | (0.27 | ) |
| |
| | | |
| | | |
| | |
Weighted average common shares outstanding - basic and diluted | |
| 90,866,938 | | |
| 87,086,345 | | |
| 72,279,210 | |
| |
| | | |
| | | |
| | |
Comprehensive loss: | |
| | | |
| | | |
| | |
Net loss | |
$ | (20,903,901 | ) | |
$ | (22,628,744 | ) | |
$ | (19,831,862 | ) |
Foreign currency translation adjustment | |
| (2,929 | ) | |
| (1,241 | ) | |
| 7,241 | |
Comprehensive loss | |
$ | (20,906,830 | ) | |
$ | (22,629,985 | ) | |
$ | (19,824,621 | ) |
See accompanying notes to consolidated
financial statements.
Neuralstem, Inc.
Consolidated Statements of Changes In
Stockholders' Equity
| |
Common
Stock Shares | | |
Common
Stock
Amount | | |
Additional
Paid-In
Capital | | |
Accumulated
Other
Comprehensive Loss | | |
Accumulated
Deficit | | |
Total
Stockholders'
Equity | |
Balance at January 1, 2013 | |
| 68,189,314 | | |
$ | 681,893 | | |
$ | 114,884,915 | | |
$ | - | | |
$ | (108,594,175 | ) | |
$ | 6,972,633 | |
Share based payments | |
| - | | |
| - | | |
| 1,665,155 | | |
| - | | |
| - | | |
| 1,665,155 | |
Issuance of common stock for warrant exercises, net of fees of $113,200 | |
| 5,302,935 | | |
| 53,029 | | |
| 5,979,277 | | |
| - | | |
| - | | |
| 6,032,306 | |
Issuance of common stock and replacement warrants as inducement
for warrant exercises | |
| 72,440 | | |
| 724 | | |
| 5,016,432 | | |
| - | | |
| - | | |
| 5,017,156 | |
Issuance of common stock and warrants for professional services,
net of forfeited shares | |
| 332,848 | | |
| 3,329 | | |
| 1,503,419 | | |
| - | | |
| - | | |
| 1,506,748 | |
Issuance of common stock and warrants from capital raises, net of
issuance costs of $534,825 | |
| 3,988,494 | | |
| 39,885 | | |
| 7,008,937 | | |
| - | | |
| - | | |
| 7,048,822 | |
Foreign currency translation adjustments | |
| | | |
| | | |
| | | |
| 7,241 | | |
| | | |
| 7,241 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| (19,831,862 | ) | |
| (19,831,862 | ) |
Balance at December 31, 2013 | |
| 77,886,031 | | |
| 778,860 | | |
| 136,058,135 | | |
| 7,241 | | |
| (128,426,037 | ) | |
| 8,418,199 | |
Share based payments | |
| - | | |
| - | | |
| 4,318,994 | | |
| - | | |
| - | | |
| 4,318,994 | |
Issuance of common stock for warrant exercises, net of fees of $113,200 | |
| 805,972 | | |
| 8,060 | | |
| 991,940 | | |
| - | | |
| - | | |
| 1,000,000 | |
Issuance of common stock and replacement warrants as inducement
for warrant exercises | |
| 1,947,535 | | |
| 19,476 | | |
| 1,288,515 | | |
| - | | |
| - | | |
| 1,307,991 | |
Issuance of common stock and warrants for professional services,
net of forfeited shares | |
| 7,122,022 | | |
| 71,220 | | |
| 19,489,214 | | |
| - | | |
| - | | |
| 19,560,434 | |
Reclassification of warrant classified as derivative liability | |
| - | | |
| - | | |
| 1,704,097 | | |
| - | | |
| - | | |
| 1,704,097 | |
Modification of executive warrant | |
| - | | |
| - | | |
| 3,109,850 | | |
| - | | |
| - | | |
| 3,109,850 | |
Issuance of common stock and warrants in conjunction with debt amendment,
net | |
| 28,119 | | |
| 281 | | |
| 929,475 | | |
| - | | |
| - | | |
| 929,756 | |
Foreign currency translation adjustments | |
| - | | |
| - | | |
| - | | |
| (1,241 | ) | |
| - | | |
| (1,241 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| (22,628,744 | ) | |
| (22,628,744 | ) |
Balance at December 31, 2014 | |
| 87,789,679 | | |
| 877,897 | | |
| 167,890,220 | | |
| 6,000 | | |
| (151,054,781 | ) | |
| 17,719,336 | |
Share based payments | |
| - | | |
| - | | |
| 2,951,367 | | |
| - | | |
| - | | |
| 2,951,367 | |
Issuance of common stock for warrant exercises net | |
| 1,724,606 | | |
| 17,246 | | |
| 3,056,289 | | |
| - | | |
| - | | |
| 3,073,535 | |
Issuance of common stock for RSU and option exercises net of forfeited
shares for exercise price and payment of taxes | |
| 1,251,189 | | |
| 12,512 | | |
| (814,566 | ) | |
| - | | |
| - | | |
| (802,054 | ) |
Issuance of common stock and warrants from capital raises, net | |
| 812,423 | | |
| 8,124 | | |
| 2,923,800 | | |
| - | | |
| - | | |
| 2,931,924 | |
Modification of executive warrant | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Issuance of common stock for restricted stock awards | |
| 427,808 | | |
| 4,278 | | |
| (4,278 | ) | |
| - | | |
| - | | |
| - | |
Foreign currency translation adjustments | |
| - | | |
| - | | |
| - | | |
| (2,929 | ) | |
| - | | |
| (2,929 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| (20,903,901 | ) | |
| (20,903,901 | ) |
Balance at December 31, 2015 | |
| 92,005,705 | | |
$ | 920,057 | | |
$ | 176,002,832 | | |
$ | 3,071 | | |
$ | (171,958,682 | ) | |
$ | 4,967,278 | |
See accompanying notes to consolidated
financial statements
Neuralstem, Inc.
Consolidated Statements of Cash Flows
| |
For the Year Ended December 31, | |
| |
2015 | | |
2014 | | |
2013 | |
| |
| | |
| | |
| |
Cash flows from operating activities: | |
| | | |
| | | |
| | |
Net loss | |
$ | (20,903,901 | ) | |
$ | (22,628,744 | ) | |
$ | (19,831,862 | ) |
Adjustments to reconcile net loss to cash used in operating activities: | |
| | | |
| | | |
| | |
Depreciation and amortization | |
| 345,460 | | |
| 348,630 | | |
| 244,725 | |
Share based compensation expenses | |
| 2,951,367 | | |
| 4,320,073 | | |
| 2,331,401 | |
Amortization of deferred financing fees and debt discount | |
| 870,530 | | |
| 829,632 | | |
| 694,175 | |
Warrant modification expense | |
| - | | |
| 3,109,850 | | |
| 5,017,156 | |
Loss from change in fair value of warrant obligations | |
| - | | |
| 334,133 | | |
| 965,329 | |
Loss on debt extinguishment | |
| - | | |
| 445,787 | | |
| - | |
| |
| | | |
| | | |
| | |
Changes in operating assets and liabilities: | |
| | | |
| | | |
| | |
Trade and other receivables | |
| 188,208 | | |
| (215,524 | ) | |
| (6,667 | ) |
Prepaid expenses | |
| (840,772 | ) | |
| 191,263 | | |
| 125,470 | |
Other assets | |
| (13,998 | ) | |
| 6,141 | | |
| (5,183 | ) |
Accounts payable and accrued expenses | |
| (1,045,765 | ) | |
| 1,382,447 | | |
| (116,750 | ) |
Accrued bonuses | |
| (485,598 | ) | |
| 181,092 | | |
| 3 | |
Other current liabilities | |
| 253,427 | | |
| (2,206 | ) | |
| 2,469 | |
Other long term liabilities | |
| (250,624 | ) | |
| (9,262 | ) | |
| (11,883 | ) |
Net cash used in operating activities | |
| (18,931,666 | ) | |
| (11,706,688 | ) | |
| (10,591,617 | ) |
| |
| | | |
| | | |
| | |
Cash flows from investing activities: | |
| | | |
| | | |
| | |
Purchases of short-term investments | |
| (7,517,453 | ) | |
| (25,007,478 | ) | |
| - | |
Maturity of short-term investments | |
| 15,007,478 | | |
| 10,000,000 | | |
| - | |
Patent costs | |
| (67,312 | ) | |
| (348,455 | ) | |
| (411,688 | ) |
Purchase of property and equipment | |
| (176,272 | ) | |
| (207,893 | ) | |
| (125,362 | ) |
Net cash provided by (used in) investing activities | |
| 7,246,441 | | |
| (15,563,826 | ) | |
| (537,050 | ) |
| |
| | | |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | | |
| | |
Proceeds from issuance of common stock from warrants exercised, net | |
| 3,073,535 | | |
| 1,794,865 | | |
| 6,107,842 | |
Proceeds from sale of common stock and warrants, net of issuance costs | |
| 2,931,924 | | |
| 19,467,857 | | |
| 7,048,822 | |
Payments of taxes on stock option exercises | |
| (802,054 | ) | |
| (426,212 | ) | |
| - | |
Proceeds from long-term debt transactions, net of issuance costs | |
| - | | |
| 4,212,561 | | |
| 7,551,329 | |
Payments of long-term debt | |
| (1,154,150 | ) | |
| (1,929,449 | ) | |
| - | |
Payment on fees for future financing | |
| (45,000 | ) | |
| - | | |
| - | |
Payments of short term notes payable | |
| (117,068 | ) | |
| (175,197 | ) | |
| (183,291 | ) |
Net cash provided by financing activities | |
| 3,887,187 | | |
| 22,944,425 | | |
| 20,524,702 | |
Effects of exchange rates on cash | |
| (4,409 | ) | |
| (983 | ) | |
| 6,244 | |
Net increase (decrease) in cash and cash equivalents | |
| (7,802,447 | ) | |
| (4,327,072 | ) | |
| 9,402,279 | |
| |
| | | |
| | | |
| | |
Cash and cash equivalents, beginning of period | |
| 12,518,980 | | |
| 16,846,052 | | |
| 7,443,773 | |
| |
| | | |
| | | |
| | |
Cash and cash equivalents, end of period | |
$ | 4,716,533 | | |
$ | 12,518,980 | | |
$ | 16,846,052 | |
See accompanying notes to consolidated
financial statements.
Neuralstem, Inc.
Consolidated Statements of Cash Flows
| |
For the Year Ended December 31, | |
| |
2015 | | |
2014 | | |
2013 | |
| |
| | |
| | |
| |
Supplemental cash flow information: | |
| | | |
| | | |
| | |
Cash paid for interest | |
$ | 954,746 | | |
$ | 762,910 | | |
$ | 624,321 | |
Cash paid for income taxes | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | |
Supplemental schedule of non cash investing and financing activities: | |
| | | |
| | | |
| | |
Issuance of common stock for cashless exercise of warrants and options | |
$ | 1,981,945 | | |
$ | 1,208,653 | | |
$ | 587,500 | |
Issuance of common stock for conversion of long-term debt | |
$ | - | | |
$ | 1,000,000 | | |
$ | - | |
Financing of insurance premiums through note payable | |
$ | - | | |
$ | 210,722 | | |
$ | 183,472 | |
Issuance of common stock and warrants for fees related to debt transactions | |
$ | - | | |
$ | 159,954 | | |
$ | 848,421 | |
Issuance of warrants for vendor services | |
$ | - | | |
$ | - | | |
$ | 658,326 | |
See accompanying notes to consolidated
financial statements.
NEURALSTEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1: Organization and Business
Nature of business
Neuralstem, Inc. and its subsidiary are
referred to as “Neuralstem,” the “Company,” “us,” or “we” throughout this report.
Beginning in 2013, our investment in, and the operations of, our wholly-owned and controlled subsidiary located in China are consolidated
in our consolidated financial statements; previously, all investments in China were expensed as incurred. The impacts of this
change were not material to any period presented.
Neuralstem is a clinical stage biopharmaceutical
company that is utilizing its proprietary human neural stem cell technology to create a comprehensive platform for the treatment
of central nervous system diseases. The Company has utilized this technology as a tool for small-molecule drug discovery and to
create cell therapy biotherapeutics to treat central nervous system diseases. The Company was founded in 1997 and currently has
laboratory and office space in Germantown, Maryland and laboratory facilities in San Diego, California, Chicago, Illinois, and
in the People’s Republic of China. Our operations to date have been directed primarily toward developing business strategies,
raising capital, research and development activities, and conducting pre-clinical testing and human clinical trials of our product
candidates and recruiting personnel.
Liquidity
The Company has incurred losses since
its inception and has not demonstrated an ability to generate revenues from sales or services and have not yet achieved profitable
operations. There is no assurance that profitable operations will ever be achieved, or if achieved, could be sustained on
a continuing basis. In addition, development activities, clinical and pre-clinical testing, and commercialization of our products
will require significant additional financing. These factors create substantial doubt about the Company’s ability to continue
as a going concern. The consolidated financial statements do not include any adjustment that might be necessary if the Company
is unable to continue as a going concern.
Our cash, cash equivalents and short term
investments balance at December 31, 2015 was approximately $12,234,000. We expect that our existing cash and cash equivalents
will only be sufficient to enable us to fund our operations for the next five to six months from that date. Our ability to continue
as a going concern is wholly dependent upon obtaining sufficient financing to fund our operations. Management is in ongoing discussions
regarding various financing options with financial institutions and believes that it will receive cash adequate to fund operations
through December 31, 2016.
Despite our ability to secure capital
in the past, there is no assurance that additional equity or debt financing will be available to us when needed. In the event
that we are not able to secure financing, we may be forced to curtail operations, delay or stop ongoing clinical trials, cease
operations altogether or file for bankruptcy.
We have spent and will continue to spend
substantial funds in the research, development, pre-clinical and clinical testing of our small molecule and stem cell product
candidates with the goal of ultimately obtaining approval from the United States Food and Drug Administration (the “FDA”)
and its international equivalents, to market and sell our products.
No assurance
can be given that (i) FDA or other regulatory agency approval will ever be granted for us to market and sell our product
candidates, or (ii) if regulatory approval is granted, that we will ever be able to sell our proposed products or be profitable.
There is no assurance that profitable
operations will ever be achieved, or if achieved, could be sustained on a continuing basis. In addition, development activities,
clinical and pre-clinical testing, and commercialization of our products will require significant additional financing.
Our long-term
cash position is inadequate to fund all of the costs associated with the full range of testing and clinical trials required by
the FDA and other international regulatory agencies for our core product candidates, we anticipate that our available cash and
expected income will be sufficient to finance our current activities at least through June, 2016.
Note 2: Significant Accounting Policies
and Basis of Presentation
Basis of Presentation
Our consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States if America
(“U.S. GAAP”). The financial statements include the accounts of the Company and our wholly owned subsidiary. All significant
intercompany transactions and balances have been eliminated.
The opinion of our independent registered
accounting firm on our financial statements contains explanatory going concern language. We have prepared our financial statements
on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities
in the normal course of business. Certain information and note disclosures normally included in annual financial statements prepared
in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations,
although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of management,
all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. We have
incurred losses since inception and have a deficit accumulated of approximately $172,000,000 as of December 31, 2015. We
anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales
from our product candidate’s currently in development or we enter into cash flow positive business development transactions.
If we are not able to secure additional financing or enter into a cash flow positive business transaction before July, 2016, we
may not be able to continue as a going concern.
Use of Estimates
The preparation
of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. The consolidated financial statements include significant
estimates for the expected economic life and value of our licensed technology, our net operating loss carry forward and related
valuation allowance for tax purposes and our stock-based compensation related to employees and directors, consultants and advisors,
including investment banks, among other things. Because of the use of estimates inherent in the financial reporting process, actual
results could differ significantly from those estimates.
Fair Value Measurements
The carrying amounts of our short-term
financial instruments, which primarily include cash and cash equivalents, other short-term investments, accounts payable and accrued
expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness is estimated
based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same
remaining maturities. The fair values of our derivative instruments were estimated using Level 3 unobservable inputs. See Note
3 for further details.
Foreign Currency Translation
The functional currency of our wholly
owned foreign subsidiary is its local currency. Assets and liabilities of our foreign subsidiary are translated into
United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the
weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have
not been sold, substantially liquidated or otherwise disposed of are accumulated in other comprehensive income or loss, a component
of stockholders' equity. Transaction gains or losses are included in the determination of net loss.
Cash, Cash Equivalents and Credit Risk
Cash equivalents consist of investments
in low risk, highly liquid money market funds and certificates of deposit with original maturities of 90 days or less. Cash deposited
with banks and other financial institutions may exceed the amount of insurance provided on such deposits. If the amount of a deposit
at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in
part, if the bank were to fail.
Short-term investments consist entirely
of fixed income certificates of deposit (“CDs”) with original maturities of greater than 90 days and not more than
one year.
Financial instruments that potentially
subject us to concentrations of credit risk consist primarily of cash equivalents and short-term investments. Our investment policy,
approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit
risk concentrations. In addition, our CDs are invested through the Certificate of Deposit Account Registry Service (“CDARS”)
program which reduces or eliminates our risk related to concentrations of investments above FDIC insurance levels. We limit our
credit and liquidity risks through our investment policy and through regular reviews of our portfolio against our policy. To date,
we have not experienced any loss or lack of access to cash in our operating accounts or to our cash equivalents and short-term
investments.
Revenue Recognition
Historically,
our revenue has been derived primarily from (i) selling treated samples for gene expression data from stem cell experiments, (ii)
providing services under various contracts and grants and (iii) licensing the use of our intellectual property to third parties.
Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery of goods and services has occurred,
the price is fixed and determinable, and collection is reasonably assured.
Research and
Development
Research and
development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated exclusively
with the pre-clinical development and clinical trials of our product candidates.
Income (Loss)
per Common Share
Basic income
(loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average
number of common shares outstanding during the period.
For periods of
net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders
by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive
potential common shares consist primarily of stock options, restricted stock units and common stock purchase warrants. The dilutive
impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method.
Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities;
the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from
the numerator and excludes the impact of the shares from the denominator.
For all periods
of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential
common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share
for the years ended December 31, 2015, 2014 and 2013. A total of approximately 36.8 ,
40.4, and 38.2 million potential dilutive shares have been excluded in the calculation of diluted net income per share for the
years ended December 31, 2015, 2014 and 2013, respectively as their inclusion would be anti-dilutive.
Share-Based
Compensation
We account for
share-based compensation at fair value. Share-based compensation cost for stock options and warrants granted to employees and
board members is determined at the grant date using an option pricing model that uses level 3 unobservable inputs; share-based
compensation cost for restricted stock and restricted stock units granted to employees and board members is determined at the
grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to
vest is recognized as expense on a straight-line basis over the requisite service period.
Intangible
and Long-Lived Assets
We assess impairment
of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a
group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived
assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum
of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. No significant impairment
losses were recognized during the years ended December 31, 2015, 2014, and 2013.
Income Taxes
We account for income taxes using the
asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences
between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary
to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions
only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is
to recognize interest and penalties on uncertain tax positions as a component of income tax expense.
Reclassification of Prior Year Presentation
Certain prior year amounts have been reclassified
for consistency with the current period presentation. These reclassifications had no material effect on the reported results of
operations.
Significant
New Accounting Pronouncements
In May 2014,
the Financial Accounting Standards Board (FASB) issued ASU 2014-09 – Revenue from Contracts with Customers. This
guidance is effective for fiscal years beginning after December 15, 2016 and early adoption is not permitted. We have not yet
determined the effects of this new guidance on our financial statements.
In August 2014,
the FASB issued ASU 2014-15 – Presentation of Financial Statements – Going Concern. This guidance requires
management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about
the entity’s ability to continue as a going concern. This guidance is effective for fiscal years beginning after December
15, 2016 and early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on our financial
statements.
Note 3: Fair Value Measurements
In April 2015,
the FASB issued update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs. The amendment requires that all costs
incurred to issue debt be presented in the balance sheet as a direct deduction from the carrying value of the debt. The new standard
is limited to the presentation of debt issuance costs and does not affect the recognition or measurement if debt issuance costs.
This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The
implementation of the amended guidance is not expected to have a material impact on the consolidated results of operations and
will result in a reclassification of the debt issuance costs from other long-term assets to long –term debt when adopted .
Fair value is
the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in
the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes
and ranks the level of observability of inputs used in measuring fair value. These levels are:
| · | Level
1 – inputs are based upon unadjusted quoted prices for identical instruments
traded in active markets. |
| · | Level
2 – inputs are based upon quoted prices for similar instruments in active markets,
quoted prices for identical or similar instruments in markets that are not active, and
model-based valuation techniques (e.g. the Black-Scholes model) for which all significant
inputs are observable in the market or can be corroborated by observable market data
for substantially the full term of the assets or liabilities. Where applicable, these
models project future cash flows and discount the future amounts to a present value using
market-based observable inputs including interest rate curves, foreign exchange rates,
and forward and spot prices for currencies and commodities. |
| · | Level
3 – inputs are generally unobservable and typically reflect management's estimates
of assumptions that market participants would use in pricing the asset or liability.
The fair values are therefore determined using model-based techniques, including option
pricing models and discounted cash flow models. |
Financial Assets and Liabilities
Measured at Fair Value on a Recurring Basis
We have segregated
our financial assets and liabilities that are measured at fair value into the most appropriate levels within the fair value hierarchy
based on the inputs used to determine the fair value at the measurement date.
The inputs used
in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value
hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority
of the Company’s funds. The fair value of other short-term financial instruments (primarily short-term investments, accounts
payable and certain accrued expenses) approximate their carrying values because of their short-term nature. The fair value of
our long-term indebtedness approximates its carrying value.
At January 1,
2014, we had common stock purchase warrants issued in conjunction with our March 2013 debt offering (see Note 4) that were accounted
for as derivative instruments whose fair market value was determined using Level 3 inputs. These warrants were exercised in their
entirety in the first quarter of 2014.
We had no financial
assets or liabilities measured at fair value on a recurring basis at December 31, 2015 or December 31, 2014.
Non-Financial Assets and Liabilities
Measure at Fair Value on a Recurring Basis
We have no non-financial assets and
liabilities that are measured at fair value on a recurring basis.
Non-Financial Assets and Liabilities
Measured at Fair Value on a Nonrecurring Basis
We measure our
long-lived assets, including property and equipment and patent assets, at fair value on a nonrecurring basis. These assets are
recognized at fair value when they are deemed to be other-than-temporarily impaired. No such fair value impairment was recognized
in the years ended December 31, 2015, 2014, or 2013.
Note 4: Debt
In March 2013,
we entered into a loan and security agreement for an initial $8 million term loan with an additional $2 million of borrowing capacity
if certain conditions involving new partnerships are met. The loan is collateralized by substantially all of our assets, including
our intellectual property.
The loan provided
for interest at a variable rate based on prime with a floor of 11% and had an original maturity of June 2016. The variable rate
was 11% and did not change during the period through the loan amendment. The loan provided for interest only payments through
December 2013 at which time monthly principal and interest payments of approximately $300,000 were due through maturity. The loan
resulted in net proceeds of approximately $7.6 million after origination and other cash fees and expenses related to the closing
of the loan.
In conjunction
with the loan agreement, we issued the lender a five-year common stock purchase warrant to purchase 648,809 shares of common stock
at an exercise price of $1.0789 per share. This warrant contained non-standard anti-dilution protection and, consequently, was
being accounted for as a derivative instrument, recorded at fair market value each period (see Note 3). The allocation of proceeds
to this warrant resulted in a debt discount which was amortized as interest expense over the term of the debt using the effective
interest method. The warrant was exercised in the first quarter of 2014.
We also incurred
expenses with various third parties in connection with the debt issuance, consisting of approximately $449,000 in cash, 350,650
shares of common stock valued at approximately $396,000, and a five-year common stock purchase warrant to purchase 648,798 shares
at an exercise price of $1.07892 per share. The warrant is classified as equity. Fees related to the debt offering are recorded
as deferred financing fees and are being amortized as interest expense over the term of the debt using the effective interest
method.
The loan agreement
provided for a conversion feature whereby the lender or the Company could each convert up to a maximum of $1 million in principal
payments into common stock of the Company. In 2014, the lender elected to convert the maximum principal payments of $1 million
into 805,972 shares of our common stock in accordance with the terms of the loan and security agreement.
In October 2014,
we entered into an agreement with the existing lender to refinance and amend the terms of our loan and security agreement. The
amended loan provided for refinancing of approximately $5.6 million of outstanding balance of the initial loan coupled with approximately
$4.4 million of new principal for a total of $10 million in principal. The amended loan provides for a variable interest rate
based on prime with a floor of 10% and matures in April 2017. The loan provides for interest only payments through September 2015;
payments of principal and interest of approximately $435,000 from January 2016 through March 2017 and a final balloon payment
of approximately $2.8 million in April 2017. The loan amendment generated approximately $4.3 million in net proceeds after fees
and expenses. The loan amendment is accounted for as a debt extinguishment in accordance with guidance provided for in ASC
470, Debt resulting in a loss on extinguishment of approximately $446,000. In conjunction with the loan amendment we recorded
a debt discount relating to the beneficial conversion feature. Such discount is being amortized as interest expense over the term
of the debt using the effective interest method.
In conjunction
with the loan amendment, we issued the lender a five-year common stock purchase warrant to purchase 75,188 shares of common stock
at an exercise price of $2.66 per share. The warrant contains standard anti-dilution protection but does not contain any anti-dilution
protection for subsequent offerings. The value of the warrant was accounted for in calculating the loss on extinguishment.
We also incurred
expenses with various third parties in connection with the loan amendment, consisting of approximately $86,000 in cash, 28,119
shares of common stock valued at approximately $80,000, and a three-year common stock purchase warrant to purchase 58,141 shares
at an exercise price of $2.66 per share. The warrant is classified as equity and has terms substantially similar to the lender
warrant. These fees related to the loan amendment are recorded as deferred financing fees and are being amortized as interest
expense over the term of the debt using the effective interest method.
At December 31,
2015, remaining principal payments due under this loan are approximately $4,570,000 and $3,766,000 payable in, 2016 and 2017,
respectively.
Note 5: Stockholders’
Equity
We have granted
share-based compensation awards to employees, board members and service providers. Awards may consist of common stock, restricted
common stock, restricted common stock units, warrants, or stock options. Our stock options and warrants have lives of up to ten
years from the grant date. The stock options and warrants vest either upon the grant date or over varying periods of time. The
stock options we grant provide for option exercise prices equal to or greater than the fair market value of the common stock at
the date of the grant. Restricted stock units grant the holder the right to receive fully paid common shares with various restrictions
on the holder’s ability to transfer the shares. Vesting of the restricted stock units is similar to that of stock options.
As of December 31, 2015, we have approximately 39.5 million shares of common stock reserved for issuance of such awards.
We record share-based
compensation expense on a straight-line basis over the requisite service period. Share-based compensation expense included
in the statements of operations was as follows:
| |
Year Ended December 31, | |
| |
2015 | | |
2014 | | |
2013 | |
| |
| | |
| | |
| |
Research and development costs | |
$ | 1,394,194 | | |
$ | 968,326 | | |
$ | 932,200 | |
General and administrative expenses | |
| 1,557,173 | | |
| 3,351,747 | | |
| 1,399,201 | |
Total | |
$ | 2,951,367 | | |
$ | 4,320,073 | | |
$ | 2,331,401 | |
No income tax
benefit was recognized in the consolidated statements of operations for stock-based compensation for the years presented due to
the Company’s net loss position.
Stock Options
A summary of stock option activity
and related information for the year ended December 31, 2015 follows:
| |
Number of Options | | |
Weighted- Average
Exercise Price | | |
Weighted- Average
Remaining Contractual Life (in years) | | |
Aggregate Intrinsic
Value | |
| |
| | |
| | |
| | |
| |
Outstanding at January 1, 2015 | |
| 18,986,395 | | |
$ | 1.89 | | |
| 5.1 | | |
$ | 20,306,807 | |
Granted | |
| 765,549 | | |
$ | 3.09 | | |
| | | |
| | |
Exercised | |
| (1,031,774 | ) | |
$ | 0.54 | | |
| | | |
$ | 68,400 | |
Forfeited/Expired | |
| (1,617,223 | ) | |
$ | 1.32 | | |
| | | |
| | |
Outstanding at December 31, 2015 | |
| 17,102,947 | | |
$ | 2.08 | | |
| 5.0 | | |
$ | 550,000 | |
| |
| | | |
| | | |
| | | |
| | |
Exercisable at December 31, 2015 | |
| 14,118,821 | | |
$ | 2.19 | | |
| 4.6 | | |
$ | 330,000 | |
| |
| | | |
| | | |
| | | |
| | |
Vested and expected to vest at December 31, 2015 | |
| 17,099,027 | | |
$ | 2.08 | | |
| 5.0 | | |
$ | 550,000 | |
Range of Exercise Prices | |
Number of Options
Outstanding | | |
Weighted- Average
Exercise Price | | |
Weighted- Average
Remaining Contractual Life (in years) | | |
Aggregate Intrinsic
Value | |
$0.50 - $1.00 | |
| 5,000,000 | | |
$ | 0.92 | | |
| 6.6 | | |
$ | 550,000 | |
$1.01 - $2.00 | |
| 4,275,984 | | |
$ | 1.22 | | |
| 6.0 | | |
| - | |
$2.01 - $3.00 | |
| 2,122,669 | | |
$ | 2.50 | | |
| 3.8 | | |
| - | |
$3.01 - $5.00 | |
| 5,704,294 | | |
$ | 3.60 | | |
| 3.4 | | |
| - | |
| |
| 17,102,947 | | |
$ | 2.08 | | |
| 5.0 | | |
$ | 550,000 | |
The Company uses
the Black-Scholes option pricing model for “plain vanilla” options and other pricing models as appropriate to calculate
the fair value of options. Significant assumptions used in these models include:
| |
2015 | | |
2014 | | |
2013 | |
| |
| | | |
| | | |
| | |
Annual dividend | |
| - | | |
| - | | |
| - | |
Expected life (in years) | |
| 4.0-6.0 | | |
| 4.0 - 8.5 | | |
| 3.0 - 6.5 | |
Risk free interest rate | |
| 1.39%-1.78% | | |
| 1.12% - 2.50% | | |
| 0.29% - 2.43% | |
Expected volatility | |
| 68.6%-71.8% | | |
| 68.8% - 100.0% | | |
| 65.1% - 77.5% | |
The Company estimates
the expected term using the "simplified-method" as it does not have sufficient historical exercise data to provide a
reasonable estimate.
The options granted
in the years ended December 31, 2015, 2014, and 2013 had weighted average grant date fair values of $1.89 ,
$1.90, and $1.01, respectively. The total fair value of the options vested during the years ended December 31, 2015, 2014, and
2013 was approximately $2,215,000, $1,814,000, and $1,170,000 respectively.
Unrecognized
compensation cost for unvested stock option awards outstanding at December 31, 2015 was approximately $3,449,000 to be recognized
over approximately 1.8 years.
RSUs
We have granted
restricted stock units (RSUs) that entitle the holders to receive shares of our common stock upon vesting and subject to certain
restrictions regarding the exercise of the RSUs and the holders’ ability to transfer the shares received upon exercise.
The fair value of RSUs granted is based upon the market price of the underlying common stock as if they were vested and issued
on the date of grant.
A summary of
our RSU activity for the year ended December 31, 2015 follows:
| |
Number of RSU's | | |
Weighted- Average Grant
Date Fair Value | |
| |
| | |
| |
Outstanding at January 1, 2015 | |
| 447,275 | | |
$ | 2.18 | |
Granted | |
| - | | |
$ | - | |
Vested and converted to common shares | |
| (219,415 | ) | |
$ | 2.21 | |
Forfeited | |
| (76,954 | ) | |
$ | 2.21 | |
Outstanding at December 31, 2015 | |
| 150,906 | | |
$ | 2.13 | |
| |
| | | |
| | |
Exercisable at December 31, 2015 | |
| 150,906 | | |
$ | 2.13 | |
There were no
RSUs granted in 2015. The RSU granted in the years ended December 31, 2014, and 2013 had weighted average grant date fair values
of $3.31, and $1.14 respectively. The total fair value of the shares vested during the years ended December 31, 2015, 2014, and
2013 was approximately $33,000, $142,000, and $254,000, respectively.
Unrecognized
compensation cost for unvested RSUs outstanding at December 31, 2015 was $0.
Stock Purchase Warrants
Warrants to purchase
common stock were issued to certain officers, directors, stockholders and service providers. We have also issued warrants in conjunction
with debt offerings and equity raises and at various times replacement warrants were issued in conjunction with warrant exercises.
A summary of warrant activity for
the year ended December 31, 2015 follows:
| |
Number of Warrants | | |
Weighted- Average
Exercised Price | | |
Weighted- Average
Remaining Contractual Life (in years) | | |
Aggregate Intrinsic
Value | |
| |
| | |
| | |
| | |
| |
Outstanding at January 1, 2015 | |
| 21,422,346 | | |
$ | 2.30 | | |
| 3.8 | | |
$ | 15,984,739 | |
Granted | |
| 150,000 | | |
$ | 1.87 | | |
| 4.5 | | |
| | |
Exercised | |
| (1,724,606 | ) | |
$ | 1.94 | | |
| | | |
| | |
Forfeited | |
| (195,644 | ) | |
$ | 2.02 | | |
| | | |
| | |
Outstanding at December 31, 2015 | |
| 19,652,096 | | |
$ | 2.34 | | |
| 3.1 | | |
$ | 309,724 | |
| |
| | | |
| | | |
| | | |
| | |
Exercisable at December 31, 2015 | |
| 19,577,096 | | |
$ | 2.34 | | |
| 3.1 | | |
$ | 309,724 | |
The stock purchase
warrants granted in the years ended December 31, 2015, 2014, and 2013 had a weighted average grant date fair value of $1.08
, $2.07, and $0.82, respectively. All stock purchase warrants were classified as equity with the exception of the warrant
issued to the lender in the March 2013 debt transaction (see Note 4).
Stock purchase
warrants exercised in 2015, 2014, and 2013 had an intrinsic value of approximately $5,126,000, $4,287,000, and $3,550,000, respectively.
In 2014 we modified
certain warrants held by our Chief Science Officer. Such modification extended the term of the warrants by an additional five
years and resulted in an expense of approximately $3.1 million included in other expense in our statements of operations for the
year ended December 31, 2014. The related stock based compensation will be recognized.
Restricted
Stock
We have granted
restricted stock to certain board members based on revised board of director year and compensation policy.
A
summary of our restricted stock activity for the year ended December 31, 2015 is as follows:
| |
Number of RS | | |
Weighted- Average
Grant Date Fair Value | |
Granted | |
| 427,808 | | |
$ | 1.87 | |
Vested | |
| (213,904 | ) | |
$ | 1.87 | |
Forfeited | |
| - | | |
$ | 0.00 | |
Outstanding at December 31, 2015 | |
| 213,904 | | |
$ | 1.87 | |
The total intrinsic value of the units
converted in 2015 was approximately $241,000.
Common Stock
In June 2014,
the Company’s shareholders approved a 150,000,000 increase in the authorized shares of common stock bringing the total authorized
shares of common stock to 300,000,000.
In January and
February 2013, we issued 258,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25
per share and we received approximately $323,000 in net proceeds from the exercises. In conjunction with the exercises, we modified
the warrants to reduce the exercise price to $1.25 and issued 258,000 replacement warrants. The replacement warrants have an exercise
price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction
of the exercise price on the original warrants. Such expense is classified as warrant modification expense. The warrants are classified
within equity.
In March 2013,
we issued 350,650 shares of common stock and 1,297,607 common stock purchase warrants to various parties in conjunction with our
debt transaction (see Note 4).
In May 2013,
we issued 440,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.07 per share
and we received approximately $433,000 in net proceeds from the exercises. In conjunction with the exercise, we modified the warrants
to reduce the exercise price to $1.07 and issued 440,000 replacement warrants. The replacement warrants have an exercise price
of $1.25 and expire in May 2016. We recognized expense for the value of the replacement warrants and the reduction of the exercise
price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified within
equity.
In May 2013,
we issued 689,675 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share
and we received approximately $844,000 in net proceeds from the exercises. In conjunction with the exercises, we modified the
warrants to reduce the exercise price to $1.25 and issued 689,675 replacement warrants. The replacement warrants have an exercise
price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction
of the exercise price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified
within equity.
In May and June
2013, we issued 378,809 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per
share and we received approximately $474,000 in net proceeds from the exercises. In conjunction with the exercise, we issued 378,809
replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense
for the value of the replacement warrants; such expense is classified as warrant modification expense. The warrants are classified
within equity.
In May and June
2013, we issued 300,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.02 and
we received approximately $306,000 in net proceeds from the exercises.
In July 2013,
we issued 942,520 shares of our common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share
and we received approximately $1,178,000 in net proceeds from the exercises. In conjunction with the exercises, we modified 782,005
of the warrants to reduce the exercise price to $1.25 and issued 942,520 replacement warrants. The replacement warrants have an
exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction
of the exercise price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified
within equity.
In July 2013,
we issued 100,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.02 and we received
approximately $102,000 in net proceeds from the exercise.
In September
2013, we issued 1,448,798 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per
share (800,000 shares) and $1.08 per share (648,798 shares) and we received approximately $1,700,000 in net proceeds from the
exercises. In conjunction with the exercise, we issued an additional 72,440 shares of our common stock as a commission for exercise.
We recognized an expense for the value of the additional common stock; such expense is classified as warrant modification expense.
In September
and December 2013, we issued 344,000 shares of common stock upon the exercise of outstanding warrants. Of these shares, 340,000
shares of stock were issued at $2.13 while 4,000 shares of stock were issued at $1.56. We received approximately $730,000 net
proceeds from the exercises.
In September
2013, we issued 401,133 shares of our common stock as a result of the cashless exercise of 650,000 outstanding common stock purchase
warrants with an average strike price of $0.90. The exercises resulted in 248,867 warrants being forfeited and
we received no proceeds.
In September
2013, we completed a registered direct offering of 2,847,500 shares of common stock at a price of $1.60 per share. We received
aggregate gross proceeds of $4,556,000 and net proceeds of approximately $4,242,000 from the offering. In connection with the
offering, we issued common stock purchase warrants to purchase 1,423,750 shares of our common stock; the warrants have an exercise
price of $2.00 and a term of five years. Additionally, we issued a common stock purchase warrant to the placement agent to purchase
up to 170,850 shares; the warrant has an exercise price of $2.00 per share and term of 19 months. The warrants are classified
within equity.
In November and
December 2013, we issued 1,140,994 shares of common stock as a result of sales under our At the Market Offering Agreement. The
shares were sold at an average price of $2.64 per share and generated approximately $2,895,000 in net proceeds.
In January, 2014,
we closed a registered direct offering of 6,872,859 shares of common stock at a price of $2.91 per share. We received aggregate
gross proceeds of $20 million and net proceeds of approximately $18,630,000 from the offering. In connection with the offering,
we also issued 3,436,435 common stock purchase warrants; the warrants have an exercise price of $3.64, a term of five years and
are classified within equity. This offering was made pursuant to our $50 million shelf registration statement declared effective
by the SEC on September 13, 2013 (Registration No. 333-190936). Additionally, as a result of this transaction an advisor to the
Company met certain capital raising milestones and consequently, the term of their common stock purchase warrant was extended
to 5 years.
In 2014, we issued
249,163 shares of common stock as a result of sales under our At the Market Offering Agreement. The shares were sold at an average
price of $3.55 per share and we received approximately $838,000 in net proceeds.
In 2014, we issued
a total of 1,234,428 shares of our common stock upon the exercise of outstanding common stock purchase warrants and stock options.
The warrants and options were exercised at an average exercise price of $1.44. We received approximately $1,714,000 of net proceeds
from the exercises.
In 2014, we issued
a total of 712,539 shares of our common stock upon the cashless and partial-cashless exercise of 1,194,372 outstanding common
stock purchase warrants and stock options. The warrants and options were exercised at an average price of $1.03. We received approximately
$20,000 of net proceeds from the exercises.
In 2014, we issued
568 shares of common stock upon conversion of certain outstanding RSU’s. We received no proceeds from this transaction.
In 2014, we issued
805,972 shares of common stock upon the conversion by the lender of $1 million of principal payments due under our March 2013
long-term debt in accordance with the terms of the loan and security agreement (see Note 4). We received no such proceeds from
this conversion.
In October 2014, we issued 28,119 shares
of common stock and common stock purchase warrants to purchase 133,329 to various parties in conjunction with our loan amendment
(see Note 4).
In February and March 2015, we issued 812,423 shares of common stock as a result of sales under our At
the Market Offering Agreement. The shares were sold at an average price of $3.77 per share and we received approximately $2,932,000
in net proceeds.
In 2015, we
issued a total of 1,724,606 shares of our common stock upon the exercise of outstanding common stock purchase warrants and stock
options. The warrants and options were exercised at an average exercise price of $1.94. We received approximately $3,056,000
of net proceeds from the exercises.
In 2015, we issued
a total of 1,251,189 shares of our common stock upon the cashless exercise of 2,209,000 outstanding common stock purchase warrants,
stock options and conversion of RSU’s. The warrants and options were exercised at an average price of $0.6157. The exercises
resulted in 1,158,020 warrants and options being forfeited and we received no proceeds from the exercises or from the conversion
of RSU’s.
In 2015, we issued 427,808 shares of common stock as restricted stock awards to our independent directors
in accordance with our Director Compensation Plan. These shares are reserved under our 2010 employee option plan and they vest
quarterly over the director comp year, in September 2015, December 2015, March 2016, and June 2016.
Note 6: Property and Equipment
The major classes of property and equipment consist
of the following at December 31:
| |
2015 | | |
2014 | |
Furniture and fixtures | |
$ | 31,610 | | |
$ | 22,603 | |
Computers and office equipment | |
| 136,558 | | |
| 100,105 | |
Leasehold improvements | |
| 40,290 | | |
| | |
Lab equipment | |
| 763,293 | | |
| 661,789 | |
| |
| 971,751 | | |
| 784,497 | |
Less accumulated depreciation | |
| (628,551 | ) | |
| (483,232 | ) |
Property and equipment, net | |
$ | 343,200 | | |
$ | 301,265 | |
The above includes approximately $73,000
of equipment located at our research facility in China. Property and equipment are recorded at cost and are depreciated using
the straight-line method over the estimated useful lives of the respective assets. Depreciation expense for the years ended December
31, 2015, 2014, and 2013 was approximately $148,000, $137,000, and $126,000 respectively.
Note 7: Intangible Assets
The Company holds
patents related to its stem cell and small molecule technologies. Patent costs are capitalized and are being amortized over the
life of the patents. The weighted average remaining unamortized life of issued patents was approximately 9.8, years at December
31, 2015. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it
exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived
assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. During the years ended
December 31, 2015, 2014 and 2013, no significant impairment losses were recognized. The Company’s intangible assets and
accumulated amortization consisted of the following at December 31, 2015 and 2014:
| |
2015 | | |
2014 | |
Patent asset | |
$ | 1,887,798 | | |
$ | 1,822,037 | |
| |
| | | |
| | |
Accumulated Amortization | |
$ | (784,331 | ) | |
$ | (588,865 | ) |
| |
| | | |
| | |
Net Intagibles | |
$ | 1,103,467 | | |
$ | 1,233,172 | |
Amortization expense for the years ended
December 31, 2015, 2014 and 2013 was approximately $197,000, $211,000, and $119,000 respectively.
The expected average future annual amortization
expense over the next five years is approximately $144,000 based on current balances of our intangible assets.
Note 8: Income Taxes
Our provision for income taxes for 2015, 2014, and 2013 consists
of the following:
| |
2015 | | |
2014 | | |
2013 | |
Current provision: | |
| | | |
| | | |
| | |
Federal | |
$ | - | | |
$ | - | | |
$ | - | |
State | |
| - | | |
| - | | |
| - | |
Foreign | |
| - | | |
| - | | |
| - | |
Total current provision | |
| - | | |
| - | | |
| - | |
| |
| | | |
| | | |
| | |
Deferred provision (benefit): | |
| | | |
| | | |
| | |
Federal | |
| (6,645,222 | ) | |
| (5,563,694 | ) | |
| (4,436,239 | ) |
State | |
| (955,515 | ) | |
| (61,835 | ) | |
| 502,696 | |
Foreign | |
| - | | |
| - | | |
| - | |
Total deferred provision (benefit) | |
| (7,600,737 | ) | |
| (5,625,529 | ) | |
| (3,933,543 | ) |
Valuation allowance | |
| 7,600,737 | | |
| 5,625,529 | | |
| 3,933,543 | |
Consolidated income tax provision | |
$ | - | | |
$ | - | | |
$ | - | |
We provide a full valuation
allowance on our net deferred tax assets because management has determined that it is more likely than not that we will not earn
income sufficient to realize the deferred tax assets during the asset reversal periods.
The difference between income taxes computed
by applying the statutory federal income tax rate to consolidated losses before income taxes and the consolidated provision for
income taxes is attributable to the following:
| |
2015 | | |
2014 | | |
2013 | |
Federal statutory rate | |
| (34.0 | )% | |
| (34.0 | )% | |
| (34.0 | )% |
State income taxes, net of Federal benefits | |
| (4.3 | )% | |
| (4.5 | )% | |
| (5.3 | )% |
Warrant modification/inducement expense | |
| 0.0 | % | |
| 5.3 | % | |
| 9.9 | % |
Other | |
| 1.4 | % | |
| 8.3 | % | |
| 9.5 | % |
Valuation allowance | |
| 36.9 | % | |
| 24.9 | % | |
| 19.9 | % |
Total | |
| 0.0 | % | |
| 0.0 | % | |
| 0.0 | % |
The tax effects of significant temporary
differences representing deferred tax assets as of December 31, 2015 and 2014:
| |
2015 | | |
2014 | | |
| |
Net operating loss carryforwards | |
$ | 39,555,984 | | |
$ | 36,008,206 | | |
| | |
Stock based compensation expense | |
| 10,659,107 | | |
| 11,183,210 | | |
| | |
Tax credit carryforwards and other | |
| 5,717,023 | | |
| 1,139,961 | | |
| | |
| |
| 55,932,114 | | |
| 48,331,377 | | |
| | |
| |
| | | |
| | | |
| | |
Valuation allowance | |
| (55,932,114 | ) | |
| (48,331,377 | ) | |
| | |
Net deferred tax assets | |
$ | - | | |
$ | - | | |
| | |
The Company had Federal net operating
loss (“NOL”) carryforwards of approximately $113.7 million and $95.4 million, excluding stock-based compensation NOLs,
at December 31, 2015 and 2014, respectively, which begin expiring in 2015. The Company also has certain Federal tax credit carryforwards
that will expire through 2035. The timing and manner in which these net operating loss carryforwards and credits may be used in
any year will be limited to the Company’s ability to generate future earnings and also may be limited by certain provisions
in the U.S. tax code. The Company has not identified any uncertain tax positions and did not recognize any adjustments for unrecognized
tax benefits. The Company remains subject to examination for income tax returns dating back to 2012.
Note 9: Selected Quarterly Data (Unaudited)
The following represents the Company’s unaudited quarterly
results for the years ended December 31:
| |
Quarter Ended | |
| |
2015 | |
| |
March 31 | | |
June 30 | | |
September 30 | | |
December 31 | |
| |
| | |
| | |
| | |
| |
Revenues | |
$ | 2,917 | | |
$ | 2,500 | | |
$ | 2,500 | | |
$ | 2,500 | |
Operating loss | |
$ | (4,612,980 | ) | |
$ | (4,994,722 | ) | |
$ | (5,197,520 | ) | |
$ | (4,351,306 | ) |
Net loss | |
$ | (5,053,145 | ) | |
$ | (5,448,037 | ) | |
$ | (5,637,568 | ) | |
$ | (4,765,151 | ) |
Net loss per share - basic and diluted | |
$ | (0.06 | ) | |
$ | (0.06 | ) | |
$ | (0.06 | ) | |
$ | (0.05 | ) |
| |
Quarter Ended | |
| |
2014 | |
| |
March 31 | | |
June 30 | | |
September 30 | | |
December 31 | |
| |
| | |
| | |
| | |
| |
Revenues | |
$ | 4,167 | | |
$ | 5,000 | | |
$ | 5,000 | | |
$ | 4,666 | |
Operating loss | |
$ | (5,176,901 | ) | |
$ | (3,511,238 | ) | |
$ | (4,106,745 | ) | |
$ | (4,640,965 | ) |
Net loss | |
$ | (5,919,057 | ) | |
$ | (6,751,282 | ) | |
$ | (4,455,237 | ) | |
$ | (5,503,168 | ) |
Net loss per share - basic and diluted | |
$ | (0.07 | ) | |
$ | (0.08 | ) | |
$ | (0.05 | ) | |
$ | (0.06 | ) |
The sum of the quarterly per share amounts
does not equal the annual amounts due to changes in the weighted average number of common shares outstanding during the year.
Note 10: Commitments and Contingencies
We currently operate two facilities located
in the United States and one facility located in China. Our corporate offices and primary research facilities are located in Germantown,
Maryland, where we license approximately 2,900 square feet. This license provides for monthly payments of approximately $10,200
per month with the term expiring on December 31, 2016.
In 2015, we entered into a lease consisting
of approximately 3,100 square feet of research space in San Diego, California. This lease provides for current monthly payments
of approximately $11,000 and expires on August 31, 2018.
We also lease a research facility in People’s
Republic of China. This lease expires on September 30, 2018 with lease payments of approximately $3,200 per month.
Future minimum payments under all leases
at December 31, 2015 are as follows:
Year | |
Amount | |
2016 | |
$ | 309,286 | |
2017 | |
| 149,569 | |
2018 | |
| 143,300 | |
2019 | |
| 38,542 | |
2020 | |
| - | |
2020 and thereafter | |
| - | |
Total minimum payments | |
$ | 640,697 | |
The Company recognized approximately $318,000,
$257,000, and $277,000, in rent expense for the years ended December 31, 2015, 2014, and 2013 respectively.
The Company is currently obligated under
two written employment agreements with our former Chief Executive Officer (“CEO”) and Chief Scientific Officer (“CSO”).
Both agreements terminate on October 31, 2017. Pursuant to the CEO’s agreement, he receives a salary of $440,000 per annum
and in the event of termination prior to the completion of the agreement the Company would pay the CEO the greater of his remaining
compensation due under the agreement or one million dollars ($1,000,000). Pursuant to the CSO’s agreement, he receives
$750,000 per annum and in the event of termination prior to the completion of the agreement the Company would pay the CSO the
greater of the remaining compensation due under the agreement or one million dollars ($1,000,000). In addition, pursuant
to both the agreements any and all stock options, warrants, restricted stock or restricted stock units granted would accelerate
and vest immediately in the event the agreements are terminated early. On March 1, 2015, Neuralstem, Inc. (the “Company”)
entered into a general release and waiver of claims (“General Release”) with I. Richard Garr in connection with his
resignation as the Company’s chief executive officer. Pursuant to the General Release, the required severance payment to
Mr. Garr pursuant to his termination were amended to the following severance in exchange for Mr. Garr’s voluntary resignation:
(i) the continued payment of Mr. Garr’s monthly salary immediately prior to his resignation until March 1, 2017, (ii) a
lump of $177,000 to be paid on June 1, 2016, January 1, 2017 and March 1, 2017, (iii) continued healthcare benefits until January
1, 2017, and (iv) the immediate vesting of any previously outstanding but unvested equity awards (collectively, the “Severance”).
On May 7, 2008,
we filed suit against StemCells, Inc., StemCells California, Inc. (collectively "StemCells") and Neurospheres Holding
Ltd. in U.S. District Court for the District of Maryland, alleging that U.S. Patent No. 7,361,505 (the "'505 patent")
is invalid, not infringed, and unenforceable. See Civil Action No. 08-1173. On May 13, 2008 we filed an Amended Complaint seeking
declaratory judgment that U.S. Patent No. 7,155,418 (the "'418 patent") is invalid and not infringed and that certain
statements made by our CEO are not trade libel or do not constitute unfair competition. On September 11, 2008, StemCells filed
its answer asserting counterclaims of infringement for the '505 patent, the '418 patent, and state law claims for trade libel
and unfair competition. This case was consolidated with the 2006 litigation discussed below.
On July 28, 2006,
StemCells, Inc., filed suit against Neuralstem, Inc. in the U.S. District Court in Maryland, alleging that Neuralstem has been
infringing, contributing to the infringement of, and or inducing the infringement of four patents allegedly owned by or exclusively
licensed to StemCells. See Civil Action No. 06-1877. We answered the Complaint denying infringement, asserting that the patents
are invalid, asserting that we have intervening rights based on amendments made to the patents during reexamination proceedings,
and further asserting that some of the patents are unenforceable due to inequitable conduct. Neuralstem has also asserted counterclaims
that StemCells has engaged in anticompetitive conduct in violation of antitrust laws. On February 28, 2011, Neuralstem filed a
Motion to Dismiss for lack of standing and concurrently filed a Motion for Leave to Amend its Answer and Counterclaim to allege
that StemCells is not the exclusive licensee of the patents-in-suit and also that Neuralstem has obtained a non-exclusive license
to the patents-in-suit. In addition, before the Court decided Neuralstem's Motion to Dismiss for lack of standing, StemCells filed
a motion for summary judgment on the issue standing. Neuralstem responded to that motion and cross-moved for summary judgment
on the issue of standing. The Court further issued its Markman Order (an order ruling on the scope and meaning of disputed patent
claim language regarding the patents at issue) on August 12, 2011. On August 26, 2011, StemCells moved for reconsideration of
two terms construed in the Markman Order and that motion remains pending. On April 6, 2012 the Court granted Neuralstem's Motion
for Leave to Amend to assert lack of standing and denied Neuralstem's Motion to Dismiss and Motion for Summary Judgment without
prejudice. The Court also denied StemCells' Motion for Summary Judgment with prejudice. The Court stayed all other matters pending
resolution of the question of standing. The case was then reassigned to Judge Roger W. Titus.
On July 22, 2015,
the Court issued its ruling on the issue of standing finding that a third-party who was not named as an inventor was a co-owner
and co-inventor of the patents-in-suit. Thus, the Court determined that StemCells lacked standing to pursue its patent infringement
claims against Neuralstem and the case was dismissed with prejudice.
On September
10, 2015, the parties entered into a settlement agreement dismissing all claims and counterclaims with prejudice.
Note 11: Transaction with Related Parties
On March 1, 2015, Neuralstem, Inc. (the
“Company”) entered into a general release and waiver of claims (“General Release”) with I. Richard Garr
in connection with his resignation as the Company’s chief executive officer. Mr. Garr’s employment agreement previously
required the Company to pay a lump sum to Mr. Garr of $1,000,000. Pursuant to the General Release, the required severance
payment to Mr. Garr pursuant to his termination were amended to the following severance in exchange for Mr. Garr’s voluntary
resignation: (i) the continued payment of Mr. Garr’s monthly salary immediately prior to his resignation until March 1,
2017, (ii) a lump of $177,000 to be paid on June 1, 2016, January 1, 2017 and March 1, 2017, (iii) continued healthcare benefits
until January 1, 2017, and (iv) the immediate vesting of any previously outstanding but unvested equity awards (collectively,
the “Severance”).
Note 12: Subsequent Events
On February 15, 2016, The Company announced
the appointment Richard Daly to the position of President and Chief Executive Officer, and as a member of the Company’s
board of directors. Mr. Daly will serve as a Class III member of the Company’s Board and will be up for re-election at the
Company’s 2017 annual shareholders meeting. On February 15, 2016, in connection with the hiring of Mr. Daly as discussed
herein, Richard Garr ceased to serve as the Company’s Chief Executive Officer, President and General Counsel. Mr. Garr will
continue to serve on the Company’s board and will continue to assist the Company through a transition period.
On March 1, 2015, Neuralstem, Inc. (the
“Company”) entered into a general release and waiver of claims (“General Release”) with I. Richard Garr
in connection with his resignation as the Company’s chief executive officer. Mr. Garr’s employment agreement previously
required the Company to pay a lump sum to Mr. Garr of $1,000,000. Pursuant to the General Release, the required severance
payment to Mr. Garr pursuant to his termination were amended to the following severance in exchange for Mr. Garr’s voluntary
resignation: (i) the continued payment of Mr. Garr’s monthly salary immediately prior to his resignation until March 1,
2017, (ii) a lump of $177,000 to be paid on June 1, 2016, January 1, 2017 and March 1, 2017, (iii) continued healthcare benefits
until January 1, 2017, and (iv) the immediate vesting of any previously outstanding but unvested equity awards (collectively,
the “Severance”).
| ITEM 9. | CHANGES IN AND DISAGREEMENTS WITH
ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE |
Not applicable.
| ITEM 9A. | CONTROLS
AND PROCEDURES |
Evaluation of Disclosure Controls and Procedures
Based on an evaluation under the supervision
and with the participation of the Company’s management, the Company’s principal executive officer and principal financial
officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e)
under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) were effective as of December 31, 2015
to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under
the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities
and Exchange Commission rules and forms and (ii) accumulated and communicated to the Company’s management, including
its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Inherent Limitations Over Internal Controls
The Company’s internal control over
financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with U.S. generally accepted accounting principles (“GAAP”).
The Company’s internal control over financial reporting includes those policies and procedures that:
(i) pertain
to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
Company’s assets;
(ii) provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
GAAP, and that the Company’s receipts and expenditures are being made only in accordance with authorizations of the Company’s
management and directors; and
(iii) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s
assets that could have a material effect on the financial statements.
Management, including the Company’s
principal executive officer and principal financial officer, does not expect that the Company’s internal controls will prevent
or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the
fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of
the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control
issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods
are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that
the degree of compliance with the policies or procedures may deteriorate.
Management’s Annual Report on Internal Control Over
Financial Reporting
The Company’s management is responsible
for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange
Act). Management conducted an assessment of the effectiveness of the Company’s internal control over financial reporting
based on the criteria set forth in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission. Based on the Company’s assessment, management has concluded that its internal
control over financial reporting was effective as of December 31, 2015 to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements in accordance with GAAP.
The effectiveness of our internal control
over financial reporting as of December 31, 2015 has been audited by Stegman & Company, an independent registered public accounting
firm, and the Firm’s attestation report on this matter is included in Item 8 of this Annual Report on Form 10-K.
Changes in Internal Control Over Financial Reporting
We previously disclosed in our quarterly
report on Form 10-Q for the period ended June 30, 2015, that we had identified deficiencies with regard to the operation of our
disclosure controls. We are committed to improving our financial oversight and as part of this commitment, we have taken the following
steps:
| · | We
hired a full-time Chief Financial Officer in May 2015 |
| · | We
hired a full-time Corporate Controller in September 2015 |
| · | We
have enhanced our whistleblower protocols |
| · | We
have implemented and are continuing to implement enhanced policies and procedures for
travel expense reimbursements and disbursements. |
| · | We
have implemented and are continuing to implement enhanced oversight by our Audit Committee
of expense reimbursements |
Management is continuing to review the
operation of its previous controls with regard to expense reimbursements and disbursement.
There were no changes in the Company’s
internal control over financial reporting during the fourth quarter of 2015, which were identified in connection with management’s
evaluation required by paragraph (d) of rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are
reasonably likely to materially affect, the Company’s internal control over financial reporting.
| Item 9B. | OTHER INFORMATION |
On February 15, 2016, Richard Daly was appointed Chief Executive
Officer, President, and as a member of the Company’s board of directors. Mr. Daly will serve as a Class III member of the
Company’s Board and will be up for re-election at the Company’s 2017 annual shareholders meeting. On February
15, 2016, in connection with the hiring of Mr. Daly as discussed herein, Richard Garr ceased to serve as the Company’s Chief
Executive Officer, President and General Counsel. On March 2, 2016, the Company and Mr. Garr (our prior CEO), entered into a general
release and waiver of claims agreement whereby in exchange for releasing the Company from any and all causes of action, rights
or claims in any way connected to his employment with the Company, Mr. Garr received the following severance: (i) Mr. Garr will
continue to earn his current monthly salary until March 2017, (ii) Mr. Garr will receive payments in the amount of $177,000 to
be paid on June 1, 2016, January 1, 2017 and March 1, 2017, (iii) Mr. Garr will continue to receive healthcare benefits until March
2017, and (iv) the immediate vesting of any previously outstanding but unvested equity awards. Mr. Garr will continue to serve
on the Company’s board and will continue to assist the Company through a transition period.
PART III
| ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS
AND CORPORATE GOVERNANCE |
The information required by this Item
is set forth under the heading “Directors, Executive Officers and Corporate Governance” in our 2016 Proxy Statement
to be filed with the SEC in connection with the solicitation of proxies for our 2016 Annual Meeting of Shareholders (“2016
Proxy Statement”) and is incorporated herein by reference. Such Proxy Statement will be filed with the SEC within 120 days
after the end of the fiscal year to which this report relates. The information required by this item regarding delinquent filers
pursuant to Item 405 of Regulation S-K will be included under the caption “Section 16(a) Beneficial Ownership Reporting
Compliance” in the 2016 Proxy Statement and is incorporated herein by reference.
| ITEM 11. | EXECUTIVE
COMPENSATION |
The information required by this Item
is set forth under the headings “Director Compensation” and “Executive Compensation” of our 2016 Proxy
Statement and is incorporated herein by reference.
| ITEM 12. | SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. |
The information required by this Item
is set forth under the headings “Beneficial Owners of Shares of Common Stock” and “Equity Compensation Plan
Information” of our 2016 Proxy Statement and is incorporated herein by reference.
| ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS, AND DIRECTOR INDEPENDENCE |
The information required by this Item
is set forth under the heading “Certain Relationships and Related Transactions” of our 2016 Proxy Statement and is
incorporated herein by reference.
| ITEM 14. | PRINCIPAL ACCOUNTING FEES AND
SERVICES |
The information required by this Item
is set forth under the heading “Independent Registered Public Accounting Firm” of our 2016 Proxy Statement and is
incorporated herein by reference.
PART IV
| ITEM 15. | EXHIBITS, FINANCIAL STATEMENT
SCHEDULES |
| 1. | Financial Statements:
See “Index to Financial Statements” in Part II, Item 8 of this
Form 10-K. |
| 2. | Exhibits: The
exhibits listed in the accompanying index to exhibits are filed or incorporated by reference
as part of this Form 10-K. |
Certain of the agreements filed as exhibits
to this Form 10-K contain representations and warranties by the parties to the agreements that have been made solely for
the benefit of the parties to the agreement. These representations and warranties:
| · | may
have been qualified by disclosures that were made to the other parties in connection
with the negotiation of the agreements, which disclosures are not necessarily reflected
in the agreements; |
| · | may
apply standards of materiality that differ from those of a reasonable investor; and |
| · | were
made only as of specified dates contained in the agreements and are subject to later
developments. |
Accordingly, these representations and
warranties may not describe the actual state of affairs as of the date they were made or at any other time, and investors should
not rely on them as statements of fact.
SIGNATURES
In accordance with Section 13 or
15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
NEURALSTEM, INC |
|
|
|
|
Dated: March 14, 2016 |
|
By: |
/S/Richard J Daly |
|
|
|
Richard J Daly
President and Chief Executive
Officer |
Pursuant to the requirements of the Securities Exchange Act
of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the following capacities
and on the dates indicated.
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/Richard J. Daly |
|
President, Chief Executive Officer, and Director |
|
March 14, 2016 |
Richard Daly |
|
(Principal executive officer) |
|
|
|
|
|
|
|
/s/ Karl Johe |
|
Chairman of the Board and Directors |
|
March 14, 2016 |
Karl Johe |
|
|
|
|
|
|
|
|
|
/s/ William Oldaker |
|
Director |
|
March 14, 2016 |
William Oldaker |
|
|
|
|
|
|
|
|
|
/s/ Scott V. Ogilvie |
|
Director |
|
March 14, 2016 |
Scott V. Ogilvie |
|
|
|
|
|
|
|
|
|
/s/ Sandford D. Smith |
|
Director |
|
March 14, 2016 |
Sandford D. Smith |
|
|
|
|
|
|
|
|
|
/s/ Catherine A. Sohn |
|
Director |
|
March 14, 2016 |
Catherine A. Sohn |
|
|
|
|
|
|
|
|
|
/s/ Stanley Westreich |
|
Director |
|
March 14, 2016 |
Stanley Westreich |
|
|
|
|
|
|
|
|
|
/s/ I. Richard Garr |
|
Director |
|
March 14, 2016 |
I. Richard Garr |
|
|
|
|
INDEX TO EXHIBITS
|
|
|
|
|
|
Incorporated by Reference |
|
|
|
|
Filed/ |
|
|
|
|
|
|
|
|
Exhibit |
|
|
|
Furnished |
|
|
|
Exhibit |
|
|
|
|
No. |
|
Description |
|
Herewith |
|
Form |
|
No. |
|
File No. |
|
Filing Date |
|
|
|
|
|
|
|
|
|
|
|
|
|
3.01(i) |
|
Amended and Restated Certificate of Incorporation of Neuralstem, Inc. filed on 7/9/14 |
|
|
|
10-Q |
|
3.01(i) |
|
001-33672 |
|
8/8/14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
3.02(ii) |
|
Amended and Restated Bylaws of Neuralstem, Inc. adopted on 11/10/2015 |
|
|
|
8-K |
|
3.01 |
|
001-33672 |
|
11/16/16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.01** |
|
Amended and Restated 2005 Stock Plan adopted on 6/28/07 |
|
|
|
10-QSB |
|
4.2(i) |
|
333-132923 |
|
8/14/07 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.02** |
|
Non-qualified Stock Option Agreement between Neuralstem, Inc. and Richard Garr dated 7/28/05 |
|
|
|
SB-2 |
|
4.4 |
|
333-132923 |
|
6/21/06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.03** |
|
Non-qualified Stock Option Agreement between Neuralstem, Inc. and Karl Johe dated 7/28/05 |
|
|
|
SB-2 |
|
4.5 |
|
333-132923 |
|
6/21/06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.04** |
|
Neuralstem, Inc. 2007 Stock Plan |
|
|
|
10-QSB |
|
4.21 |
|
333-132923 |
|
8/14/07 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.05 |
|
Form of Common Stock Purchase Warrant Issued to Karl Johe on 6/5/07 |
|
|
|
10-KSB |
|
4.22 |
|
333-132923 |
|
3/27/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.06 |
|
Form of Placement Agent Warrant Issued to Midtown Partners & Company on 12/18/08 |
|
|
|
8-K |
|
4.1 |
|
001-33672 |
|
12/18/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.07 |
|
Form of Consultant Common Stock Purchase Warrant issued on 1/5/09 |
|
|
|
S-3/A |
|
10.1 |
|
333-157079 |
|
02/3/09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.08 |
|
Form of Series D, E and F Warrants |
|
|
|
8-K |
|
4.01 |
|
001-33672 |
|
7/1/09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.09 |
|
Form of Placement Agent Warrant |
|
|
|
8-K |
|
4.02 |
|
001-33672 |
|
7/1/09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.10 |
|
Form of Consultant Warrant Issued 1/8/10 |
|
|
|
10-K |
|
4.20 |
|
001-33672 |
|
3/31/10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.11 |
|
Form of Replacement Warrant Issued 1/29/10 |
|
|
|
10-K |
|
4.21 |
|
001-33672 |
|
3/31/10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.12 |
|
Form of Series C Replacement Warrant Issued March of 2010 and May, June and July of 2013 (Original Ex. Price $2.13 and $1.25) |
|
|
|
10-K |
|
4.22 |
|
001-33672 |
|
3/31/10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.13 |
|
Form of employee and consultant option grant pursuant to our 2007 Stock Plan and 2010 Equity Compensation Plan |
|
|
|
10-K |
|
4.23 |
|
001-33672 |
|
3/31/10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.14 |
|
Form of Warrants dated 6/29/10 |
|
|
|
8-K |
|
4.01 |
|
001-33672 |
|
6/29/10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.15** |
|
Amended Neuralstem 2010 Equity Compensation Plan adopted on June 21, 2013 |
|
|
|
DEF 14A |
|
Appendix I |
|
001-33672 |
|
4/30/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.16 |
|
Form of Consultant Warrant issued 10/1/09 and 10/1/10 |
|
|
|
S-3 |
|
4.07 |
|
333-169847 |
|
10/8/10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.17** |
|
Form of Restricted Stock Award Agreement pursuant to our 2007 Stock Plan and 2010 Equity Compensation Plan |
|
|
|
S-8 |
|
4.06 |
|
333-172563 |
|
3/1/11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.18** |
|
Form of Restricted Stock Unit Agreement |
|
|
|
S-8 |
|
4.08 |
|
333-172563 |
|
3/1/11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.19 |
|
Form of Common Stock Purchase Warrant issued pursuant to February 2012 registered offering |
|
|
|
8-K |
|
4.01 |
|
001-33672 |
|
2/8/12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.20 |
|
Form of Common Stock Purchase Warrant issued to Consultants in June of 2012 and March 19, 2013 |
|
|
|
10-Q |
|
4.20 |
|
001-33672 |
|
8/9/12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.21 |
|
Form of Underwriter Warrant issued to Aegis Capital Corp. on 8/20/12 |
|
|
|
8-K |
|
4.1 |
|
001-33672 |
|
8/17/12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.22 |
|
Form of Placement Agent Warrant issued to Aegis Capital Corp. on 9/13/12 |
|
|
|
8-K |
|
4.1 |
|
001-33672 |
|
9/19/12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.23 |
|
Form of Consulting Warrant issued January 2011 and March 2012 |
|
|
|
S-3 |
|
4.01 |
|
333-188859 |
|
5/24/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Form of Replacement Warrant issued January, February and May of 2013 (Original Ex. Prices $3.17 and $2.14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.24 |
|
Form of Lender Warrant issued March 22, 2013 |
|
|
|
8-K |
|
4.01 |
|
001-33672 |
|
3/27/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.25 |
|
Form of Advisor Warrant issued March 22, 2013 |
|
|
|
8-K |
|
4.02 |
|
001-33672 |
|
3/27/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.26 |
|
Form of Warrant issued June of 2013 and July of 2014 to Legal Counsel |
|
|
|
10-Q |
|
4.26 |
|
001-33672 |
|
8/8/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.27 |
|
Form of Warrant issued in September 2013 in connection with Issuer’s registered direct offering |
|
|
|
8-K |
|
4.01 |
|
011-33672 |
|
9/10/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.28 |
|
Form of Warrant issued to strategic advisor in August 2013 |
|
|
|
10-Q |
|
4.28 |
|
001-33672 |
|
11/12/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.29 |
|
Form of Investor Warrant issued January 2014 |
|
|
|
8-K |
|
4.01 |
|
001-33672 |
|
1/6/14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.30 |
|
Form of Lender Warrant Issued October 28, 2014 |
|
|
|
8-K |
|
4.01 |
|
001-33672 |
|
10/29/14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.31** |
|
Inducement Stock Option Plan adopted 2/15/2016 |
|
|
|
8-K |
|
4.01 |
|
001-33672 |
|
2/19/16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4.32** |
|
Form of Inducement Award Non-Qualified Stock Option Grant pursuant to Inducement Stock Option Plan |
|
|
|
8-K |
|
4.02 |
|
001-33672 |
|
2/19/16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.01** |
|
Employment Agreement with I. Richard Garr dated January 1, 2007 and amended as of November 1, 2005 |
|
|
|
SB-2 |
|
10.1 |
|
333-132923 |
|
6/21/06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.02** |
|
Amended terms to the Employment Agreement of I Richard Garr dated January 1, 2008 |
|
|
|
10-K |
|
10.02 |
|
001-33672 |
|
3/31/09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.03** |
|
Amended terms to the employment Agreement of I. Richard Garr dated March 1, 2015 |
|
|
|
8-K |
|
10.01 |
|
001-33672 |
|
3/2/15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.04** |
|
Employment Agreement with Karl Johe dated January 1, 2007 and amended as of November 1, 2005 |
|
|
|
SB-2 |
|
10.2 |
|
333-132923 |
|
6/21/06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.05** |
|
Amended terms to the Employment Agreement of Karl Johe dated January 1, 2009 |
|
|
|
10-K |
|
10.04 |
|
001-33672 |
|
3/31/09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.06** |
|
Employment Agreement with Thomas Hazel, Ph.D dated August 11, 2008 |
|
|
|
10-K/A |
|
10.05 |
|
001-33672 |
|
10/5/10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.07** |
|
Employment Agreement with Richard Daly dated February 15, 2016 |
|
|
|
8-K |
|
10.01 |
|
001-33672 |
|
2/19/16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.08 |
|
Consulting Agreement dated January 2010 between Market Development Consulting Group and the Company and amendments No. 1 and 2. |
|
|
|
10-K |
|
10.07 |
|
001-33672 |
|
3/16/11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.09** |
|
Renewal of I. Richard Garr Employment Agreement dated 7/25/12 |
|
|
|
8-K |
|
10.01 |
|
001-33672 |
|
7/27/12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.10** |
|
Renewal of Dr. Karl Johe Employment Agreement dated 7/25/12 |
|
|
|
8-K |
|
10.02 |
|
001-33672 |
|
7/27/12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.11** |
|
Renewal of Dr. Tom Hazel Employment Agreement dated 7/25/12 |
|
|
|
8-K |
|
10.03 |
|
001-33672 |
|
7/27/12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.12 |
|
Loan and Security Agreement dated March 2013 |
|
|
|
8-K |
|
10.01 |
|
001-33672 |
|
3/27/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.13 |
|
Intellectual Property and Security Agreement dated March 2013 |
|
|
|
8-K |
|
10.02 |
|
001-33672 |
|
3/27/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.14 |
|
At the Market Offering Agreement entered into on October 25, 2013 |
|
|
|
8-K |
|
10.01 |
|
001-33672 |
|
10/25/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.15** |
|
Form of Amendment to Karl Johe Employment Agreement |
|
|
|
8-K |
|
10.01 |
|
001-33672 |
|
9/18/14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.16 |
|
Form of Second Amendment to Loan and Security Agreement dated March of 2013 that was entered into on October 28, 2014 |
|
|
|
8-K |
|
10.01 |
|
001-33672 |
|
10/29/14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.17** |
|
Offer Letter Between Neuralstem, Inc. and Jonathan Lloyd Jones |
|
|
|
8-K |
|
10.01 |
|
001-33672 |
|
5/11/15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.18** |
|
General Release and Waiver of Claims with I. Richard Garr dated 3/2/2016 |
|
|
|
8-K |
|
10.01 |
|
001-33672 |
|
3/4/16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
14.01 |
|
Neuralstem Code of Ethics |
|
|
|
SB-2 |
|
14.1 |
|
333-132923 |
|
6/21/06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
14.02 |
|
Neuralstem Financial Code of Profession Conduct adopted on May 16, 2007 |
|
|
|
8-K |
|
14.2 |
|
333-132923 |
|
6/6/07 |
21.01 |
|
Subsidiaries of the Registrant |
|
|
|
10-K |
|
21.01 |
|
001-33672 |
|
3/10/14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
23.01 |
|
Consent of Stegman & Company |
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.1 |
|
Certification of the Principal Executive Officer and Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32.1 |
|
Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. § 1350 |
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.INS |
|
XBRL Instance Document |
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.SCH |
|
XBRL Taxonomy Extension Schema |
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.CAL |
|
XBRL Taxonomy Extension Calculation Linkbase |
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.DEF |
|
XBRL Taxonomy Extension Definition Linkbase |
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.LAB |
|
XBRL Taxonomy Extension Label Linkbase |
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.PRE |
|
XBRL Taxonomy Extension Presentation Linkbase |
|
* |
|
|
|
|
|
|
|
|
* Filed herein
** Management contracts or compensation plans or arrangements
in which directors or executive officers are eligible to participate.
Exhibit 23.01
CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
We hereby consent to the incorporation
by reference in the Registration Statements filed by Neuralstem, Inc. on Forms S-3 (Nos. 333-150574, 333-157079, 333-165973, 333-169847,
333-173221, 333-188859, 333-190936 and 333-196567) and on Forms S-8 (Nos. 333-172563 and 333-194881) of our report dated March
14, 2016 relating to the consolidated financial statements and the effectiveness of internal control over financial reporting,
which appears in the Annual Report (Form 10-K) for the year ended December 31, 2015.
Baltimore, Maryland
March 14, 2016
EXHIBIT 31.1
SECTION 302 CERTIFICATION
I, Richard J. Daly, certify that:
(1) I
have reviewed this Annual Report on Form 10-K of Neuralstem, Inc;
(2) Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this report;
(3) Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;
(4) The
registrant's other certifying officer(s) and I am responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its unconsolidated investments, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;
(b) Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated
the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and
(d) Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most
recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control
over financial reporting; and
(5) The
registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:
(a) All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
and
(b) Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal
control over financial reporting.
Date: March 14, 2016 |
By: /s/ Richard J Daly |
|
Richard J Daly, |
|
Chief Executive Officer |
EXHIBIT 31.2
SECTION 302 CERTIFICATION
I, Jonathan Lloyd Jones, certify that:
(1) I
have reviewed this Annual Report on Form 10-K of Neuralstem, Inc;
(2) Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this report;
(3) Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;
(4) The
registrant's other certifying officer(s) and I am responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its unconsolidated investments, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;
(b) Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated
the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and
(d) Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most
recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control
over financial reporting; and
(5) The
registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:
(a) All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
and
(b) Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal
control over financial reporting.
Date: March 14, 2016 |
By: /s/ Jonathan Lloyd Jones |
|
Jonathan Lloyd Jones, |
|
Chief Financial Officer |
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002
I, Richard J. Daly, certify, as of the
dates hereof, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the
Annual Report of Neuralstem, Inc. on Form 10-K for the fiscal year ended December 31, 2015 fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-K fairly presents
in all material respects the financial condition and results of operations of Neuralstem, Inc. at the dates and for the periods
indicated.
Date: March 14, 2016
By: |
|
/s/ Richard J Daly |
|
|
Richard J Daly |
|
|
Chief Executive Officer |
A signed original of this written statement required by Section
906 has been provided to Neuralstem, Inc. and will be retained by Neuralstem, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.
Exhibit 32.2
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002
I, Jonathan Lloyd Jones, certify, as of
the dates hereof, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that
the Annual Report of Neuralstem, Inc. on Form 10-K for the fiscal year ended December 31, 2015 fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-K fairly presents
in all material respects the financial condition and results of operations of Neuralstem, Inc. at the dates and for the periods
indicated.
Date: March 14, 2016
By: |
|
/Jonathan Lloyd Jones |
|
|
Jonathan Lloyd Jones |
|
|
Chief Financial Officer |
A signed original of this written statement required by Section
906 has been provided to Neuralstem, Inc. and will be retained by Neuralstem, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.
v3.3.1.900
Document And Entity Information - USD ($)
|
12 Months Ended |
|
|
Dec. 31, 2015 |
Mar. 01, 2016 |
Jun. 30, 2015 |
Document Information [Line Items] |
|
|
|
Document Type |
10-K
|
|
|
Amendment Flag |
false
|
|
|
Document Period End Date |
Dec. 31, 2015
|
|
|
Document Fiscal Year Focus |
2015
|
|
|
Document Fiscal Period Focus |
FY
|
|
|
Entity Registrant Name |
Neuralstem, Inc.
|
|
|
Entity Central Index Key |
0001357459
|
|
|
Current Fiscal Year End Date |
--12-31
|
|
|
Entity Well-known Seasoned Issuer |
No
|
|
|
Entity Voluntary Filers |
No
|
|
|
Entity Current Reporting Status |
Yes
|
|
|
Entity Filer Category |
Accelerated Filer
|
|
|
Entity Public Float |
|
|
$ 168,902,179
|
Trading Symbol |
CUR
|
|
|
Entity Common Stock, Shares Outstanding |
|
92,044,042
|
|
X |
- DefinitionIf the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionState aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
+ References
+ Details
Name: |
dei_EntityPublicFloat |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
+ Details
Name: |
dei_EntityVoluntaryFilers |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
+ Details
Name: |
dei_EntityWellKnownSeasonedIssuer |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Consolidated Balance Sheets - USD ($)
|
Dec. 31, 2015 |
Dec. 31, 2014 |
CURRENT ASSETS |
|
|
Cash and cash equivalents |
$ 4,716,533
|
$ 12,518,980
|
Short term investments |
7,517,453
|
15,007,478
|
Trade and other receivables |
37,316
|
225,524
|
Deferred financing fees, current portion |
89,562
|
135,694
|
Prepaid expenses |
1,159,782
|
274,106
|
Total current assets |
13,520,646
|
28,161,782
|
Property and equipment, net |
343,200
|
301,265
|
Patents, net |
1,103,467
|
1,233,172
|
Deferred financing fees, net of current portion |
9,154
|
89,143
|
Other assets |
71,797
|
58,713
|
Total assets |
15,048,264
|
29,844,075
|
CURRENT LIABILITIES |
|
|
Accounts payable and accrued expenses |
1,455,826
|
2,504,978
|
Accrued bonuses |
161,362
|
646,960
|
Current portion of long-term debt, net of discount |
4,634,742
|
730,012
|
Other current liabilities |
263,104
|
126,745
|
Total current liabilities |
6,515,034
|
4,008,695
|
Long-term debt, net of discount and current portion |
3,391,808
|
8,056,470
|
Other long term liabilities |
174,144
|
59,574
|
Total liabilities |
10,080,986
|
12,124,739
|
Commitments and contingencies (Note 10) |
0
|
0
|
STOCKHOLDERS' EQUITY |
|
|
Preferred stock, 7,000,000 shares authorized, zero shares issued and outstanding |
0
|
0
|
Common stock, $0.01 par value; 300 million shares authorized, 92,005,705 and 87,789,679 shares issued and outstanding in 2015 and 2014, respectively |
920,057
|
877,897
|
Additional paid-in capital |
176,002,832
|
167,890,220
|
Accumulated other comprehensive income |
3,071
|
6,000
|
Accumulated deficit |
(171,958,682)
|
(151,054,781)
|
Total stockholders' equity |
4,967,278
|
17,719,336
|
Total liabilities and stockholders' equity |
$ 15,048,264
|
$ 29,844,075
|
X |
- DefinitionSum of the carrying values excluding accrued bonuses as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
+ Details
Name: |
cur_AccountsPayableAndAccruedExpensesExcludingAccruedBonuses |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765
+ Details
Name: |
us-gaap_AccruedBonusesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAccumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a),19) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CommitmentsAndContingencies |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionNet amount of current deferred finance costs capitalized at the end of the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28555-108399
+ Details
Name: |
us-gaap_DeferredFinanceCostsCurrentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionNet amount of long-term deferred finance costs capitalized at the end of the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28555-108399
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DeferredFinanceCostsNoncurrentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_IntangibleAssetsNetExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.
+ References
+ Details
Name: |
us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LongTermDebtCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LongTermDebtNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=51662447&loc=d3e5879-108316
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Assets -URI http://asc.fasb.org/extlink&oid=6509628
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details
Name: |
us-gaap_PrepaidExpenseCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionInvestments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.2) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Subparagraph g -Article 7
+ Details
Name: |
us-gaap_ShortTermInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Consolidated Balance Sheets [Parenthetical] - $ / shares
|
Dec. 31, 2015 |
Dec. 31, 2014 |
Preferred stock, shares authorized |
7,000,000
|
7,000,000
|
Preferred stock, shares issued |
0
|
0
|
Preferred stock, shares outstanding |
0
|
0
|
Common stock, par value (in dollars per share) |
$ 0.01
|
$ 0.01
|
Common stock, shares authorized |
300,000,000
|
300,000,000
|
Common Stock, Shares, Issued |
92,005,705
|
87,789,679
|
Common stock, shares outstanding |
92,005,705
|
87,789,679
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.3.1.900
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
|
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Revenues |
$ 10,417
|
$ 18,833
|
$ 110,000
|
Operating expenses: |
|
|
|
Research and development costs |
12,637,278
|
8,361,559
|
7,285,752
|
General and administrative expenses |
6,529,667
|
9,093,123
|
5,348,189
|
Total operating expenses |
19,166,945
|
17,454,682
|
12,633,941
|
Operating loss |
(19,156,528)
|
(17,435,849)
|
(12,523,941)
|
Other income (expense): |
|
|
|
Interest income |
69,549
|
67,651
|
68,000
|
Interest expense |
(1,816,206)
|
(1,620,776)
|
(1,394,274)
|
Warrant modification expense |
0
|
(3,109,850)
|
(5,017,156)
|
Loss from change in fair value of derivative instruments |
0
|
(334,133)
|
(965,329)
|
Loss on debt extinguisment |
0
|
(445,787)
|
0
|
Other expense |
(716)
|
0
|
0
|
Litigation settlement |
0
|
250,000
|
838
|
Total other income (expense) |
(1,747,373)
|
(5,192,895)
|
(7,307,921)
|
Net loss |
$ (20,903,901)
|
$ (22,628,744)
|
$ (19,831,862)
|
Net loss per share - basic and diluted (in dollars per share) |
$ (0.23)
|
$ (0.26)
|
$ (0.27)
|
Weighted average common shares outstanding - basic and diluted (in shares) |
90,866,938
|
87,086,345
|
72,279,210
|
Comprehensive loss: |
|
|
|
Net loss |
$ (20,903,901)
|
$ (22,628,744)
|
$ (19,831,862)
|
Foreign currency translation adjustment |
(2,929)
|
(1,241)
|
7,241
|
Comprehensive loss |
$ (20,906,830)
|
$ (22,629,985)
|
$ (19,824,621)
|
X |
- DefinitionAmount charged to warrant modification expense for the period.
+ References
+ Details
Name: |
cur_WarrantModificationExpense |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTaxAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
+ Details
Name: |
us-gaap_EarningsPerShareBasicAndDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section 25 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(b)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_InvestmentIncomeInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of judgment or settlement awarded to (against) the entity in respect of litigation.
+ References
+ Details
Name: |
us-gaap_LitigationSettlementAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ References
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount before tax of other comprehensive income (loss) attributable to parent entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569643-111683
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 35 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6939497&loc=d3e30304-110892
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -Subparagraph (b,d) -URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 10A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OtherNonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_Revenues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
+ Details
Name: |
us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Consolidated Statements of Changes In Stockholders' Equity - USD ($)
|
Total |
Common Stock [Member] |
Additional Paid-In Capital [Member] |
Accumulated Other Comprehensive Loss [Member] |
Accumulated Deficit [Member] |
Balance at Dec. 31, 2012 |
$ 6,972,633
|
$ 681,893
|
$ 114,884,915
|
$ 0
|
$ (108,594,175)
|
Balance (in shares) at Dec. 31, 2012 |
|
68,189,314
|
|
|
|
Share based payments |
1,665,155
|
$ 0
|
1,665,155
|
0
|
0
|
Issuance of common stock for warrant exercises, net |
6,032,306
|
$ 53,029
|
5,979,277
|
0
|
0
|
Issuance of common stock for warrant exercises, net (in shares) |
|
5,302,935
|
|
|
|
Issuance of common stock and replacement warrants as inducement for warrant exercises |
5,017,156
|
$ 724
|
5,016,432
|
0
|
0
|
Issuance of common stock and replacement warrants as inducement for warrant exercises (in shares) |
|
72,440
|
|
|
|
Issuance of common stock and warrants for professional services, net of forfeited shares |
1,506,748
|
$ 3,329
|
1,503,419
|
0
|
0
|
Issuance of common stock and warrants for professional services, net of forfeited shares (in shares) |
|
332,848
|
|
|
|
Issuance of common stock for restricted stock awards |
7,048,822
|
$ 39,885
|
7,008,937
|
0
|
0
|
Issuance of common stock for restricted stock awards (in shares) |
|
3,988,494
|
|
|
|
Foreign currency translation adjustments |
7,241
|
|
|
7,241
|
|
Net loss |
(19,831,862)
|
$ 0
|
0
|
0
|
(19,831,862)
|
Balance at Dec. 31, 2013 |
8,418,199
|
$ 778,860
|
136,058,135
|
7,241
|
(128,426,037)
|
Balance (in shares) at Dec. 31, 2013 |
|
77,886,031
|
|
|
|
Share based payments |
4,318,994
|
$ 0
|
4,318,994
|
0
|
0
|
Issuance of common stock for warrant exercises, net |
1,000,000
|
$ 8,060
|
991,940
|
0
|
0
|
Issuance of common stock for warrant exercises, net (in shares) |
|
805,972
|
|
|
|
Issuance of common stock and replacement warrants as inducement for warrant exercises |
1,307,991
|
$ 19,476
|
1,288,515
|
0
|
0
|
Issuance of common stock and replacement warrants as inducement for warrant exercises (in shares) |
|
1,947,535
|
|
|
|
Issuance of common stock and warrants for professional services, net of forfeited shares |
19,560,434
|
$ 71,220
|
19,489,214
|
0
|
0
|
Issuance of common stock and warrants for professional services, net of forfeited shares (in shares) |
|
7,122,022
|
|
|
|
Reclassification of warrant classified as derivative liability |
1,704,097
|
$ 0
|
1,704,097
|
0
|
0
|
Modification of executive warrant |
3,109,850
|
0
|
3,109,850
|
0
|
0
|
Issuance of common stock and warrants in conjunction with debt amendment, net |
929,756
|
$ 281
|
929,475
|
0
|
0
|
Issuance of common stock and warrants in conjunction with debt amendment, net (in shares) |
|
28,119
|
|
|
|
Foreign currency translation adjustments |
(1,241)
|
$ 0
|
0
|
(1,241)
|
0
|
Net loss |
(22,628,744)
|
0
|
0
|
0
|
(22,628,744)
|
Balance at Dec. 31, 2014 |
17,719,336
|
$ 877,897
|
167,890,220
|
6,000
|
(151,054,781)
|
Balance (in shares) at Dec. 31, 2014 |
|
87,789,679
|
|
|
|
Share based payments |
2,951,367
|
$ 0
|
2,951,367
|
0
|
0
|
Issuance of common stock for warrant exercises, net |
3,073,535
|
$ 17,246
|
3,056,289
|
0
|
0
|
Issuance of common stock for warrant exercises, net (in shares) |
|
1,724,606
|
|
|
|
Issuance of common stock and warrants for professional services, net of forfeited shares |
(802,054)
|
$ 12,512
|
(814,566)
|
0
|
0
|
Issuance of common stock and warrants for professional services, net of forfeited shares (in shares) |
|
1,251,189
|
|
|
|
Modification of executive warrant |
0
|
$ 0
|
0
|
0
|
0
|
Issuance of common stock from vested restricted stock units |
0
|
$ 4,278
|
(4,278)
|
0
|
0
|
Issuance of common stock from vested restricted stock units (in shares) |
|
427,808
|
|
|
|
Issuance of common stock for restricted stock awards |
2,931,924
|
$ 8,124
|
2,923,800
|
0
|
0
|
Issuance of common stock for restricted stock awards (in shares) |
|
812,423
|
|
|
|
Foreign currency translation adjustments |
(2,929)
|
$ 0
|
0
|
(2,929)
|
0
|
Net loss |
(20,903,901)
|
0
|
0
|
0
|
(20,903,901)
|
Balance at Dec. 31, 2015 |
$ 4,967,278
|
$ 920,057
|
$ 176,002,832
|
$ 3,071
|
$ (171,958,682)
|
Balance (in shares) at Dec. 31, 2015 |
|
92,005,705
|
|
|
|
X |
- DefinitionNumber of common stock issuance and replacement warrants as inducement for warrant exercises during the period.
+ References
+ Details
Name: |
cur_IssuanceOfCommonStockAndReplacementWarrantsAsInducementForWarrantExercisesShares |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of common stock issuance and replacement warrants as inducement for warrant exercises during the period.
+ References
+ Details
Name: |
cur_IssuanceOfCommonStockAndReplacementWarrantsAsInducementForWarrantExercisesValue |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of common stock issuance and warrants for professional services net of forfeited during the period.
+ References
+ Details
Name: |
cur_IssuanceOfCommonStockAndWarrantsForProfessionalServicesNetOfForfeitedShares |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of common stock issuance and warrants for professional services net of forfeited during the period.
+ References
+ Details
Name: |
cur_IssuanceOfCommonStockAndWarrantsForProfessionalServicesNetOfForfeitedValue |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIssuance Of Common Stock From Vested Restricted Stock.
+ References
+ Details
Name: |
cur_IssuanceOfCommonStockFromVestedRestrictedStock |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIssuance of common stock from vested restricted stock units.
+ References
+ Details
Name: |
cur_IssuanceOfCommonStockFromVestedRestrictedStockUnits |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of common share and warrants from capital raises.
+ References
+ Details
Name: |
cur_IssuanceOfShareAndWarrantsForServicesOrClaims |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis element represents amount reclassification of warrant classified as derivative liability
+ References
+ Details
Name: |
cur_ReclassificationOfWarrantClassifiedAsDerivativeLiability |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThis element represents number of stock issued during period in conjunction with debt amendment.
+ References
+ Details
Name: |
cur_StockIssuedDuringPeriodInConjunctionWithDebtAmendmentShare |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis element represents amount of stock issued during period in conjunction with debt amendment
+ References
+ Details
Name: |
cur_StockIssuedDuringPeriodInConjunctionWithDebtAmendmentValue |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of stock issued during period from warrants exercised.
+ References
+ Details
Name: |
cur_StockIssuedDuringPeriodSharesFromWarrantsExercised |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIt represents the stock issued during period from warrants exercised.
+ References
+ Details
Name: |
cur_StockIssuedDuringPeriodValueFromWarrantsExercised |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThis element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11149-113907
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11178-113907
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28183637&loc=d3e4724-112606
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Warrant -URI http://asc.fasb.org/extlink&oid=6528364
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAdjustments to temporary equity resulting from foreign currency translation adjustments.
+ References
+ Details
Name: |
us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionPrice per share of stock issued during the reporting period.
+ References
+ Details
Name: |
cur_StockIssuedDuringPeriodPricePerShareNewIssues |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
+ Details
Name: |
us-gaap_PaymentsOfStockIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_ClassOfWarrantOrRightAxis=cur_WarrantsExercisedMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Consolidated Statements of Cash Flows - USD ($)
|
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Cash flows from operating activities: |
|
|
|
Net loss |
$ (20,903,901)
|
$ (22,628,744)
|
$ (19,831,862)
|
Adjustments to reconcile net loss to cash used in operating activities: |
|
|
|
Depreciation and amortization |
345,460
|
348,630
|
244,725
|
Share based compensation expenses |
2,951,367
|
4,320,073
|
2,331,401
|
Amortization of deferred financing fees and debt discount |
870,530
|
829,632
|
694,175
|
Warrant modification expense |
0
|
3,109,850
|
5,017,156
|
Loss from change in fair value of warrant obligations |
0
|
334,133
|
965,329
|
Loss on debt extinguishment |
0
|
445,787
|
0
|
Changes in operating assets and liabilities: |
|
|
|
Trade and other receivables |
188,208
|
(215,524)
|
(6,667)
|
Prepaid expenses |
(840,772)
|
191,263
|
125,470
|
Other assets |
(13,998)
|
6,141
|
(5,183)
|
Accounts payable and accrued expenses |
(1,045,765)
|
1,382,447
|
(116,750)
|
Accrued bonuses |
(485,598)
|
181,092
|
3
|
Other current liabilities |
253,427
|
(2,206)
|
2,469
|
Other long term liabilities |
(250,624)
|
(9,262)
|
(11,883)
|
Net cash used in operating activities |
(18,931,666)
|
(11,706,688)
|
(10,591,617)
|
Cash flows from investing activities: |
|
|
|
Purchases of short-term investments |
(7,517,453)
|
(25,007,478)
|
0
|
Maturity of short-term investments |
15,007,478
|
10,000,000
|
0
|
Patent costs |
(67,312)
|
(348,455)
|
(411,688)
|
Purchase of property and equipment |
(176,272)
|
(207,893)
|
(125,362)
|
Net cash provided by (used in) investing activities |
7,246,441
|
(15,563,826)
|
(537,050)
|
Cash flows from financing activities: |
|
|
|
Proceeds from issuance of common stock from warrants exercised, net |
3,073,535
|
1,794,865
|
6,107,842
|
Proceeds from sale of common stock and warrants, net of issuance costs |
2,931,924
|
19,467,857
|
7,048,822
|
Payments of taxes on stock option exercises |
(802,054)
|
(426,212)
|
0
|
Proceeds from long-term debt transactions, net of issuance costs |
0
|
4,212,561
|
7,551,329
|
Payments of long term debt |
(1,154,150)
|
(1,929,449)
|
0
|
Payment on fees for future financing |
(45,000)
|
0
|
0
|
Payments of short term notes payable |
(117,068)
|
(175,197)
|
(183,291)
|
Net cash provided by financing activities |
3,887,187
|
22,944,425
|
20,524,702
|
Effects of exchange rates on cash |
(4,409)
|
(983)
|
6,244
|
Net increase (decrease) in cash and cash equivalents |
(7,802,447)
|
(4,327,072)
|
9,402,279
|
Cash and cash equivalents, beginning of period |
12,518,980
|
16,846,052
|
7,443,773
|
Cash and cash equivalents, end of period |
4,716,533
|
12,518,980
|
16,846,052
|
Supplemental cash flow information: |
|
|
|
Cash paid for interest |
954,746
|
762,910
|
624,321
|
Cash paid for income taxes |
0
|
0
|
0
|
Supplemental schedule of non cash investing and financing activities: |
|
|
|
Issuance of common stock for cashless exercise of warrants and options |
1,981,945
|
1,208,653
|
587,500
|
Issuance of common stock for conversion of long-term debt |
0
|
1,000,000
|
0
|
Financing of insurance premiums through note payable |
0
|
210,722
|
183,472
|
Issuance of common stock and warrants for fees related to debt transactions |
0
|
159,954
|
848,421
|
Issuance of warrants for vendor services |
$ 0
|
$ 0
|
$ 658,326
|
X |
- DefinitionRepresents the value for financing of insurance premiums through note payable during the period.
+ References
+ Details
Name: |
cur_FinancingOfInsurancePremiumsThroughNotePayable |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIt represents the amount of common stock for cashless exercise of warrants and options.
+ References
+ Details
Name: |
cur_IssuanceOfCommonStockForCashlessExcerciseOfWarrantsAndOptions |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCommon stock issued for conversion of long term debt.
+ References
+ Details
Name: |
cur_IssuanceOfCommonStockForConversionOfLongtermDebt |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFair value of warrants issued to nonemployees as payment for services rendered or acknowledged claims.
+ References
+ Details
Name: |
cur_IssuanceOfWarrantsForVendorServices |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRepresents Payment of employee taxes on stock option exercise during the period.
+ References
+ Details
Name: |
cur_PaymentOfEmployeeTaxesOnStockOptionExercise |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount charged to warrant modification expense for the period.
+ References
+ Details
Name: |
cur_WarrantModificationExpense |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis element represents the amortization of deferred leasing fees incurred by the lessor and amortized over the term of the lease. Such fees represent (a) costs to originate a lease incurred in transactions with independent third parties that (i) result directly from and are essential to acquire that lease and (ii) would not have been incurred had that leasing transaction not occurred and (b) certain costs directly related to specified activities performed by the lessor for that lease. Those activities are: evaluating the prospective lessee's financial condition; evaluating and recording guarantees, collateral, and other security arrangements; negotiating lease terms; preparing and processing lease documents; and closing the transaction.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 25 -Paragraph 17 -URI http://asc.fasb.org/extlink&oid=6748888&loc=d3e40246-112709
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_AmortizationOfDeferredLeasingFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_DepreciationAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details
Name: |
us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section 25 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.
+ References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherCurrentLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.
+ References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherNoncurrentAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.
+ References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of cash paid for interest during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details
Name: |
us-gaap_InterestPaid |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
+ Details
Name: |
us-gaap_PaymentOfFinancingAndStockIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
+ Details
Name: |
us-gaap_PaymentsToAcquireIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
+ Details
Name: |
us-gaap_PaymentsToAcquireInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfPrivatePlacement |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOrSaleOfEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
+ Details
Name: |
us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_RepaymentsOfLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_RepaymentsOfShortTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.3.1.900
Organization and Business
|
12 Months Ended |
Dec. 31, 2015 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] |
Note 1: Organization and Business Nature of business Neuralstem, Inc. and its subsidiary are referred to as “Neuralstem,” the “Company,” “us,” or “we” throughout this report. Beginning in 2013, our investment in, and the operations of, our wholly-owned and controlled subsidiary located in China are consolidated in our consolidated financial statements; previously, all investments in China were expensed as incurred. The impacts of this change were not material to any period presented. Neuralstem is a clinical stage biopharmaceutical company that is utilizing its proprietary human neural stem cell technology to create a comprehensive platform for the treatment of central nervous system diseases. The Company has utilized this technology as a tool for small-molecule drug discovery and to create cell therapy biotherapeutics to treat central nervous system diseases. The Company was founded in 1997 and currently has laboratory and office space in Germantown, Maryland and laboratory facilities in San Diego, California, Chicago, Illinois, and in the People’s Republic of China. Our operations to date have been directed primarily toward developing business strategies, raising capital, research and development activities, and conducting pre-clinical testing and human clinical trials of our product candidates and recruiting personnel. Liquidity The Company has incurred losses since its inception and has not demonstrated an ability to generate revenues from sales or services and have not yet achieved profitable operations. There is no assurance that profitable operations will ever be achieved, or if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and pre-clinical testing, and commercialization of our products will require significant additional financing. These factors create substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. Our cash, cash equivalents and short term investments balance at December 31, 2015 was approximately $12,234,000. We expect that our existing cash and cash equivalents will only be sufficient to enable us to fund our operations for the next five to six months from that date. Our ability to continue as a going concern is wholly dependent upon obtaining sufficient financing to fund our operations. Management is in ongoing discussions regarding various financing options with financial institutions and believes that it will receive cash adequate to fund operations through December 31, 2016. Despite our ability to secure capital in the past, there is no assurance that additional equity or debt financing will be available to us when needed. In the event that we are not able to secure financing, we may be forced to curtail operations, delay or stop ongoing clinical trials, cease operations altogether or file for bankruptcy. We have spent and will continue to spend substantial funds in the research, development, pre-clinical and clinical testing of our small molecule and stem cell product candidates with the goal of ultimately obtaining approval from the United States Food and Drug Administration (the “FDA”) and its international equivalents, to market and sell our products. No assurance can be given that (i) FDA or other regulatory agency approval will ever be granted for us to market and sell our product candidates, or (ii) if regulatory approval is granted, that we will ever be able to sell our proposed products or be profitable. There is no assurance that profitable operations will ever be achieved, or if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and pre-clinical testing, and commercialization of our products will require significant additional financing. Our long-term cash position is inadequate to fund all of the costs associated with the full range of testing and clinical trials required by the FDA and other international regulatory agencies for our core product candidates, we anticipate that our available cash and expected income will be sufficient to finance our current activities at least through June, 2016.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Significant Accounting Policies and Basis of Presentation
|
12 Months Ended |
Dec. 31, 2015 |
Accounting Policies [Abstract] |
|
Significant Accounting Policies [Text Block] |
Note 2: Significant Accounting Policies and Basis of Presentation Basis of Presentation Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States if America (“U.S. GAAP”). The financial statements include the accounts of the Company and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated. The opinion of our independent registered accounting firm on our financial statements contains explanatory going concern language. We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. We have incurred losses since inception and have a deficit accumulated of approximately $172,000,000 as of December 31, 2015. We anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales from our product candidate’s currently in development or we enter into cash flow positive business development transactions. If we are not able to secure additional financing or enter into a cash flow positive business transaction before July, 2016, we may not be able to continue as a going concern. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology, our net operating loss carry forward and related valuation allowance for tax purposes and our stock-based compensation related to employees and directors, consultants and advisors, including investment banks, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates. Fair Value Measurements The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, other short-term investments, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness is estimated based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. The fair values of our derivative instruments were estimated using Level 3 unobservable inputs. See Note 3 for further details. Foreign Currency Translation The functional currency of our wholly owned foreign subsidiary is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of are accumulated in other comprehensive income or loss, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss. Cash, Cash Equivalents and Credit Risk Cash equivalents consist of investments in low risk, highly liquid money market funds and certificates of deposit with original maturities of 90 days or less. Cash deposited with banks and other financial institutions may exceed the amount of insurance provided on such deposits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail. Short-term investments consist entirely of fixed income certificates of deposit (“CDs”) with original maturities of greater than 90 days and not more than one year. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and short-term investments. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. In addition, our CDs are invested through the Certificate of Deposit Account Registry Service (“CDARS”) program which reduces or eliminates our risk related to concentrations of investments above FDIC insurance levels. We limit our credit and liquidity risks through our investment policy and through regular reviews of our portfolio against our policy. To date, we have not experienced any loss or lack of access to cash in our operating accounts or to our cash equivalents and short-term investments. Revenue Recognition Historically, our revenue has been derived primarily from (i) selling treated samples for gene expression data from stem cell experiments, (ii) providing services under various contracts and grants and (iii) licensing the use of our intellectual property to third parties. Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery of goods and services has occurred, the price is fixed and determinable, and collection is reasonably assured. Research and Development Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated exclusively with the pre-clinical development and clinical trials of our product candidates. Income (Loss) per Common Share Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the years ended December 31, 2015, 2014 and 2013. A total of approximately 36.8 , 40.4, and 38.2 million potential dilutive shares have been excluded in the calculation of diluted net income per share for the years ended December 31, 2015, 2014 and 2013, respectively as their inclusion would be anti-dilutive. Share-Based Compensation We account for share-based compensation at fair value. Share-based compensation cost for stock options and warrants granted to employees and board members is determined at the grant date using an option pricing model that uses level 3 unobservable inputs; share-based compensation cost for restricted stock and restricted stock units granted to employees and board members is determined at the grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period. Intangible and Long-Lived Assets We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. No significant impairment losses were recognized during the years ended December 31, 2015, 2014, and 2013. Income Taxes We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the reported results of operations. Significant New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued ASU 2014-09 Revenue from Contracts with Customers. This guidance is effective for fiscal years beginning after December 15, 2016 and early adoption is not permitted. We have not yet determined the effects of this new guidance on our financial statements. In August 2014, the FASB issued ASU 2014-15 Presentation of Financial Statements Going Concern. This guidance requires management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. This guidance is effective for fiscal years beginning after December 15, 2016 and early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on our financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790
+ Details
Name: |
us-gaap_SignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Fair Value Measurements
|
12 Months Ended |
Dec. 31, 2015 |
Fair Value Disclosures [Abstract] |
|
Fair Value Disclosures [Text Block] |
Note 3: Fair Value Measurements In April 2015, the FASB issued update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs. The amendment requires that all costs incurred to issue debt be presented in the balance sheet as a direct deduction from the carrying value of the debt. The new standard is limited to the presentation of debt issuance costs and does not affect the recognition or measurement if debt issuance costs. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The implementation of the amended guidance is not expected to have a material impact on the consolidated results of operations and will result in a reclassification of the debt issuance costs from other long-term assets to long term debt when adopted . Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These levels are: | · | Level 1 inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. | | · | Level 2 inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques (e.g. the Black-Scholes model) for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and forward and spot prices for currencies and commodities. | | · | Level 3 inputs are generally unobservable and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models. | Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate levels within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of the Company’s funds. The fair value of other short-term financial instruments (primarily short-term investments, accounts payable and certain accrued expenses) approximate their carrying values because of their short-term nature. The fair value of our long-term indebtedness approximates its carrying value. At January 1, 2014, we had common stock purchase warrants issued in conjunction with our March 2013 debt offering (see Note 4) that were accounted for as derivative instruments whose fair market value was determined using Level 3 inputs. These warrants were exercised in their entirety in the first quarter of 2014. We had no financial assets or liabilities measured at fair value on a recurring basis at December 31, 2015 or December 31, 2014. Non-Financial Assets and Liabilities Measure at Fair Value on a Recurring Basis We have no non-financial assets and liabilities that are measured at fair value on a recurring basis. Non-Financial Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis We measure our long-lived assets, including property and equipment and patent assets, at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. No such fair value impairment was recognized in the years ended December 31, 2015, 2014, or 2013.
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611
+ Details
Name: |
us-gaap_FairValueDisclosuresTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Debt
|
12 Months Ended |
Dec. 31, 2015 |
Debt Disclosure [Abstract] |
|
Debt Disclosure [Text Block] |
Note 4: Debt In March 2013, we entered into a loan and security agreement for an initial $8 million term loan with an additional $2 million of borrowing capacity if certain conditions involving new partnerships are met. The loan is collateralized by substantially all of our assets, including our intellectual property. The loan provided for interest at a variable rate based on prime with a floor of 11% and had an original maturity of June 2016. The variable rate was 11% and did not change during the period through the loan amendment. The loan provided for interest only payments through December 2013 at which time monthly principal and interest payments of approximately $300,000 were due through maturity. The loan resulted in net proceeds of approximately $7.6 million after origination and other cash fees and expenses related to the closing of the loan. In conjunction with the loan agreement, we issued the lender a five-year common stock purchase warrant to purchase 648,809 shares of common stock at an exercise price of $1.0789 per share. This warrant contained non-standard anti-dilution protection and, consequently, was being accounted for as a derivative instrument, recorded at fair market value each period (see Note 3). The allocation of proceeds to this warrant resulted in a debt discount which was amortized as interest expense over the term of the debt using the effective interest method. The warrant was exercised in the first quarter of 2014. We also incurred expenses with various third parties in connection with the debt issuance, consisting of approximately $449,000 in cash, 350,650 shares of common stock valued at approximately $396,000, and a five-year common stock purchase warrant to purchase 648,798 shares at an exercise price of $1.07892 per share. The warrant is classified as equity. Fees related to the debt offering are recorded as deferred financing fees and are being amortized as interest expense over the term of the debt using the effective interest method. The loan agreement provided for a conversion feature whereby the lender or the Company could each convert up to a maximum of $1 million in principal payments into common stock of the Company. In 2014, the lender elected to convert the maximum principal payments of $1 million into 805,972 shares of our common stock in accordance with the terms of the loan and security agreement. In October 2014, we entered into an agreement with the existing lender to refinance and amend the terms of our loan and security agreement. The amended loan provided for refinancing of approximately $5.6 million of outstanding balance of the initial loan coupled with approximately $4.4 million of new principal for a total of $10 million in principal. The amended loan provides for a variable interest rate based on prime with a floor of 10% and matures in April 2017. The loan provides for interest only payments through September 2015; payments of principal and interest of approximately $435,000 from January 2016 through March 2017 and a final balloon payment of approximately $2.8 million in April 2017. The loan amendment generated approximately $4.3 million in net proceeds after fees and expenses. The loan amendment is accounted for as a debt extinguishment in accordance with guidance provided for in ASC 470, Debt resulting in a loss on extinguishment of approximately $446,000. In conjunction with the loan amendment we recorded a debt discount relating to the beneficial conversion feature. Such discount is being amortized as interest expense over the term of the debt using the effective interest method. In conjunction with the loan amendment, we issued the lender a five-year common stock purchase warrant to purchase 75,188 shares of common stock at an exercise price of $2.66 per share. The warrant contains standard anti-dilution protection but does not contain any anti-dilution protection for subsequent offerings. The value of the warrant was accounted for in calculating the loss on extinguishment. We also incurred expenses with various third parties in connection with the loan amendment, consisting of approximately $86,000 in cash, 28,119 shares of common stock valued at approximately $80,000, and a three-year common stock purchase warrant to purchase 58,141 shares at an exercise price of $2.66 per share. The warrant is classified as equity and has terms substantially similar to the lender warrant. These fees related to the loan amendment are recorded as deferred financing fees and are being amortized as interest expense over the term of the debt using the effective interest method. At December 31, 2015, remaining principal payments due under this loan are approximately $4,570,000 and $3,766,000 payable in, 2016 and 2017, respectively.
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20,22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DebtDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Stockholders' Equity
|
12 Months Ended |
Dec. 31, 2015 |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] |
|
Stockholders' Equity Note Disclosure [Text Block] |
Note 5: Stockholders’ Equity We have granted share-based compensation awards to employees, board members and service providers. Awards may consist of common stock, restricted common stock, restricted common stock units, warrants, or stock options. Our stock options and warrants have lives of up to ten years from the grant date. The stock options and warrants vest either upon the grant date or over varying periods of time. The stock options we grant provide for option exercise prices equal to or greater than the fair market value of the common stock at the date of the grant. Restricted stock units grant the holder the right to receive fully paid common shares with various restrictions on the holder’s ability to transfer the shares. Vesting of the restricted stock units is similar to that of stock options. As of December 31, 2015, we have approximately 39.5 million shares of common stock reserved for issuance of such awards. We record share-based compensation expense on a straight-line basis over the requisite service period. Share-based compensation expense included in the statements of operations was as follows: | | Year Ended December 31, | | | | 2015 | | 2014 | | 2013 | | | | | | | | | | | | | Research and development costs | | $ | 1,394,194 | | $ | 968,326 | | $ | 932,200 | | General and administrative expenses | | | 1,557,173 | | | 3,351,747 | | | 1,399,201 | | Total | | $ | 2,951,367 | | $ | 4,320,073 | | $ | 2,331,401 | | No income tax benefit was recognized in the consolidated statements of operations for stock-based compensation for the years presented due to the Company’s net loss position. Stock Options A summary of stock option activity and related information for the year ended December 31, 2015 follows: | | Number of Options | | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Life (in years) | | Aggregate Intrinsic Value | | | | | | | | | | | | | | | | Outstanding at January 1, 2015 | | | 18,986,395 | | $ | 1.89 | | | 5.1 | | $ | 20,306,807 | | Granted | | | 765,549 | | $ | 3.09 | | | | | | | | Exercised | | | (1,031,774) | | $ | 0.54 | | | | | $ | 68,400 | | Forfeited/Expired | | | (1,617,223) | | $ | 1.32 | | | | | | | | Outstanding at December 31, 2015 | | | 17,102,947 | | $ | 2.08 | | | 5.0 | | $ | 550,000 | | | | | | | | | | | | | | | | Exercisable at December 31, 2015 | | | 14,118,821 | | $ | 2.19 | | | 4.6 | | $ | 330,000 | | | | | | | | | | | | | | | | Vested and expected to vest at December 31, 2015 | | | 17,099,027 | | $ | 2.08 | | | 5.0 | | $ | 550,000 | | Range of Exercise Prices | | Number of Options Outstanding | | Weighted- Average Exercise Price | | Weighted- Average Remaining Contractual Life (in years) | | Aggregate Intrinsic Value | | $0.50 - $1.00 | | | 5,000,000 | | $ | 0.92 | | | 6.6 | | $ | 550,000 | | $1.01 - $2.00 | | | 4,275,984 | | $ | 1.22 | | | 6.0 | | | - | | $2.01 - $3.00 | | | 2,122,669 | | $ | 2.50 | | | 3.8 | | | - | | $3.01 - $5.00 | | | 5,704,294 | | $ | 3.60 | | | 3.4 | | | - | | | | | 17,102,947 | | $ | 2.08 | | | 5.0 | | $ | 550,000 | | The Company uses the Black-Scholes option pricing model for “plain vanilla” options and other pricing models as appropriate to calculate the fair value of options. Significant assumptions used in these models include: | | 2015 | | 2014 | | 2013 | | | | | | | | | | Annual dividend | | - | | - | | - | | Expected life (in years) | | 4.0-6.0 | | 4.0 - 8.5 | | 3.0 - 6.5 | | Risk free interest rate | | 1.39%-1.78% | | 1.12% - 2.50% | | 0.29% - 2.43% | | Expected volatility | | 68.6%-71.8% | | 68.8% - 100.0% | | 65.1% - 77.5% | | The Company estimates the expected term using the "simplified-method" as it does not have sufficient historical exercise data to provide a reasonable estimate. The options granted in the years ended December 31, 2015, 2014, and 2013 had weighted average grant date fair values of $1.89 , $1.90, and $1.01, respectively. The total fair value of the options vested during the years ended December 31, 2015, 2014, and 2013 was approximately $2,215,000, $1,814,000, and $1,170,000 respectively. Unrecognized compensation cost for unvested stock option awards outstanding at December 31, 2015 was approximately $3,449,000 to be recognized over approximately 1.8 years. RSUs We have granted restricted stock units (RSUs) that entitle the holders to receive shares of our common stock upon vesting and subject to certain restrictions regarding the exercise of the RSUs and the holders’ ability to transfer the shares received upon exercise. The fair value of RSUs granted is based upon the market price of the underlying common stock as if they were vested and issued on the date of grant. A summary of our RSU activity for the year ended December 31, 2015 follows: | | Number of RSU's | | Weighted- Average Grant Date Fair Value | | | | | | | | | | Outstanding at January 1, 2015 | | | 447,275 | | $ | 2.18 | | Granted | | | - | | $ | - | | Vested and converted to common shares | | | (219,415) | | $ | 2.21 | | Forfeited | | | (76,954) | | $ | 2.21 | | Outstanding at December 31, 2015 | | | 150,906 | | $ | 2.13 | | | | | | | | | | Exercisable at December 31, 2015 | | | 150,906 | | $ | 2.13 | | There were no RSUs granted in 2015. The RSU granted in the years ended December 31, 2014, and 2013 had weighted average grant date fair values of $3.31, and $1.14 respectively. The total fair value of the shares vested during the years ended December 31, 2015, 2014, and 2013 was approximately $33,000, $142,000, and $254,000, respectively. Unrecognized compensation cost for unvested RSUs outstanding at December 31, 2015 was $0. Stock Purchase Warrants Warrants to purchase common stock were issued to certain officers, directors, stockholders and service providers. We have also issued warrants in conjunction with debt offerings and equity raises and at various times replacement warrants were issued in conjunction with warrant exercises. A summary of warrant activity for the year ended December 31, 2015 follows: | | Number of Warrants | | Weighted- Average Exercised Price | | Weighted- Average Remaining Contractual Life (in years) | | Aggregate Intrinsic Value | | | | | | | | | | | | | | | | Outstanding at January 1, 2015 | | | 21,422,346 | | $ | 2.30 | | | 3.8 | | $ | 15,984,739 | | Granted | | | 150,000 | | $ | 1.87 | | | 4.5 | | | | | Exercised | | | (1,724,606) | | $ | 1.94 | | | | | | | | Forfeited | | | (195,644) | | $ | 2.02 | | | | | | | | Outstanding at December 31, 2015 | | | 19,652,096 | | $ | 2.34 | | | 3.1 | | $ | 309,724 | | | | | | | | | | | | | | | | Exercisable at December 31, 2015 | | | 19,577,096 | | $ | 2.34 | | | 3.1 | | $ | 309,724 | | The stock purchase warrants granted in the years ended December 31, 2015, 2014, and 2013 had a weighted average grant date fair value of $1.08 , $2.07, and $0.82, respectively. All stock purchase warrants were classified as equity with the exception of the warrant issued to the lender in the March 2013 debt transaction (see Note 4). Stock purchase warrants exercised in 2015, 2014, and 2013 had an intrinsic value of approximately $5,126,000, $4,287,000, and $3,550,000, respectively. In 2014 we modified certain warrants held by our Chief Science Officer. Such modification extended the term of the warrants by an additional five years and resulted in an expense of approximately $3.1 million included in other expense in our statements of operations for the year ended December 31, 2014. The related stock based compensation will be recognized. Restricted Stock We have granted restricted stock to certain board members based on revised board of director year and compensation policy. A summary of our restricted stock activity for the year ended December 31, 2015 is as follows: | | | | | Weighted- | | | | Number | | Average Grant | | | | of RS | | Date Fair Value | | Granted | | | 427,808 | | $ | 1.87 | | Vested | | | (213,904) | | $ | 1.87 | | Forfeited | | | - | | $ | 0.00 | | Outstanding at December 31, 2015 | | | 213,904 | | $ | 1.87 | | The total intrinsic value of the units converted in 2015 was approximately $241,000. Common Stock In June 2014, the Company’s shareholders approved a 150,000,000 increase in the authorized shares of common stock bringing the total authorized shares of common stock to 300,000,000. In January and February 2013, we issued 258,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share and we received approximately $323,000 in net proceeds from the exercises. In conjunction with the exercises, we modified the warrants to reduce the exercise price to $1.25 and issued 258,000 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction of the exercise price on the original warrants. Such expense is classified as warrant modification expense. The warrants are classified within equity. In March 2013, we issued 350,650 shares of common stock and 1,297,607 common stock purchase warrants to various parties in conjunction with our debt transaction (see Note 4). In May 2013, we issued 440,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.07 per share and we received approximately $433,000 in net proceeds from the exercises. In conjunction with the exercise, we modified the warrants to reduce the exercise price to $1.07 and issued 440,000 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in May 2016. We recognized expense for the value of the replacement warrants and the reduction of the exercise price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified within equity. In May 2013, we issued 689,675 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share and we received approximately $844,000 in net proceeds from the exercises. In conjunction with the exercises, we modified the warrants to reduce the exercise price to $1.25 and issued 689,675 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction of the exercise price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified within equity. In May and June 2013, we issued 378,809 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share and we received approximately $474,000 in net proceeds from the exercises. In conjunction with the exercise, we issued 378,809 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants; such expense is classified as warrant modification expense. The warrants are classified within equity. In May and June 2013, we issued 300,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.02 and we received approximately $306,000 in net proceeds from the exercises. In July 2013, we issued 942,520 shares of our common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share and we received approximately $1,178,000 in net proceeds from the exercises. In conjunction with the exercises, we modified 782,005 of the warrants to reduce the exercise price to $1.25 and issued 942,520 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction of the exercise price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified within equity. In July 2013, we issued 100,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.02 and we received approximately $102,000 in net proceeds from the exercise. In September 2013, we issued 1,448,798 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share (800,000 shares) and $1.08 per share (648,798 shares) and we received approximately $1,700,000 in net proceeds from the exercises. In conjunction with the exercise, we issued an additional 72,440 shares of our common stock as a commission for exercise. We recognized an expense for the value of the additional common stock; such expense is classified as warrant modification expense. In September and December 2013, we issued 344,000 shares of common stock upon the exercise of outstanding warrants. Of these shares, 340,000 shares of stock were issued at $2.13 while 4,000 shares of stock were issued at $1.56. We received approximately $730,000 net proceeds from the exercises. In September 2013, we issued 401,133 shares of our common stock as a result of the cashless exercise of 650,000 outstanding common stock purchase warrants with an average strike price of $0.90. The exercises resulted in 248,867 warrants being forfeited and we received no proceeds. In September 2013, we completed a registered direct offering of 2,847,500 shares of common stock at a price of $1.60 per share. We received aggregate gross proceeds of $4,556,000 and net proceeds of approximately $4,242,000 from the offering. In connection with the offering, we issued common stock purchase warrants to purchase 1,423,750 shares of our common stock; the warrants have an exercise price of $2.00 and a term of five years. Additionally, we issued a common stock purchase warrant to the placement agent to purchase up to 170,850 shares; the warrant has an exercise price of $2.00 per share and term of 19 months. The warrants are classified within equity. In November and December 2013, we issued 1,140,994 shares of common stock as a result of sales under our At the Market Offering Agreement. The shares were sold at an average price of $2.64 per share and generated approximately $2,895,000 in net proceeds. In January, 2014, we closed a registered direct offering of 6,872,859 shares of common stock at a price of $2.91 per share. We received aggregate gross proceeds of $20 million and net proceeds of approximately $18,630,000 from the offering. In connection with the offering, we also issued 3,436,435 common stock purchase warrants; the warrants have an exercise price of $3.64, a term of five years and are classified within equity. This offering was made pursuant to our $50 million shelf registration statement declared effective by the SEC on September 13, 2013 (Registration No. 333-190936). Additionally, as a result of this transaction an advisor to the Company met certain capital raising milestones and consequently, the term of their common stock purchase warrant was extended to 5 years. In 2014, we issued 249,163 shares of common stock as a result of sales under our At the Market Offering Agreement. The shares were sold at an average price of $3.55 per share and we received approximately $838,000 in net proceeds. In 2014, we issued a total of 1,234,428 shares of our common stock upon the exercise of outstanding common stock purchase warrants and stock options. The warrants and options were exercised at an average exercise price of $1.44. We received approximately $1,714,000 of net proceeds from the exercises. In 2014, we issued a total of 712,539 shares of our common stock upon the cashless and partial-cashless exercise of 1,194,372 outstanding common stock purchase warrants and stock options. The warrants and options were exercised at an average price of $1.03. We received approximately $20,000 of net proceeds from the exercises. In 2014, we issued 568 shares of common stock upon conversion of certain outstanding RSU’s. We received no proceeds from this transaction. In 2014, we issued 805,972 shares of common stock upon the conversion by the lender of $1 million of principal payments due under our March 2013 long-term debt in accordance with the terms of the loan and security agreement (see Note 4). We received no such proceeds from this conversion. In October 2014, we issued 28,119 shares of common stock and common stock purchase warrants to purchase 133,329 to various parties in conjunction with our loan amendment (see Note 4). In February and March 2015, we issued 812,423 shares of common stock as a result of sales under our At the Market Offering Agreement. The shares were sold at an average price of $3.77 per share and we received approximately $2,932,000 in net proceeds. In 2015, we issued a total of 1,724,606 shares of our common stock upon the exercise of outstanding common stock purchase warrants and stock options. The warrants and options were exercised at an average exercise price of $1.94. We received approximately $3,056,000 of net proceeds from the exercises. In 2015, we issued a total of 1,251,189 shares of our common stock upon the cashless exercise of 2,209,000 outstanding common stock purchase warrants, stock options and conversion of RSU’s. The warrants and options were exercised at an average price of $0.6157. The exercises resulted in 1,158,020 warrants and options being forfeited and we received no proceeds from the exercises or from the conversion of RSU’s. In 2015, we issued 427,808 shares of common stock as restricted stock awards to our independent directors in accordance with our Director Compensation Plan. These shares are reserved under our 2010 employee option plan and they vest quarterly over the director comp year, in September 2015, December 2015, March 2016, and June 2016.
|
X |
- DefinitionThe entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656
Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494
Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644
Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E
Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Property and Equipment
|
12 Months Ended |
Dec. 31, 2015 |
Property, Plant and Equipment [Abstract] |
|
Property, Plant and Equipment Disclosure [Text Block] |
Note 6: Property and Equipment The major classes of property and equipment consist of the following at December 31: | | 2015 | | 2014 | | Furniture and fixtures | | $ | 31,610 | | $ | 22,603 | | Computers and office equipment | | | 136,558 | | | 100,105 | | Leasehold improvements | | | 40,290 | | | | | Lab equipment | | | 763,293 | | | 661,789 | | | | | 971,751 | | | 784,497 | | Less accumulated depreciation | | | (628,551) | | | (483,232) | | Property and equipment, net | | $ | 343,200 | | $ | 301,265 | | The above includes approximately $73,000 of equipment located at our research facility in China. Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the respective assets. Depreciation expense for the years ended December 31, 2015, 2014, and 2013 was approximately $148,000, $137,000, and $126,000 respectively.
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13-14) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Intangible Assets
|
12 Months Ended |
Dec. 31, 2015 |
Finite-Lived Intangible Assets, Net [Abstract] |
|
Intangible Assets Disclosure [Text Block] |
Note 7: Intangible Assets The Company holds patents related to its stem cell and small molecule technologies. Patent costs are capitalized and are being amortized over the life of the patents. The weighted average remaining unamortized life of issued patents was approximately 9.8, years at December 31, 2015. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. During the years ended December 31, 2015, 2014 and 2013, no significant impairment losses were recognized. The Company’s intangible assets and accumulated amortization consisted of the following at December 31, 2015 and 2014: | | 2015 | | 2014 | | Patent asset | | $ | 1,887,798 | | $ | 1,822,037 | | | | | | | | | | Accumulated Amortization | | $ | (784,331) | | $ | (588,865) | | | | | | | | | | Net Intagibles | | $ | 1,103,467 | | $ | 1,233,172 | | Amortization expense for the years ended December 31, 2015, 2014 and 2013 was approximately $197,000, $211,000, and $119,000 respectively. The expected average future annual amortization expense over the next five years is approximately $144,000 based on current balances of our intangible assets.
|
X |
- References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNetAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all or part of the information related to intangible assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275
+ Details
Name: |
us-gaap_IntangibleAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Income Taxes
|
12 Months Ended |
Dec. 31, 2015 |
Income Tax Disclosure [Abstract] |
|
Income Tax Disclosure [Text Block] |
Our provision for income taxes for 2015, 2014, and 2013 consists of the following: | | 2015 | | 2014 | | 2013 | | Current provision: | | | | | | | | | | | Federal | | $ | - | | $ | - | | $ | - | | State | | | - | | | - | | | - | | Foreign | | | - | | | - | | | - | | Total current provision | | | - | | | - | | | - | | | | | | | | | | | | | Deferred provision (benefit): | | | | | | | | | | | Federal | | | (6,645,222) | | | (5,563,694) | | | (4,436,239) | | State | | | (955,515) | | | (61,835) | | | 502,696 | | Foreign | | | - | | | - | | | - | | Total deferred provision (benefit) | | | (7,600,737) | | | (5,625,529) | | | (3,933,543) | | Valuation allowance | | | 7,600,737 | | | 5,625,529 | | | 3,933,543 | | Consolidated income tax provision | | $ | - | | $ | - | | $ | - | | We provide a full valuation allowance on our net deferred tax assets because management has determined that it is more likely than not that we will not earn income sufficient to realize the deferred tax assets during the asset reversal periods. The difference between income taxes computed by applying the statutory federal income tax rate to consolidated losses before income taxes and the consolidated provision for income taxes is attributable to the following: | | 2015 | | | 2014 | | | 2013 | | Federal statutory rate | | | (34.0) | % | | | (34.0) | % | | | (34.0) | % | State income taxes, net of Federal benefits | | | (4.3) | % | | | (4.5) | % | | | (5.3) | % | Warrant modification/inducement expense | | | 0.0 | % | | | 5.3 | % | | | 9.9 | % | Other | | | 1.4 | % | | | 8.3 | % | | | 9.5 | % | Valuation allowance | | | 36.9 | % | | | 24.9 | % | | | 19.9 | % | Total | | | 0.0 | % | | | 0.0 | % | | | 0.0 | % | The tax effects of significant temporary differences representing deferred tax assets as of December 31, 2015 and 2014: | | 2015 | | 2014 | | Net operating loss carryforwards | | $ | 39,555,984 | | $ | 36,008,206 | | Stock based compensation expense | | | 10,659,107 | | | 11,183,210 | | Tax credit carryforwards and other | | | 5,717,023 | | | 1,139,961 | | | | | 55,932,114 | | | 48,331,377 | | | | | | | | | | Valuation allowance | | | (55,932,114) | | | (48,331,377) | | Net deferred tax assets | | $ | - | | $ | - | | The Company had Federal net operating loss (“NOL”) carryforwards of approximately $113.7 million and $95.4 million, excluding stock-based compensation NOLs, at December 31, 2015 and 2014, respectively, which begin expiring in 2015. The Company also has certain Federal tax credit carryforwards that will expire through 2035. The timing and manner in which these net operating loss carryforwards and credits may be used in any year will be limited to the Company’s ability to generate future earnings and also may be limited by certain provisions in the U.S. tax code. The Company has not identified any uncertain tax positions and did not recognize any adjustments for unrecognized tax benefits. The Company remains subject to examination for income tax returns dating back to 2012.
|
X |
- DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details
Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Selected Quarterly Data
|
12 Months Ended |
Dec. 31, 2015 |
Quarterly Financial Information Disclosure [Abstract] |
|
Quarterly Financial Information [Text Block] |
Note 9 Selected Quarterly Data (Unaudited) The following represents the Company’s unaudited quarterly results for the years ended December 31: | | Quarter Ended | | | | 2015 | | | | March 31 | | June 30 | | September 30 | | December 31 | | | | | | | | | | | | | | | | Revenues | | $ | 2,917 | | $ | 2,500 | | $ | 2,500 | | $ | 2,500 | | Operating loss | | $ | (4,612,980) | | $ | (4,994,722) | | $ | (5,197,520) | | $ | (4,351,306) | | Net loss | | $ | (5,053,145) | | $ | (5,448,037) | | $ | (5,637,568) | | $ | (4,765,151) | | Net loss per share - basic and diluted | | $ | (0.06) | | $ | (0.06) | | $ | (0.06) | | $ | (0.05) | | | | Quarter Ended | | | | 2014 | | | | March 31 | | June 30 | | September 30 | | December 31 | | | | | | | | | | | | | | | | Revenues | | $ | 4,167 | | $ | 5,000 | | $ | 5,000 | | $ | 4,666 | | Operating loss | | $ | (5,176,901) | | $ | (3,511,238) | | $ | (4,106,745) | | $ | (4,640,965) | | Net loss | | $ | (5,919,057) | | $ | (6,751,282) | | $ | (4,455,237) | | $ | (5,503,168) | | Net loss per share - basic and diluted | | $ | (0.07) | | $ | (0.08) | | $ | (0.05) | | $ | (0.06) | | The sum of the quarterly per share amounts does not equal the annual amounts due to changes in the weighted average number of common shares outstanding during the year.
|
X |
- DefinitionThe entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a)-(j) -URI http://asc.fasb.org/extlink&oid=51825399&loc=d3e1280-108306
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section G -Subsection 1
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K (SK) -Number 229 -Section 302 -Paragraph a
+ Details
Name: |
us-gaap_QuarterlyFinancialInformationTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Commitments and Contingencies
|
12 Months Ended |
Dec. 31, 2015 |
Commitments and Contingencies Disclosure [Abstract] |
|
Commitments and Contingencies Disclosure [Text Block] |
Note 10 Commitments and Contingencies We currently operate two facilities located in the United States and one facility located in China. Our corporate offices and primary research facilities are located in Germantown, Maryland, where we license approximately 2,900 square feet. This license provides for monthly payments of approximately $10,200 per month with the term expiring on December 31, 2016. In 2015, we entered into a lease consisting of approximately 3,100 square feet of research space in San Diego, California. This lease provides for current monthly payments of approximately $11,000 and expires on August 31, 2018. We also lease a research facility in People’s Republic of China. This lease expires on September 30, 2018 with lease payments of approximately $3,200 per month. Future minimum payments under all leases at December 31, 2015 are as follows: Year | | Amount | | 2016 | | $ | 309,286 | | 2017 | | | 149,569 | | 2018 | | | 143,300 | | 2019 | | | 38,542 | | 2020 | | | - | | 2020 and thereafter | | | - | | Total minimum payments | | $ | 640,697 | | The Company recognized approximately $318,000, $257,000, and $277,000, in rent expense for the years ended December 31, 2015, 2014, and 2013 respectively. The Company is currently obligated under two written employment agreements with our former Chief Executive Officer (“CEO”) and Chief Scientific Officer (“CSO”). Both agreements terminate on October 31, 2017. Pursuant to the CEO’s agreement, he receives a salary of $440,000 per annum and in the event of termination prior to the completion of the agreement the Company would pay the CEO the greater of his remaining compensation due under the agreement or one million dollars ($1,000,000). Pursuant to the CSO’s agreement, he receives $750,000 per annum and in the event of termination prior to the completion of the agreement the Company would pay the CSO the greater of the remaining compensation due under the agreement or one million dollars ($1,000,000). In addition, pursuant to both the agreements any and all stock options, warrants, restricted stock or restricted stock units granted would accelerate and vest immediately in the event the agreements are terminated early. On March 1, 2015, Neuralstem, Inc. (the “Company”) entered into a general release and waiver of claims (“General Release”) with I. Richard Garr in connection with his resignation as the Company’s chief executive officer. Pursuant to the General Release, the required severance payment to Mr. Garr pursuant to his termination were amended to the following severance in exchange for Mr. Garr’s voluntary resignation: (i) the continued payment of Mr. Garr’s monthly salary immediately prior to his resignation until March 1, 2017, (ii) a lump of $177,000 to be paid on June 1, 2016, January 1, 2017 and March 1, 2017, (iii) continued healthcare benefits until January 1, 2017, and (iv) the immediate vesting of any previously outstanding but unvested equity awards (collectively, the “Severance”). On May 7, 2008, we filed suit against StemCells, Inc., StemCells California, Inc. (collectively "StemCells") and Neurospheres Holding Ltd. in U.S. District Court for the District of Maryland, alleging that U.S. Patent No. 7,361,505 (the "'505 patent") is invalid, not infringed, and unenforceable. See Civil Action No. 08-1173. On May 13, 2008 we filed an Amended Complaint seeking declaratory judgment that U.S. Patent No. 7,155,418 (the "'418 patent") is invalid and not infringed and that certain statements made by our CEO are not trade libel or do not constitute unfair competition. On September 11, 2008, StemCells filed its answer asserting counterclaims of infringement for the '505 patent, the '418 patent, and state law claims for trade libel and unfair competition. This case was consolidated with the 2006 litigation discussed below. On July 28, 2006, StemCells, Inc., filed suit against Neuralstem, Inc. in the U.S. District Court in Maryland, alleging that Neuralstem has been infringing, contributing to the infringement of, and or inducing the infringement of four patents allegedly owned by or exclusively licensed to StemCells. See Civil Action No. 06-1877. We answered the Complaint denying infringement, asserting that the patents are invalid, asserting that we have intervening rights based on amendments made to the patents during reexamination proceedings, and further asserting that some of the patents are unenforceable due to inequitable conduct. Neuralstem has also asserted counterclaims that StemCells has engaged in anticompetitive conduct in violation of antitrust laws. On February 28, 2011, Neuralstem filed a Motion to Dismiss for lack of standing and concurrently filed a Motion for Leave to Amend its Answer and Counterclaim to allege that StemCells is not the exclusive licensee of the patents-in-suit and also that Neuralstem has obtained a non-exclusive license to the patents-in-suit. In addition, before the Court decided Neuralstem's Motion to Dismiss for lack of standing, StemCells filed a motion for summary judgment on the issue standing. Neuralstem responded to that motion and cross-moved for summary judgment on the issue of standing. The Court further issued its Markman Order (an order ruling on the scope and meaning of disputed patent claim language regarding the patents at issue) on August 12, 2011. On August 26, 2011, StemCells moved for reconsideration of two terms construed in the Markman Order and that motion remains pending. On April 6, 2012 the Court granted Neuralstem's Motion for Leave to Amend to assert lack of standing and denied Neuralstem's Motion to Dismiss and Motion for Summary Judgment without prejudice. The Court also denied StemCells' Motion for Summary Judgment with prejudice. The Court stayed all other matters pending resolution of the question of standing. The case was then reassigned to Judge Roger W. Titus. On July 22, 2015, the Court issued its ruling on the issue of standing finding that a third-party who was not named as an inventor was a co-owner and co-inventor of the patents-in-suit. Thus, the Court determined that StemCells lacked standing to pursue its patent infringement claims against Neuralstem and the case was dismissed with prejudice. On September 10, 2015, the parties entered into a settlement agreement dismissing all claims and counterclaims with prejudice.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Transaction with Related Parties
|
12 Months Ended |
Dec. 31, 2015 |
Related Party Transactions [Abstract] |
|
Related Party Transactions Disclosure [Text Block] |
Note 11: Transaction with Related Parties On March 1, 2015, Neuralstem, Inc. (the “Company”) entered into a general release and waiver of claims (“General Release”) with I. Richard Garr in connection with his resignation as the Company’s chief executive officer. Mr. Garr’s employment agreement previously required the Company to pay a lump sum to Mr. Garr of $1,000,000. Pursuant to the General Release, the required severance payment to Mr. Garr pursuant to his termination were amended to the following severance in exchange for Mr. Garr’s voluntary resignation: (i) the continued payment of Mr. Garr’s monthly salary immediately prior to his resignation until March 1, 2017, (ii) a lump of $177,000 to be paid on June 1, 2016, January 1, 2017 and March 1, 2017, (iii) continued healthcare benefits until January 1, 2017, and (iv) the immediate vesting of any previously outstanding but unvested equity awards (collectively, the “Severance”).
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Subsequent Events
|
12 Months Ended |
Dec. 31, 2015 |
Subsequent Events [Abstract] |
|
Subsequent Events [Text Block] |
Note 12: Subsequent Events On February 15, 2016, The Company announced the appointment Richard Daly to the position of President and Chief Executive Officer, and as a member of the Company’s board of directors. Mr. Daly will serve as a Class III member of the Company’s Board and will be up for re-election at the Company’s 2017 annual shareholders meeting. On February 15, 2016, in connection with the hiring of Mr. Daly as discussed herein, Richard Garr ceased to serve as the Company’s Chief Executive Officer, President and General Counsel. Mr. Garr will continue to serve on the Company’s board and will continue to assist the Company through a transition period. On March 1, 2015, Neuralstem, Inc. (the “Company”) entered into a general release and waiver of claims (“General Release”) with I. Richard Garr in connection with his resignation as the Company’s chief executive officer. Mr. Garr’s employment agreement previously required the Company to pay a lump sum to Mr. Garr of $1,000,000. Pursuant to the General Release, the required severance payment to Mr. Garr pursuant to his termination were amended to the following severance in exchange for Mr. Garr’s voluntary resignation: (i) the continued payment of Mr. Garr’s monthly salary immediately prior to his resignation until March 1, 2017, (ii) a lump of $177,000 to be paid on June 1, 2016, January 1, 2017 and March 1, 2017, (iii) continued healthcare benefits until January 1, 2017, and (iv) the immediate vesting of any previously outstanding but unvested equity awards (collectively, the “Severance”).
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Significant Accounting Policies and Basis of Presentation (Policies)
|
12 Months Ended |
Dec. 31, 2015 |
Accounting Policies [Abstract] |
|
Basis of Accounting, Policy [Policy Text Block] |
Basis of Presentation Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States if America (“U.S. GAAP”). The financial statements include the accounts of the Company and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated. The opinion of our independent registered accounting firm on our financial statements contains explanatory going concern language. We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. We have incurred losses since inception and have a deficit accumulated of approximately $172,000,000 as of December 31, 2015. We anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales from our product candidate’s currently in development or we enter into cash flow positive business development transactions. If we are not able to secure additional financing or enter into a cash flow positive business transaction before July, 2016, we may not be able to continue as a going concern.
|
Use of Estimates, Policy [Policy Text Block] |
Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology, our net operating loss carry forward and related valuation allowance for tax purposes and our stock-based compensation related to employees and directors, consultants and advisors, including investment banks, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.
|
Fair Value Measurement, Policy [Policy Text Block] |
Fair Value Measurements The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, other short-term investments, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness is estimated based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. The fair values of our derivative instruments were estimated using Level 3 unobservable inputs. See Note 3 for further details.
|
Foreign Currency Transactions and Translations Policy [Policy Text Block] |
Foreign Currency Translation The functional currency of our wholly owned foreign subsidiary is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of are accumulated in other comprehensive income or loss, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss.
|
Cash and Cash Equivalents, Policy [Policy Text Block] |
Cash, Cash Equivalents and Credit Risk Cash equivalents consist of investments in low risk, highly liquid money market funds and certificates of deposit with original maturities of 90 days or less. Cash deposited with banks and other financial institutions may exceed the amount of insurance provided on such deposits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail. Short-term investments consist entirely of fixed income certificates of deposit (“CDs”) with original maturities of greater than 90 days and not more than one year. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and short-term investments. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. In addition, our CDs are invested through the Certificate of Deposit Account Registry Service (“CDARS”) program which reduces or eliminates our risk related to concentrations of investments above FDIC insurance levels. We limit our credit and liquidity risks through our investment policy and through regular reviews of our portfolio against our policy. To date, we have not experienced any loss or lack of access to cash in our operating accounts or to our cash equivalents and short-term investments.
|
Revenue Recognition, Policy [Policy Text Block] |
Revenue Recognition Historically, our revenue has been derived primarily from (i) selling treated samples for gene expression data from stem cell experiments, (ii) providing services under various contracts and grants and (iii) licensing the use of our intellectual property to third parties. Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery of goods and services has occurred, the price is fixed and determinable, and collection is reasonably assured.
|
Research and Development Expense, Policy [Policy Text Block] |
Research and Development Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated exclusively with the pre-clinical development and clinical trials of our product candidates.
|
Earnings Per Share, Policy [Policy Text Block] |
Income (Loss) per Common Share Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the years ended December 31, 2015, 2014 and 2013. A total of approximately 36.8 , 40.4, and 38.2 million potential dilutive shares have been excluded in the calculation of diluted net income per share for the years ended December 31, 2015, 2014 and 2013, respectively as their inclusion would be anti-dilutive.
|
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] |
Share-Based Compensation We account for share-based compensation at fair value. Share-based compensation cost for stock options and warrants granted to employees and board members is determined at the grant date using an option pricing model that uses level 3 unobservable inputs; share-based compensation cost for restricted stock and restricted stock units granted to employees and board members is determined at the grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period.
|
Goodwill and Intangible Assets, Policy [Policy Text Block] |
Intangible and Long-Lived Assets We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. No significant impairment losses were recognized during the years ended December 31, 2015, 2014, and 2013.
|
Income Tax, Policy [Policy Text Block] |
Income Taxes We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense.
|
Reclassification, Policy [Policy Text Block] |
Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the reported results of operations.
|
New Accounting Pronouncements, Policy [Policy Text Block] |
Significant New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued ASU 2014-09 Revenue from Contracts with Customers. This guidance is effective for fiscal years beginning after December 15, 2016 and early adoption is not permitted. We have not yet determined the effects of this new guidance on our financial statements. In August 2014, the FASB issued ASU 2014-15 Presentation of Financial Statements Going Concern. This guidance requires management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. This guidance is effective for fiscal years beginning after December 15, 2016 and early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on our financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
+ Details
Name: |
us-gaap_BasisOfAccountingPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 305 -SubTopic 10 -Section 05 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Financial Reporting Release (FRR) -Number 203 -Paragraph 02-03
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
+ Details
Name: |
us-gaap_EarningsPerSharePolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
+ Details
Name: |
us-gaap_FairValueMeasurementPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details
Name: |
us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 30 -Section 05 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 740 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318
+ Details
Name: |
us-gaap_IncomeTaxPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
+ Details
Name: |
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for reclassifications that affects the comparability of the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755
+ Details
Name: |
us-gaap_PriorPeriodReclassificationAdjustmentDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Research and Development -URI http://asc.fasb.org/extlink&oid=6523717
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpensePolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.B.Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section B -Paragraph Question 1
+ Details
Name: |
us-gaap_RevenueRecognitionPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b),(f) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Stockholders' Equity (Tables)
|
12 Months Ended |
Dec. 31, 2015 |
Stockholders Equity [Line Items] |
|
Schedule of Share-based Compensation, Activity [Table Text Block] |
We record share-based compensation expense on a straight-line basis over the requisite service period. Share-based compensation expense included in the statements of operations was as follows: | | Year Ended December 31, | | | | 2015 | | 2014 | | 2013 | | | | | | | | | | | | | Research and development costs | | $ | 1,394,194 | | $ | 968,326 | | $ | 932,200 | | General and administrative expenses | | | 1,557,173 | | | 3,351,747 | | | 1,399,201 | | Total | | $ | 2,951,367 | | $ | 4,320,073 | | $ | 2,331,401 | |
|
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] |
A summary of stock option activity and related information for the year ended December 31, 2015 follows: | | Number of Options | | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Life (in years) | | Aggregate Intrinsic Value | | | | | | | | | | | | | | | | Outstanding at January 1, 2015 | | | 18,986,395 | | $ | 1.89 | | | 5.1 | | $ | 20,306,807 | | Granted | | | 765,549 | | $ | 3.09 | | | | | | | | Exercised | | | (1,031,774) | | $ | 0.54 | | | | | $ | 68,400 | | Forfeited/Expired | | | (1,617,223) | | $ | 1.32 | | | | | | | | Outstanding at December 31, 2015 | | | 17,102,947 | | $ | 2.08 | | | 5.0 | | $ | 550,000 | | | | | | | | | | | | | | | | Exercisable at December 31, 2015 | | | 14,118,821 | | $ | 2.19 | | | 4.6 | | $ | 330,000 | | | | | | | | | | | | | | | | Vested and expected to vest at December 31, 2015 | | | 17,099,027 | | $ | 2.08 | | | 5.0 | | $ | 550,000 | |
|
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] |
Range of Exercise Prices | | Number of Options Outstanding | | Weighted- Average Exercise Price | | Weighted- Average Remaining Contractual Life (in years) | | Aggregate Intrinsic Value | | $0.50 - $1.00 | | | 5,000,000 | | $ | 0.92 | | | 6.6 | | $ | 550,000 | | $1.01 - $2.00 | | | 4,275,984 | | $ | 1.22 | | | 6.0 | | | - | | $2.01 - $3.00 | | | 2,122,669 | | $ | 2.50 | | | 3.8 | | | - | | $3.01 - $5.00 | | | 5,704,294 | | $ | 3.60 | | | 3.4 | | | - | | | | | 17,102,947 | | $ | 2.08 | | | 5.0 | | $ | 550,000 | |
|
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Black Sholes Model [Table Text Block] |
The Company uses the Black-Scholes option pricing model for “plain vanilla” options and other pricing models as appropriate to calculate the fair value of options. Significant assumptions used in these models include: | | 2015 | | 2014 | | 2013 | | | | | | | | | | Annual dividend | | - | | - | | - | | Expected life (in years) | | 4.0-6.0 | | 4.0 - 8.5 | | 3.0 - 6.5 | | Risk free interest rate | | 1.39%-1.78% | | 1.12% - 2.50% | | 0.29% - 2.43% | | Expected volatility | | 68.6%-71.8% | | 68.8% - 100.0% | | 65.1% - 77.5% | |
|
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] |
A summary of our RSU activity for the year ended December 31, 2015 follows: | | Number of RSU's | | Weighted- Average Grant Date Fair Value | | | | | | | | | | Outstanding at January 1, 2015 | | | 447,275 | | $ | 2.18 | | Granted | | | - | | $ | - | | Vested and converted to common shares | | | (219,415) | | $ | 2.21 | | Forfeited | | | (76,954) | | $ | 2.21 | | Outstanding at December 31, 2015 | | | 150,906 | | $ | 2.13 | | | | | | | | | | Exercisable at December 31, 2015 | | | 150,906 | | $ | 2.13 | |
|
Schedule Of Share Based Compensation Warrant Activity [Table Text Block] |
A summary of warrant activity for the year ended December 31, 2015 follows: | | Number of Warrants | | Weighted- Average Exercised Price | | Weighted- Average Remaining Contractual Life (in years) | | Aggregate Intrinsic Value | | | | | | | | | | | | | | | | Outstanding at January 1, 2015 | | | 21,422,346 | | $ | 2.30 | | | 3.8 | | $ | 15,984,739 | | Granted | | | 150,000 | | $ | 1.87 | | | 4.5 | | | | | Exercised | | | (1,724,606) | | $ | 1.94 | | | | | | | | Forfeited | | | (195,644) | | $ | 2.02 | | | | | | | | Outstanding at December 31, 2015 | | | 19,652,096 | | $ | 2.34 | | | 3.1 | | $ | 309,724 | | | | | | | | | | | | | | | | Exercisable at December 31, 2015 | | | 19,577,096 | | $ | 2.34 | | | 3.1 | | $ | 309,724 | |
|
Restricted Stock [Member] |
|
Stockholders Equity [Line Items] |
|
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] |
A summary of our restricted stock activity for the year ended December 31, 2015 is as follows: | | | | | Weighted- | | | | Number | | Average Grant | | | | of RS | | Date Fair Value | | Granted | | | 427,808 | | $ | 1.87 | | Vested | | | (213,904) | | $ | 1.87 | | Forfeited | | | - | | $ | 0.00 | | Outstanding at December 31, 2015 | | | 213,904 | | $ | 1.87 | |
|
X |
- DefinitionTabular disclosure of warrants issued by the entity for financing and compensation related purposes.
+ References
+ Details
Name: |
cur_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock |
Namespace Prefix: |
cur_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis line item represents stockholders equity.
+ References
+ Details
Name: |
cur_StockholdersEquityLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.
+ References
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.
+ References
+ Details
Name: |
us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Property and Equipment (Tables)
|
12 Months Ended |
Dec. 31, 2015 |
Property, Plant and Equipment [Abstract] |
|
Property, Plant and Equipment [Table Text Block] |
The major classes of property and equipment consist of the following at December 31: | | 2015 | | 2014 | | Furniture and fixtures | | $ | 31,610 | | $ | 22,603 | | Computers and office equipment | | | 136,558 | | | 100,105 | | Leasehold improvements | | | 40,290 | | | | | Lab equipment | | | 763,293 | | | 661,789 | | | | | 971,751 | | | 784,497 | | Less accumulated depreciation | | | (628,551) | | | (483,232) | | Property and equipment, net | | $ | 343,200 | | $ | 301,265 | |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph b -Article 5
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Intangible Assets (Tables)
|
12 Months Ended |
Dec. 31, 2015 |
Finite-Lived Intangible Assets, Net [Abstract] |
|
Schedule of Finite-Lived Intangible Assets [Table Text Block] |
The Company’s intangible assets and accumulated amortization consisted of the following at December 31, 2015 and 2014: | | 2015 | | 2014 | | Patent asset | | $ | 1,887,798 | | $ | 1,822,037 | | | | | | | | | | Accumulated Amortization | | $ | (784,331) | | $ | (588,865) | | | | | | | | | | Net Intagibles | | $ | 1,103,467 | | $ | 1,233,172 | |
|
X |
- References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNetAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275
+ Details
Name: |
us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2015 |
Income Tax Disclosure [Abstract] |
|
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] |
Our provision for income taxes for 2015, 2014, and 2013 consists of the following: | | 2015 | | 2014 | | 2013 | | Current provision: | | | | | | | | | | | Federal | | $ | - | | $ | - | | $ | - | | State | | | - | | | - | | | - | | Foreign | | | - | | | - | | | - | | Total current provision | | | - | | | - | | | - | | | | | | | | | | | | | Deferred provision (benefit): | | | | | | | | | | | Federal | | | (6,645,222) | | | (5,563,694) | | | (4,436,239) | | State | | | (955,515) | | | (61,835) | | | 502,696 | | Foreign | | | - | | | - | | | - | | Total deferred provision (benefit) | | | (7,600,737) | | | (5,625,529) | | | (3,933,543) | | Valuation allowance | | | 7,600,737 | | | 5,625,529 | | | 3,933,543 | | Consolidated income tax provision | | $ | - | | $ | - | | $ | - | |
|
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] |
The difference between income taxes computed by applying the statutory federal income tax rate to consolidated losses before income taxes and the consolidated provision for income taxes is attributable to the following: | | 2015 | | | 2014 | | | 2013 | | Federal statutory rate | | | (34.0) | % | | | (34.0) | % | | | (34.0) | % | State income taxes, net of Federal benefits | | | (4.3) | % | | | (4.5) | % | | | (5.3) | % | Warrant modification/inducement expense | | | 0.0 | % | | | 5.3 | % | | | 9.9 | % | Other | | | 1.4 | % | | | 8.3 | % | | | 9.5 | % | Valuation allowance | | | 36.9 | % | | | 24.9 | % | | | 19.9 | % | Total | | | 0.0 | % | | | 0.0 | % | | | 0.0 | % |
|
Schedule Of Deferred Tax Assets [Table Text Block] |
The tax effects of significant temporary differences representing deferred tax assets as of December 31, 2015 and 2014: | | 2015 | | 2014 | | Net operating loss carryforwards | | $ | 39,555,984 | | $ | 36,008,206 | | Stock based compensation expense | | | 10,659,107 | | | 11,183,210 | | Tax credit carryforwards and other | | | 5,717,023 | | | 1,139,961 | | | | | 55,932,114 | | | 48,331,377 | | | | | | | | | | Valuation allowance | | | (55,932,114) | | | (48,331,377) | | Net deferred tax assets | | $ | - | | $ | - | |
|
X |
- DefinitionTabular disclosure of the components of net deferred tax asset recognized in an entity's statement of financial position, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
+ Details
Name: |
cur_ScheduleOfDeferredTaxAssetsTableTextBlock |
Namespace Prefix: |
cur_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319
+ Details
Name: |
us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319
+ Details
Name: |
us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Selected Quarterly Data (Tables)
|
12 Months Ended |
Dec. 31, 2015 |
Quarterly Financial Information Disclosure [Abstract] |
|
Schedule of Quarterly Financial Information [Table Text Block] |
The following represents the Company’s unaudited quarterly results for the years ended December 31: | | Quarter Ended | | | | 2015 | | | | March 31 | | June 30 | | September 30 | | December 31 | | | | | | | | | | | | | | | | Revenues | | $ | 2,917 | | $ | 2,500 | | $ | 2,500 | | $ | 2,500 | | Operating loss | | $ | (4,612,980) | | $ | (4,994,722) | | $ | (5,197,520) | | $ | (4,351,306) | | Net loss | | $ | (5,053,145) | | $ | (5,448,037) | | $ | (5,637,568) | | $ | (4,765,151) | | Net loss per share - basic and diluted | | $ | (0.06) | | $ | (0.06) | | $ | (0.06) | | $ | (0.05) | | | | Quarter Ended | | | | 2014 | | | | March 31 | | June 30 | | September 30 | | December 31 | | | | | | | | | | | | | | | | Revenues | | $ | 4,167 | | $ | 5,000 | | $ | 5,000 | | $ | 4,666 | | Operating loss | | $ | (5,176,901) | | $ | (3,511,238) | | $ | (4,106,745) | | $ | (4,640,965) | | Net loss | | $ | (5,919,057) | | $ | (6,751,282) | | $ | (4,455,237) | | $ | (5,503,168) | | Net loss per share - basic and diluted | | $ | (0.07) | | $ | (0.08) | | $ | (0.05) | | $ | (0.06) | |
|
X |
- DefinitionTabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a)-(j) -URI http://asc.fasb.org/extlink&oid=51825399&loc=d3e1280-108306
+ Details
Name: |
us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737
+ Details
Name: |
us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- References
+ Details
Name: |
cur_OrganizationAndBusinessLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CashCashEquivalentsAndShortTermInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.3.1.900
X |
- DefinitionThis line item represents significant accounting policies.
+ References
+ Details
Name: |
cur_SignificantAccountingPoliciesLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.3.1.900
Debt (Details Textual) - USD ($)
|
1 Months Ended |
12 Months Ended |
Oct. 31, 2014 |
Mar. 31, 2013 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Debt Instrument [Line Items] |
|
|
|
|
|
Debt Instrument, Face Amount |
|
$ 8,000,000
|
|
|
|
Debt Instrument, Unused Borrowing Capacity, Amount |
|
$ 2,000,000
|
|
|
|
Debt Instrument, Interest Rate at Period End |
|
|
11.00%
|
|
|
Stock Issued During Period, Shares, New Issues |
|
350,650
|
|
|
|
Debt Conversion, Converted Instrument, Shares Issued |
|
|
|
805,972
|
|
Debt Conversion, Converted Instrument, Amount |
|
|
|
$ 1,000,000
|
|
Debt Instrument, Periodic Payment |
|
|
$ 300,000
|
|
|
Proceeds from Debt, Net of Issuance Costs |
$ 4,300,000
|
|
7,600,000
|
|
|
Gains (Losses) on Extinguishment of Debt |
446,000
|
|
$ 0
|
$ (445,787)
|
$ 0
|
Debt Instrument, Convertible, Terms of Conversion Feature |
|
|
The loan agreement provided for a conversion feature whereby the lender or the Company could each convert up to a maximum of $1 million in principal payments into common stock of the Company.
|
|
|
Debt Instrument Refinanced Loan |
5,600,000
|
|
|
|
|
Debt Instrument Principal Amount |
10,000,000
|
|
|
|
|
Debt Instrument Additional Principal Borrowed |
$ 4,400,000
|
|
|
|
|
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate |
10.00%
|
|
|
|
|
Maturity 2016 [Member] |
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
Debt Instrument, Face Amount |
|
|
$ 4,570,000
|
|
|
Maturity 2017 [Member] |
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
Debt Instrument, Face Amount |
|
|
3,766,000
|
|
|
April 2017 [Member] |
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid |
$ 2,800,000
|
|
|
|
|
January 2016 Through March 2017 [Member] |
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
Debt Instrument, Periodic Payment |
|
|
$ 435,000
|
|
|
Warrant One [Member] |
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
Number Of Common Stock Shares Granted By Issue Of Warrants |
|
648,809
|
|
|
|
Exercise Price Per share Of Common Stock To Be Issued Upon Conversion Of Warrants |
|
$ 1.0789
|
|
|
|
Warrants Expiration Period |
|
5 years
|
|
|
|
Warrant Two [Member] |
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
Payments of Debt Issuance Costs |
|
$ 449,000
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
350,650
|
|
|
|
Number Of Common Stock Shares Granted By Issue Of Warrants |
|
648,798
|
|
|
|
Exercise Price Per share Of Common Stock To Be Issued Upon Conversion Of Warrants |
|
$ 1.07892
|
|
|
|
Stock Issued During Period, Value, New Issues |
|
$ 396,000
|
|
|
|
Warrants Expiration Period |
|
5 years
|
|
|
|
Warrant Three [Member] |
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
Number Of Common Stock Shares Granted By Issue Of Warrants |
75,188
|
|
|
|
|
Exercise Price Per share Of Common Stock To Be Issued Upon Conversion Of Warrants |
$ 2.66
|
|
|
|
|
Warrants Expiration Period |
3 years
|
|
|
|
|
Warrant Four [Member] |
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
Payments of Debt Issuance Costs |
$ 86,000
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
28,119
|
|
|
|
|
Number Of Common Stock Shares Granted By Issue Of Warrants |
58,141
|
|
|
|
|
Exercise Price Per share Of Common Stock To Be Issued Upon Conversion Of Warrants |
$ 2.66
|
|
|
|
|
Stock Issued During Period, Value, New Issues |
$ 80,000
|
|
|
|
|
Warrants Expiration Period |
5 years
|
|
|
|
|
X |
- DefinitionThis element represents amount of additional principal borrowed under amended term debt.
+ References
+ Details
Name: |
cur_DebtInstrumentAdditionalPrincipalBorrowed |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThis element represents amount of total principal of the amended term debt.
+ References
+ Details
Name: |
cur_DebtInstrumentPrincipalAmount |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThis element represents amount of principal refinanced under amended term debt.
+ References
+ Details
Name: |
cur_DebtInstrumentRefinancedLoan |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionExercised price per share of common stock to be issued upon conversion of warrants.
+ References
+ Details
Name: |
cur_ExercisePricePershareOfCommonStockToBeIssuedUponConversionOfWarrants |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of common shares granted for the issue of warrants during the reporting period.
+ References
+ Details
Name: |
cur_NumberOfCommonStockSharesGrantedByIssueOfWarrants |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIt represents the warrant expiry date.
+ References
+ Details
Name: |
cur_WarrantsExpirationPeriod |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentAmount1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentSharesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 16 -Article 9
+ Details
Name: |
us-gaap_DebtInstrumentCarryingAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionDescription of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateEffectivePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the required periodic payments including both interest and principal payments.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823
+ Details
Name: |
us-gaap_DebtInstrumentPeriodicPayment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of payment greater than the preceding installment payments to be paid at final maturity date of debt.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(b)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LongTermDebtPercentageBearingVariableInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
+ Details
Name: |
us-gaap_PaymentsOfDebtIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.
+ References
+ Details
Name: |
us-gaap_ProceedsFromDebtNetOfIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
cur_MaturityDateAxis=cur_Maturity2016Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
cur_MaturityDateAxis=cur_Maturity2017Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
cur_MaturityDateAxis=cur_April2017Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
cur_MaturityDateAxis=cur_January2016ThroughMarch2017Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=cur_WarrantOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=cur_WarrantTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=cur_WarrantThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=cur_WarrantFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Stockholders' Equity (Details) - USD ($)
|
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Stockholders Equity [Line Items] |
|
|
|
Share-based compensation expense |
$ 2,951,367
|
$ 4,320,073
|
$ 2,331,401
|
Research and development expenses [Member] |
|
|
|
Stockholders Equity [Line Items] |
|
|
|
Share-based compensation expense |
1,394,194
|
968,326
|
932,200
|
General and administrative expenses [Member] |
|
|
|
Stockholders Equity [Line Items] |
|
|
|
Share-based compensation expense |
$ 1,557,173
|
$ 3,351,747
|
$ 1,399,201
|
X |
- DefinitionThis line item represents stockholders equity.
+ References
+ Details
Name: |
cur_StockholdersEquityLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F
+ Details
Name: |
us-gaap_AllocatedShareBasedCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Stockholders' Equity (Details 1) - USD ($)
|
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Stockholders Equity [Line Items] |
|
|
Outstanding, Number of Options, at January 1, 2015 |
18,986,395
|
|
Granted, Number of Options |
765,549
|
|
Exercised, Number of Options |
(1,031,774)
|
|
Forfeited/Expired, Number of Options |
(1,617,223)
|
|
Outstanding, Number of Options, at December 31, 2015 |
17,102,947
|
18,986,395
|
Exercisable, Number of Options, at December 31, 2015 |
14,118,821
|
|
Vested and expected to vest, Number of Options |
17,099,027
|
|
Outstanding, Weighted-Average Exercise Price, at January 1, 2015 |
$ 1.89
|
|
Granted, Weighted-Average Exercise Price |
3.09
|
|
Exercised, Weighted-Average Exercise Price |
0.54
|
|
Forfeited, Weighted-Average Exercise Price |
1.32
|
|
Outstanding, Weighted-Average Exercise Price, at December 31, 2015 |
2.08
|
$ 1.89
|
Exercisable, Weighted-Average Exercise Price, at December 31, 2015 |
2.19
|
|
Vested and expected to vest, Weighted-Average Exercise Price |
$ 2.08
|
|
Outstanding, Weighted-Average Remaining Contractual Life (in Years) |
5 years
|
5 years 1 month 6 days
|
Exercisable, Weighted-Average Remaining Contractual Life (in Years) |
4 years 7 months 6 days
|
|
Vested and expected to vest, Weighted-Average Remaining Contractual Life (in Years) |
5 years
|
|
Outstanding, Aggregate Intrinsic Value, at January 1, 2015 |
$ 20,306,807
|
|
Exercised, Aggregate Intrinsic Value |
68,400
|
|
Outstanding, Aggregate Intrinsic Value, at December 31, 2015 |
550,000
|
$ 20,306,807
|
Exercisable, Aggregate Intrinsic Value, at December 31, 2015 |
330,000
|
|
Vested and expected to vest, Aggregate Intrinsic Value |
$ 550,000
|
|
X |
- DefinitionThis line item represents stockholders equity.
+ References
+ Details
Name: |
cur_StockholdersEquityLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNet number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAs of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAs of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Stockholders' Equity (Details 2) - USD ($)
|
12 Months Ended |
|
Dec. 31, 2015 |
Dec. 31, 2014 |
Stockholders Equity [Line Items] |
|
|
Number of Options Outstanding |
17,102,947
|
|
Weighted-Average Exercise Price |
$ 2.08
|
$ 1.89
|
Weighted-Average Remaining Contractual Life (in Years) |
5 years
|
|
Aggregate Intrinsic Value |
$ 550,000
|
$ 20,306,807
|
Range One [Member] |
|
|
Stockholders Equity [Line Items] |
|
|
Range of Exercise Price (Lower) |
$ 0.50
|
|
Range of Exercise Price (Upper) |
$ 1.00
|
|
Number of Options Outstanding |
5,000,000
|
|
Weighted-Average Exercise Price |
$ 0.92
|
|
Weighted-Average Remaining Contractual Life (in Years) |
6 years 7 months 6 days
|
|
Aggregate Intrinsic Value |
$ 550,000
|
|
Range Two [Member] |
|
|
Stockholders Equity [Line Items] |
|
|
Range of Exercise Price (Lower) |
$ 1.01
|
|
Range of Exercise Price (Upper) |
$ 2.00
|
|
Number of Options Outstanding |
4,275,984
|
|
Weighted-Average Exercise Price |
$ 1.22
|
|
Weighted-Average Remaining Contractual Life (in Years) |
6 years
|
|
Aggregate Intrinsic Value |
$ 0
|
|
Range Three [Member] |
|
|
Stockholders Equity [Line Items] |
|
|
Range of Exercise Price (Lower) |
$ 2.01
|
|
Range of Exercise Price (Upper) |
$ 3.00
|
|
Number of Options Outstanding |
2,122,669
|
|
Weighted-Average Exercise Price |
$ 2.5
|
|
Weighted-Average Remaining Contractual Life (in Years) |
3 years 9 months 18 days
|
|
Range Four [Member] |
|
|
Stockholders Equity [Line Items] |
|
|
Range of Exercise Price (Lower) |
$ 3.01
|
|
Range of Exercise Price (Upper) |
$ 5.00
|
|
Number of Options Outstanding |
5,704,294
|
|
Weighted-Average Exercise Price |
$ 3.6
|
|
Weighted-Average Remaining Contractual Life (in Years) |
3 years 4 months 24 days
|
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis line item represents stockholders equity.
+ References
+ Details
Name: |
cur_StockholdersEquityLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_RangeAxis=cur_RangeOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RangeAxis=cur_RangeTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RangeAxis=cur_RangeThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RangeAxis=cur_RangeFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionThis line item represents stockholders equity.
+ References
+ Details
Name: |
cur_StockholdersEquityLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.D.2) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section D -Subsection 2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_RangeAxis=us-gaap_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RangeAxis=us-gaap_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Stockholders' Equity (Details 4) - Restricted Stock Units (RSUs) [Member] - $ / shares
|
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Stockholders Equity [Line Items] |
|
|
Outstanding Number of RSU's at January 1, 2015 |
447,275
|
|
Granted Number of RSU's |
0
|
|
Vested and converted to common shares Number of RSUs |
(219,415)
|
(568)
|
Forfeited Number of RSU's |
(76,954)
|
|
Outstanding Number of RSU's at December 31, 2015 |
150,906
|
447,275
|
Exercisable Number of RSU's at December 31, 2015 |
150,906
|
|
Outstanding Weighted-Average Exercise Price, at January 1, 2015 |
$ 2.18
|
|
Granted Weighted-Average Grant Date Fair Value |
0
|
|
Vested and converted to common shares Weighted-Average Grant Date Fair Value |
2.21
|
|
Forfeited Weighted-Average Grant Date Fair Value |
2.21
|
|
Outstanding Weighted-Average Exercise Price, at December 31, 2015 |
2.13
|
$ 2.18
|
Exercisable Weighted-Average Grant Date Fair Value at December 31, 2015 |
$ 2.13
|
|
X |
- DefinitionThe weighted average fair value as of grant date of equity-based payment instruments, excluding stock (or unit) options, in the reporting period.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exercisable number equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average fair value as of grant date of equity-based payment instruments, excluding stock (or unit) options, in the reporting period.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted average fair value as of grant date of equity-based payment instruments, excluding stock (or unit) options, in the reporting period.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageFairValue |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThis line item represents stockholders equity.
+ References
+ Details
Name: |
cur_StockholdersEquityLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Stockholders' Equity (Details 5) - Warrant [Member] - USD ($)
|
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Stockholders Equity [Line Items] |
|
|
Outstanding Number of Warrants at January 1, 2015 |
21,422,346
|
|
Granted Number of Warrants |
150,000
|
|
Exercised Number of Warrants |
(1,724,606)
|
|
Forfeited Number of Warrants |
(195,644)
|
|
Outstanding Number of Warrants at December 31, 2015 |
19,652,096
|
21,422,346
|
Exercisable Number of Warrants at December 31, 2015 |
19,577,096
|
|
Outstanding Weighted-Average Exercise Price, at January 1, 2015 |
$ 2.3
|
|
Granted Weighted-Average Exercise Price |
1.87
|
|
Exercised Weighted-Average Exercise Price |
1.94
|
|
Forfeited Weighted Average Exercise Price |
2.02
|
|
Outstanding Weighted-Average Exercise Price, at December 31, 2015 |
2.34
|
$ 2.3
|
Exercisable Weighted-Average Exercise Price, at December 31, 2015 |
$ 2.34
|
|
Outstanding Weighted-Average Remaining Contractual Life (in years) |
3 years 1 month 6 days
|
3 years 9 months 18 days
|
Granted Weighted-Average Remaining Contractual Life (in years) |
4 years 6 months
|
|
Exercisable Weighted-Average Remaining Contractual Life (in years), at December 31, 2015 |
3 years 1 month 6 days
|
|
Outstanding Aggregate Intrinsic Value, at January 1, 2015 |
$ 15,984,739
|
|
Outstanding Aggregate Intrinsic Value, at December 31, 2015 |
309,724
|
$ 15,984,739
|
Exercisable Aggregate Intrinsic Value, at December 31, 2015 |
$ 309,724
|
|
X |
- DefinitionThe aggregate intrinsic value of equity-based instruments, excluding stock (or unit) options, that validly exist and are exercisable as of the balance sheet date.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average remaining contractual term of equity-based instruments, excluding stock (or unit) options, that validly exist and are exercisable as of the balance sheet date.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average remaining contractual life of equity-based instruments, excluding stock (or unit) options, granted during the period.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average exercise price of equity-based instruments, excluding stock (or unit) options, that validly exist and are exercisable as of the balance sheet date.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisable |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted average fair value as of grant date of equity-based payment instruments, excluding stock (or unit) options, in the reporting period.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageFairValue |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of equity-based instruments, excluding stock (or unit) options, that validly exist and are exercisable as of the balance sheet date.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBbasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThis line item represents stockholders equity.
+ References
+ Details
Name: |
cur_StockholdersEquityLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of non-option equity instruments exercised by participants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIntrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionThe weighted average fair value as of grant date of equity-based payment instruments, excluding stock (or unit) options, in the reporting period.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average fair value as of grant date of equity-based payment instruments, excluding stock (or unit) options, in the reporting period.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageFairValue |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionShare-based compensation arrangement by share-based payment award, equity instruments other than options, conversion of common shares.
+ References
+ Details
Name: |
cur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConverisonOfCommonShares |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis line item represents stockholders equity.
+ References
+ Details
Name: |
cur_StockholdersEquityLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Stockholders' Equity (Details Textual) - USD ($)
|
1 Months Ended |
2 Months Ended |
4 Months Ended |
12 Months Ended |
|
Oct. 31, 2014 |
Jan. 31, 2014 |
Sep. 30, 2013 |
Jul. 31, 2013 |
May. 31, 2013 |
Mar. 31, 2013 |
Jun. 30, 2013 |
Feb. 28, 2013 |
Dec. 31, 2013 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Jun. 30, 2014 |
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value |
|
|
|
|
|
|
|
|
|
$ 1.89
|
$ 1.90
|
$ 1.01
|
|
Warrants Issued During Period |
|
6,872,859
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Warrant Or Right Exercise Price Of Warrants Issued |
|
|
|
|
|
|
|
$ 1.25
|
|
|
|
|
|
Share Price |
|
$ 2.91
|
|
|
$ 1.07
|
|
|
$ 1.25
|
|
|
|
|
|
Stock Issued During Period Share From Warrants In Conjunction With Debt Transaction |
|
|
|
|
|
1,297,607
|
|
|
|
|
|
|
|
Proceeds from Issuance of Common Stock |
|
$ 20,000,000
|
|
|
|
|
|
|
|
|
|
|
|
Net proceeds received from issuance |
|
$ 18,630,000
|
|
|
|
|
|
$ 323,000
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
350,650
|
|
|
|
|
|
|
|
Issuance of common stock from warrants and options exercised (in shares) |
|
|
|
|
440,000
|
|
|
258,000
|
|
|
|
|
|
Stock or Unit Option Plan Expense |
|
|
|
|
|
|
|
|
|
$ 3,449,000
|
|
|
|
Compensation Expenses Unvested Restricted Stock term period |
|
|
|
|
|
|
|
|
|
1 year 9 months 18 days
|
|
|
|
Common Stock, Capital Shares Reserved for Future Issuance |
|
|
|
|
|
|
|
|
|
39,500,000
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
|
$ 1.25
|
|
|
|
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value |
|
|
|
|
|
|
|
|
|
$ 2,215,000
|
$ 1,814,000
|
$ 1,170,000
|
|
Increased Common stock Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
300,000,000
|
Increase In Common Stock Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
150,000,000
|
Stock Issued During Period, Shares, Issued for Services |
|
|
|
|
|
|
|
258,000
|
|
|
|
|
|
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period |
|
|
|
|
|
|
|
|
|
1,617,223
|
|
|
|
March 2013 long-term debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Conversion, Original Debt, Amount |
|
|
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
|
Market Offering Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
|
|
|
|
|
|
|
|
|
$ 3.77
|
$ 3.55
|
|
|
Proceeds from Issuance of Common Stock |
|
|
|
|
|
|
|
|
$ 2,895,000
|
$ 2,932,000
|
|
|
|
Net proceeds received from issuance |
|
|
|
|
|
|
|
|
|
|
$ 838,000
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
|
1,140,994
|
812,423
|
249,163
|
|
|
Sale of Stock, Price Per Share |
|
|
|
|
|
|
|
|
$ 2.64
|
|
|
$ 2.64
|
|
Direct Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Issued During Period |
|
3,436,435
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Warrant Or Right Exercise Price Of Warrants Issued |
|
$ 3.64
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Exercisable Years |
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
Direct Offering [Member] | Shelf Registration [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock, Shelf Registration |
|
$ 50,000,000
|
|
|
|
|
|
|
|
|
|
|
|
Phase One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Issued During Period |
|
|
|
942,520
|
440,000
|
|
|
|
|
|
|
|
|
Class Of Warrant Or Right Exercise Price Of Warrants Issued |
|
|
|
$ 1.25
|
$ 1.07
|
|
|
|
|
|
|
|
|
Share Price |
|
|
|
$ 1.25
|
|
|
|
|
|
|
|
|
|
Net proceeds received from issuance |
|
|
$ 1,700,000
|
$ 1,178,000
|
$ 433,000
|
|
|
|
|
|
|
|
|
Issuance of common stock from warrants and options exercised (in shares) |
|
|
1,448,798
|
942,520
|
|
|
|
|
344,000
|
|
|
|
|
Warrants Modified During Period |
|
|
|
782,005
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
$ 1.25
|
$ 1.25
|
|
|
|
|
|
|
|
|
Phase One [Member] | Warrants And Options [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net proceeds received from issuance |
|
|
|
|
|
|
|
|
|
$ 3,056,000
|
$ 1,714,000
|
|
|
Issuance of common stock from warrants and options exercised (in shares) |
|
|
|
|
|
|
|
|
|
1,724,606
|
1,234,428
|
|
|
Class Of Warrant Or Right Exercise Price Of Warrants And Options Issued |
|
|
|
|
|
|
|
|
|
$ 1.94
|
$ 1.44
|
|
|
Phase Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Issued During Period |
|
|
|
|
689,675
|
|
|
|
|
|
|
|
|
Class Of Warrant Or Right Exercise Price Of Warrants Issued |
|
|
|
|
$ 1.25
|
|
|
|
|
|
|
|
|
Share Price |
|
|
|
$ 1.02
|
$ 1.25
|
|
|
|
|
|
|
|
|
Net proceeds received from issuance |
|
|
|
$ 102,000
|
$ 844,000
|
|
|
|
$ 730,000
|
|
$ 20,000
|
|
|
Issuance of common stock from warrants and options exercised (in shares) |
|
|
|
100,000
|
689,675
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
$ 1.25
|
|
|
|
|
|
|
|
|
Cashless And Partial Cashless Exercises Price for Warrants and Options |
|
|
|
|
|
|
|
|
|
|
$ 1.03
|
|
|
Stock Issued For Cashless And Partial Cashless Exercises Of Warrants and Options |
|
|
|
|
|
|
|
|
|
|
712,539
|
|
|
Number of Warrants and Options Exercised |
|
|
|
|
|
|
|
|
|
|
1,194,372
|
|
|
Phase Two [Member] | Warrants And Options [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cashless And Partial Cashless Exercises Price for Warrants and Options |
|
|
|
|
|
|
|
|
|
$ 0.6157
|
|
|
|
Stock Issued For Cashless And Partial Cashless Exercises Of Warrants and Options |
|
|
|
|
|
|
|
|
|
1,251,189
|
|
|
|
Number of Warrants and Options Exercised |
|
|
|
|
|
|
|
|
|
2,209,000
|
|
|
|
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period |
|
|
|
|
|
|
|
|
|
1,158,020
|
|
|
|
Phase three [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Issued During Period |
|
|
650,000
|
|
|
|
378,809
|
|
|
|
|
|
|
Class Of Warrant Or Right Exercise Price Of Warrants Issued |
|
|
$ 0.90
|
|
|
|
|
|
|
|
|
|
|
Share Price |
|
|
|
|
|
|
$ 1.25
|
|
|
|
|
|
|
Net proceeds received from issuance |
|
|
|
|
|
|
$ 474,000
|
|
|
|
|
|
|
Issuance of common stock from warrants and options exercised (in shares) |
|
|
401,133
|
|
|
|
378,809
|
|
|
|
|
|
|
Warrants Forfeited During Period |
|
|
248,867
|
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
$ 1.25
|
|
|
|
|
|
|
Phase Four [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Warrant Or Right Exercise Price Of Warrants Issued |
|
|
$ 2.00
|
|
|
|
|
|
|
|
|
|
|
Share Price |
|
|
$ 1.60
|
|
|
|
$ 1.02
|
|
|
|
|
|
|
Proceeds from Issuance of Common Stock |
|
|
$ 4,556,000
|
|
|
|
|
|
|
|
|
|
|
Net proceeds received from issuance |
|
|
$ 4,242,000
|
|
|
|
$ 306,000
|
|
|
|
|
|
|
Issuance of common stock from warrants and options exercised (in shares) |
|
|
1,423,750
|
|
|
|
300,000
|
|
|
|
|
|
|
Stock Issued During Period Shares Placement |
|
|
2,847,500
|
|
|
|
|
|
|
|
|
|
|
Minimum [Member] | Phase One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Issued During Period |
|
|
648,798
|
|
|
|
|
|
|
|
|
|
|
Class Of Warrant Or Right Exercise Price Of Warrants Issued |
|
|
$ 1.08
|
|
|
|
|
|
|
|
|
|
|
Minimum [Member] | Phase Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Issued During Period |
|
|
|
|
|
|
|
|
4,000
|
|
|
|
|
Class Of Warrant Or Right Exercise Price Of Warrants Issued |
|
|
|
|
|
|
|
|
$ 1.56
|
|
|
|
|
Maximum [Member] | Phase One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Issued During Period |
|
|
800,000
|
|
|
|
|
|
340,000
|
|
|
|
|
Class Of Warrant Or Right Exercise Price Of Warrants Issued |
|
|
|
|
|
|
|
|
$ 2.13
|
|
|
|
|
Share Price |
|
|
$ 1.25
|
|
|
|
|
|
|
|
|
|
|
Chief Science Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Expenses |
|
|
|
|
|
|
|
|
|
|
$ 3,100,000
|
|
|
Various Parties [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
28,119
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value |
|
|
|
|
|
|
|
|
|
$ 1.08
|
$ 2.07
|
$ 0.82
|
|
Stock Issued During Period Share From Warrants In Conjunction With Debt Transaction |
133,329
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value |
|
|
|
|
|
|
|
|
|
$ 5,126,000
|
$ 4,287,000
|
$ 3,550,000
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding |
|
|
|
|
|
|
|
|
|
309,724
|
$ 15,984,739
|
|
|
Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value |
|
|
|
|
|
|
|
|
|
|
$ 3.31
|
$ 1.14
|
|
Stock or Unit Option Plan Expense |
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period |
|
|
|
|
|
|
|
|
|
219,415
|
568
|
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value |
|
|
|
|
|
|
|
|
|
$ 33,000
|
$ 142,000
|
$ 254,000
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding |
|
|
|
|
|
|
|
|
|
$ 241,000
|
|
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period |
|
|
|
|
|
|
|
|
|
427,808
|
|
|
|
Restricted Stock Units (RSUs) [Member] | March 2013 long-term debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period |
|
|
|
|
|
|
|
|
|
|
805,972
|
|
|
Common Stock [Member] | Phase One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
72,440
|
|
|
|
|
|
|
|
|
|
|
Private Placement [Member] | Phase Four [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Issued During Period |
|
|
170,850
|
|
|
|
|
|
|
|
|
|
|
Class Of Warrant Or Right Exercise Price Of Warrants Issued |
|
|
$ 2.00
|
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionThis element represents cashless and partial cashless exercises price for warrants and options.
+ References
+ Details
Name: |
cur_CashlessAndPartialCashlessExercisesPriceForWarrantsAndOptions |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exercise price of each class of warrants and options issued.
+ References
+ Details
Name: |
cur_ClassOfWarrantOrRightExercisePriceOfWarrantsAndOptionsIssued |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exercise price of each class of warrants or rights issued.
+ References
+ Details
Name: |
cur_ClassOfWarrantOrRightExercisePriceOfWarrantsIssued |
Namespace Prefix: |
cur_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of common stock shelf registration statement were registering the sale of securities.
+ References
+ Details
Name: |
cur_CommonStockShelfRegistration |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionIt represents the compensation expenses unvested restricted stock term period.
+ References
+ Details
Name: |
cur_CompensationExpensesUnvestedRestrictedStockTermPeriod |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis element represent increases in number of shares of common stock authorized. Common stock represent the ownership interest in a corporation.
+ References
+ Details
Name: |
cur_IncreaseInCommonStockSharesAuthorized |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThis element represents total increased number of shares of common stock authorized. Common stock represent the ownership interest in a corporation.
+ References
+ Details
Name: |
cur_IncreasedCommonStockSharesAuthorized |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThis element represents the number of warrants and options exercised.
+ References
+ Details
Name: |
cur_NumberOfWarrantsAndOptionsExercised |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of stock issued during period from warrants and options exercised.
+ References
+ Details
Name: |
cur_StockIssuedDuringPeriodShareFromWarrantsAndOptionsExercised |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of stock issued from warrants to various parties in conjunction with our debt transaction during the period.
+ References
+ Details
Name: |
cur_StockIssuedDuringPeriodShareFromWarrantsInConjunctionWithDebtTransaction |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares registered under direct placement.
+ References
+ Details
Name: |
cur_StockIssuedDuringPeriodSharesPlacement |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis element represents stock issued for cashless and partial cashless exercises of both options and warrants.
+ References
+ Details
Name: |
cur_StockIssuedForCashlessAndPartialCashlessExercisesOfWarrantsAndOptions |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis line item represents stockholders equity.
+ References
+ Details
Name: |
cur_StockholdersEquityLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionReflects the net amount of proceeds received from shares issued during the period.
+ References
+ Details
Name: |
cur_WarrantsAndSharesIssuedValueNet |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe number of exercisable years of warrants.
+ References
+ Details
Name: |
cur_WarrantsExercisableYears |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of warrants forfeited during the reporting period.
+ References
+ Details
Name: |
cur_WarrantsForfeitedDuringPeriod |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionReflects the number of warrants issued.
+ References
+ Details
Name: |
cur_WarrantsIssuedDuringPeriod |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of warrants modified during period.
+ References
+ Details
Name: |
cur_WarrantsModifiedDuringPeriod |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(4)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate number of common shares reserved for future issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CommonStockCapitalSharesReservedForFutureIssuance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
+ Details
Name: |
us-gaap_DebtConversionOriginalDebtAmount1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThis element represents a sum total of expenses not separately reflected on the income statement for the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.7) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4,6) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OtherExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share instruments newly issued under a share-based compensation plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIntrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_StockOptionPlanExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cur_March2013LongtermDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
cur_TypeOfAgreementAxis=cur_MarketOfferingAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
cur_TypeOfAgreementAxis=cur_DirectOfferingMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RegistrationPaymentArrangementByArrangementAxis=cur_ShelfRegistrationMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TradingActivityByTypeAxis=cur_PhaseOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=cur_WarrantsAndOptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TradingActivityByTypeAxis=cur_PhaseTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TradingActivityByTypeAxis=cur_PhaseThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TradingActivityByTypeAxis=cur_PhaseFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RangeAxis=us-gaap_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RangeAxis=us-gaap_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TitleOfIndividualAxis=cur_ChiefScienceOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TitleOfIndividualAxis=cur_VariousPartiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Property and Equipment (Details) - USD ($)
|
Dec. 31, 2015 |
Dec. 31, 2014 |
Property, Plant and Equipment [Line Items] |
|
|
Property, Plant and Equipment, Gross |
$ 971,751
|
$ 784,497
|
Less accumulated depreciation |
(628,551)
|
(483,232)
|
Property and equipment, net |
343,200
|
301,265
|
Furniture and Fixtures [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property, Plant and Equipment, Gross |
31,610
|
22,603
|
Computers and office equipment [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property, Plant and Equipment, Gross |
136,558
|
100,105
|
Leasehold Improvements [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property, Plant and Equipment, Gross |
40,290
|
|
Lab equipment [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property, Plant and Equipment, Gross |
$ 763,293
|
$ 661,789
|
X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.14) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Property and Equipment (Details Textual) - USD ($)
|
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Property, Plant and Equipment [Line Items] |
|
|
|
Property, Plant and Equipment, Gross |
$ 971,751
|
$ 784,497
|
|
Depreciation |
148,000
|
$ 137,000
|
$ 126,000
|
CHINA |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Property, Plant and Equipment, Gross |
$ 73,000
|
|
|
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementGeographicalAxis=country_CN |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Intangible Assets (Details) - Patents [Member] - USD ($)
|
Dec. 31, 2015 |
Dec. 31, 2014 |
Finite-Lived Intangible Assets [Line Items] |
|
|
Patent asset |
$ 1,887,798
|
$ 1,822,037
|
Accumulated Amortization |
(784,331)
|
(588,865)
|
Net Intagibles |
$ 1,103,467
|
$ 1,233,172
|
X |
- DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Intangible Assets (Details Textual) - USD ($)
|
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Finite-Lived Intangible Assets [Line Items] |
|
|
|
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life |
9 years 9 months 18 days
|
|
|
Amortization of Intangible Assets |
$ 197,000
|
$ 211,000
|
$ 119,000
|
Finite-Lived Intangible Assets, Amortization Expense, Year Five |
$ 144,000
|
|
|
X |
- DefinitionWeighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275
+ Details
Name: |
us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_AmortizationOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Income Taxes (Details) - USD ($)
|
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Current provision: |
|
|
|
Federal |
$ 0
|
$ 0
|
$ 0
|
State |
0
|
0
|
0
|
Foreign |
0
|
0
|
0
|
Total current provision |
0
|
0
|
0
|
Deferred provision (benefit): |
|
|
|
Federal |
(6,645,222)
|
(5,563,694)
|
(4,436,239)
|
State |
(955,515)
|
(61,835)
|
502,696
|
Foreign |
0
|
0
|
0
|
Total deferred provision (benefit) |
(7,600,737)
|
(5,625,529)
|
(3,933,543)
|
Valuation allowance |
7,600,737
|
5,625,529
|
3,933,543
|
Consolidated income tax provision |
$ 0
|
$ 0
|
$ 0
|
X |
- DefinitionAmount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6509736
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Paragraph Question 1-7
+ Details
Name: |
us-gaap_CurrentFederalTaxExpenseBenefit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319
+ Details
Name: |
us-gaap_CurrentForeignTaxExpenseBenefit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6509736
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Subsection 7
+ Details
Name: |
us-gaap_CurrentStateAndLocalTaxExpenseBenefit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (g),(h) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Deferred Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6510177
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Subsection 7
+ Details
Name: |
us-gaap_DeferredOtherTaxExpenseBenefit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.3.1.900
v3.3.1.900
Income Taxes (Details 2) - USD ($)
|
Dec. 31, 2015 |
Dec. 31, 2014 |
Income Tax [Line Items] |
|
|
Net operating loss carryforwards |
$ 39,555,984
|
$ 36,008,206
|
Stock based compensation expense |
10,659,107
|
11,183,210
|
Tax credit carryforwards and other |
5,717,023
|
1,139,961
|
Gross deferred tax assets |
55,932,114
|
48,331,377
|
Valuation allowance |
(55,932,114)
|
(48,331,377)
|
Net deferred tax assets |
$ 0
|
$ 0
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Deferred Tax Asset -URI http://asc.fasb.org/extlink&oid=6510090
+ Details
Name: |
us-gaap_DeferredTaxAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b),(c) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details
Name: |
us-gaap_DeferredTaxAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51675352&loc=d3e28680-109314
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319
+ Details
Name: |
us-gaap_DeferredTaxAssetsOperatingLossCarryforwards |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to other deductible tax credit carryforwards not separately disclosed.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319
+ Details
Name: |
us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 25 -Paragraph 20 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51675352&loc=d3e28680-109314
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319
+ Details
Name: |
us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details
Name: |
us-gaap_DeferredTaxAssetsValuationAllowance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.3.1.900
X |
- DefinitionA description of Expiration term of operating loss carryforward included in operating loss carryforward
+ References
+ Details
Name: |
cur_Operatinglosscarryforwardsexpirationterm |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319
+ Details
Name: |
us-gaap_OperatingLossCarryforwards |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.3.1.900
Selected Quarterly Data (Details) - USD ($)
|
3 Months Ended |
12 Months Ended |
Dec. 31, 2015 |
Sep. 30, 2015 |
Jun. 30, 2015 |
Mar. 31, 2015 |
Dec. 31, 2014 |
Sep. 30, 2014 |
Jun. 30, 2014 |
Mar. 31, 2014 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Effect of Fourth Quarter Events [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Revenues |
$ 2,500
|
$ 2,500
|
$ 2,500
|
$ 2,917
|
$ 4,666
|
$ 5,000
|
$ 5,000
|
$ 4,167
|
$ 10,417
|
$ 18,833
|
$ 110,000
|
Operating loss |
(4,351,306)
|
(5,197,520)
|
(4,994,722)
|
(4,612,980)
|
(4,640,965)
|
(4,106,745)
|
(3,511,238)
|
(5,176,901)
|
(19,156,528)
|
(17,435,849)
|
(12,523,941)
|
Net loss |
$ (4,765,151)
|
$ (5,637,568)
|
$ (5,448,037)
|
$ (5,053,145)
|
$ (5,503,168)
|
$ (4,455,237)
|
$ (6,751,282)
|
$ (5,919,057)
|
$ (20,903,901)
|
$ (22,628,744)
|
$ (19,831,862)
|
Net loss per share - basic and diluted (in dollars per share) |
$ (0.05)
|
$ (0.06)
|
$ (0.06)
|
$ (0.06)
|
$ (0.06)
|
$ (0.05)
|
$ (0.08)
|
$ (0.07)
|
$ (0.23)
|
$ (0.26)
|
$ (0.27)
|
X |
- DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
+ Details
Name: |
us-gaap_EarningsPerShareBasicAndDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_EffectOfFourthQuarterEventsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ References
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_Revenues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.3.1.900
X |
- References
+ Details
Name: |
cur_FutureMinimumLeasePaymentsForCapitalLeasesLineItems |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFuture minimum rental payments in aggregate as of the balance sheet date under operating leases.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718
+ Details
Name: |
us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFuture rental payments receivable within one year of the balance sheet date under an operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718
+ Details
Name: |
us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFuture rental payments receivable within the fifth year from the balance sheet date under an operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718
+ Details
Name: |
us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFuture rental payments receivable within the fourth year from the balance sheet date under an operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718
+ Details
Name: |
us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFourYears |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFuture rental payments receivable within the third year from the balance sheet date under an operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718
+ Details
Name: |
us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFuture rental payments receivable within the second year from the balance sheet date under an operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718
+ Details
Name: |
us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFuture minimum lease payments receivable under operating leases for periods greater than five years following the balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718
+ Details
Name: |
us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableThereafter |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.3.1.900
Commitments and Contingencies (Details Textual)
|
12 Months Ended |
Dec. 31, 2015
USD ($)
a
|
Dec. 31, 2014
USD ($)
|
Dec. 31, 2013
USD ($)
|
Gain Contingencies [Line Items] |
|
|
|
Operating Leases, Rent Expense |
$ 318,000
|
$ 257,000
|
$ 277,000
|
Severance Costs |
$ 1,000,000
|
|
|
Chief Executive Officer [Member] |
|
|
|
Gain Contingencies [Line Items] |
|
|
|
Compensation Description On Termination Of Agreement |
agreements terminate on October 31, 2017. Pursuant to the CEOs agreement, he receives a salary of $440,000 per annum and in the event of termination prior to the completion of the agreement the Company would pay the CEO the greater of his remaining compensation due under the agreement or one million dollars ($1,000,000).
|
|
|
Officers Compensation |
$ 177,000
|
|
|
Chief Scientific Officer [Member] |
|
|
|
Gain Contingencies [Line Items] |
|
|
|
Compensation Description On Termination Of Agreement |
Pursuant to the CSOs agreement, he receives $750,000 per annum and in the event of termination prior to the completion of the agreement the Company would pay the CSO the greater of the remaining compensation due under the agreement or one million dollars ($1,000,000).
|
|
|
SanDiego California [Member] |
|
|
|
Gain Contingencies [Line Items] |
|
|
|
Lease Expiration Date |
Aug. 31, 2018
|
|
|
Lease Monthly Payment |
$ 11,000
|
|
|
Area of Land | a |
3,100
|
|
|
Germantown [Member] |
|
|
|
Gain Contingencies [Line Items] |
|
|
|
Lease Expiration Date |
Dec. 31, 2016
|
|
|
Lease Monthly Payment |
$ 10,200
|
|
|
Area of Land | a |
2,900
|
|
|
Peoples Republic Of China [Member] |
|
|
|
Gain Contingencies [Line Items] |
|
|
|
Lease Expiration Date |
Sep. 30, 2018
|
|
|
Lease Monthly Payment |
$ 3,200
|
|
|
X |
- DefinitionDescription of compensation payable on termination of selected employees in accordance with their employment contracts.
+ References
+ Details
Name: |
cur_CompensationDescriptionOnTerminationOfAgreement |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresents the monthly lease payment due for the reporting period.
+ References
+ Details
Name: |
cur_LeaseMonthlyPayment |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_GainContingenciesLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
+ Details
Name: |
us-gaap_LeaseAndRentalExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDate which lease or group of leases is set to expire, in CCYY-MM-DD format.
+ References
+ Details
Name: |
us-gaap_LeaseExpirationDate1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OfficersCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a)(10) -URI http://asc.fasb.org/extlink&oid=58740216&loc=d3e1928-114920
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section P -Subsection 3, 4
+ Details
Name: |
us-gaap_SeveranceCosts1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TitleOfIndividualAxis=cur_ChiefScientificOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cur_SandiegoCaliforniaMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cur_GermantownMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cur_PeoplesRepublicOfChinaMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Transaction with Related Parties (Details Textual)
|
12 Months Ended |
Dec. 31, 2015
USD ($)
|
Related Party Transaction [Line Items] |
|
Severance Costs |
$ 1,000,000
|
Chief Executive Officer [Member] |
|
Related Party Transaction [Line Items] |
|
Compensation Description On Termination Of Agreement |
(i) the continued payment of Mr. Garrs monthly salary immediately prior to his resignation until March 1, 2017, (ii) a lump of $177,000 to be paid on June 1, 2016, January 1, 2017 and March 1, 2017, (iii) continued healthcare benefits until January 1, 2017, and (iv) the immediate vesting of any previously outstanding but unvested equity awards (collectively, the Severance).
|
Severance Costs |
$ 1,000,000
|
Officers Compensation |
$ 177,000
|
X |
- DefinitionDescription of compensation payable on termination of selected employees in accordance with their employment contracts.
+ References
+ Details
Name: |
cur_CompensationDescriptionOnTerminationOfAgreement |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OfficersCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a)(10) -URI http://asc.fasb.org/extlink&oid=58740216&loc=d3e1928-114920
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section P -Subsection 3, 4
+ Details
Name: |
us-gaap_SeveranceCosts1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.3.1.900
Subsequent Events (Details textual)
|
12 Months Ended |
Dec. 31, 2015
USD ($)
|
Subsequent Event [Line Items] |
|
Severance Costs |
$ 1,000,000
|
Chief Executive Officer [Member] |
|
Subsequent Event [Line Items] |
|
Compensation Description On Termination Of Agreement |
(i) the continued payment of Mr. Garrs monthly salary immediately prior to his resignation until March 1, 2017, (ii) a lump of $177,000 to be paid on June 1, 2016, January 1, 2017 and March 1, 2017, (iii) continued healthcare benefits until January 1, 2017, and (iv) the immediate vesting of any previously outstanding but unvested equity awards (collectively, the Severance).
|
Severance Costs |
$ 1,000,000
|
Officers Compensation |
$ 177,000
|
X |
- DefinitionDescription of compensation payable on termination of selected employees in accordance with their employment contracts.
+ References
+ Details
Name: |
cur_CompensationDescriptionOnTerminationOfAgreement |
Namespace Prefix: |
cur_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OfficersCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a)(10) -URI http://asc.fasb.org/extlink&oid=58740216&loc=d3e1928-114920
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section P -Subsection 3, 4
+ Details
Name: |
us-gaap_SeveranceCosts1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
+ Details
Name: |
us-gaap_SubsequentEventLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From May 2024 to Jun 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Jun 2023 to Jun 2024